RESULT_COUNT: 924,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
PBYI,PBYI:US,BBG0018YXYX7,Bitcoin vs. Biotech: Which Is the Smarter Investment?,2017-10-08 12:18:00 +0000,http://finance.yahoo.com/r/c512706e-b5a3-3d5c-807f-cd3187f922fa/bitcoin-vs-biotech-which-is-the-smarter-investment.aspx?yptr=yahoo&.tsrc=rss,It comes down to risk vs. reward.
PBYI,PBYI:UW,BBG002NFCGM3,Bitcoin vs. Biotech: Which Is the Smarter Investment?,2017-10-08 12:18:00 +0000,http://finance.yahoo.com/r/c512706e-b5a3-3d5c-807f-cd3187f922fa/bitcoin-vs-biotech-which-is-the-smarter-investment.aspx?yptr=yahoo&.tsrc=rss,It comes down to risk vs. reward.
PBYI,PBYI:US,BBG0018YXYX7,"XBI, CLVS, SRPT, PBYI: Large Inflows Detected at ETF",2017-10-05 16:49:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gunbgtXORhM/xbi-clvs-srpt-pbyi-large-inflows-detected-at-etf-cm855842,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 101 6 million dollar inflow that s a 2 4 increase week over week in outstanding
PBYI,PBYI:UW,BBG002NFCGM3,"XBI, CLVS, SRPT, PBYI: Large Inflows Detected at ETF",2017-10-05 16:49:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gunbgtXORhM/xbi-clvs-srpt-pbyi-large-inflows-detected-at-etf-cm855842,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 101 6 million dollar inflow that s a 2 4 increase week over week in outstanding
PBYI,PBYI:UW,BBG002NFCGM3,"Lifshitz & Miller LLP Announces Investigation of Equifax Inc., Intercept Pharmaceuticals, Inc., Inventure Foods, Inc., Puma Biotechnology, Inc., Tintri, Inc., Twenty-First Century Fox, Inc. and Ubiquiti Networks, Inc.",2017-10-03 23:01:00 +0000,https://finance.yahoo.com/news/lifshitz-miller-llp-announces-investigation-230100079.html?.tsrc=rss,"NEW YORK , Oct. 3, 2017 /PRNewswire/ -- Equifax Inc. (EFX) Lifshitz & Miller announces an investigation on behalf of EFX investors concerning whether EFX lacked adequate internal controls after EFX disclosed ..."
PBYI,PBYI:US,BBG0018YXYX7,"Lifshitz & Miller LLP Announces Investigation of Equifax Inc., Intercept Pharmaceuticals, Inc., Inventure Foods, Inc., Puma Biotechnology, Inc., Tintri, Inc., Twenty-First Century Fox, Inc. and Ubiquiti Networks, Inc.",2017-10-03 23:01:00 +0000,https://finance.yahoo.com/news/lifshitz-miller-llp-announces-investigation-230100079.html?.tsrc=rss,"NEW YORK , Oct. 3, 2017 /PRNewswire/ -- Equifax Inc. (EFX) Lifshitz & Miller announces an investigation on behalf of EFX investors concerning whether EFX lacked adequate internal controls after EFX disclosed ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference,2017-09-18 20:20:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-present-cantor-fitzgerald-202000986.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company, including recent developments, at 1:40 p.m."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference,2017-09-18 20:20:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-present-cantor-fitzgerald-202000986.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company, including recent developments, at 1:40 p.m."
PBYI,PBYI:US,BBG0018YXYX7,"Before You Buy Puma Biotechnology Inc’s (PBYI), You Should Consider This",2017-09-13 18:55:26 +0000,https://finance.yahoo.com/news/buy-puma-biotechnology-inc-pbyi-185526596.html?.tsrc=rss,"If you are looking to invest in Puma Biotechnology Inc’s (NASDAQ:PBYI), or currently own the stock, then you need to understand its beta in order to understand how it canRead More..."
PBYI,PBYI:UW,BBG002NFCGM3,"Before You Buy Puma Biotechnology Inc’s (PBYI), You Should Consider This",2017-09-13 18:55:26 +0000,https://finance.yahoo.com/news/buy-puma-biotechnology-inc-pbyi-185526596.html?.tsrc=rss,"If you are looking to invest in Puma Biotechnology Inc’s (NASDAQ:PBYI), or currently own the stock, then you need to understand its beta in order to understand how it canRead More..."
PBYI,PBYI:US,BBG0018YXYX7,4 Biotech Stocks for the Long-Term,2017-09-13 18:35:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p0qq_jnkZAc/4-biotech-stocks-for-the-long-term-cm845299,InvestorPlace Stock Market News Stock Advice amp Trading Tips Biotech is one those sectors that can absolutely kill it compared to the broad market or get killed when times are tough Biotech stocks have been a favorite of fast money too since it moves faster than
PBYI,PBYI:UW,BBG002NFCGM3,4 Biotech Stocks for the Long-Term,2017-09-13 18:35:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p0qq_jnkZAc/4-biotech-stocks-for-the-long-term-cm845299,InvestorPlace Stock Market News Stock Advice amp Trading Tips Biotech is one those sectors that can absolutely kill it compared to the broad market or get killed when times are tough Biotech stocks have been a favorite of fast money too since it moves faster than
PBYI,PBYI:UW,BBG002NFCGM3,4 Biotech Stocks for the Long-Term,2017-09-13 14:05:30 +0000,https://finance.yahoo.com/news/4-biotech-stocks-long-term-140530574.html?.tsrc=rss,"Biotech stocks have been a favorite of fast money, too, since it moves faster than the Standard & Poor’s 500 – in both directions.  Some stocks, such as Vertex Pharmaceuticals (NASDAQ:VRTX), are already up triple-digit percentages this year.  Or, they may be emerging from long trading ranges where uncertainty previously ruled."
PBYI,PBYI:US,BBG0018YXYX7,4 Biotech Stocks for the Long-Term,2017-09-13 14:05:30 +0000,https://finance.yahoo.com/news/4-biotech-stocks-long-term-140530574.html?.tsrc=rss,"Biotech stocks have been a favorite of fast money, too, since it moves faster than the Standard & Poor’s 500 – in both directions.  Some stocks, such as Vertex Pharmaceuticals (NASDAQ:VRTX), are already up triple-digit percentages this year.  Or, they may be emerging from long trading ranges where uncertainty previously ruled."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congress,2017-09-08 13:03:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-presents-5-analysis-130300582.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced the presentation of positive results from the Phase III clinical trial of Puma's drug neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy in a proffered paper oral session at the European Society of Medical Oncology 2017 Congress in Madrid, Spain."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congress,2017-09-08 13:03:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-presents-5-analysis-130300582.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced the presentation of positive results from the Phase III clinical trial of Puma's drug neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy in a proffered paper oral session at the European Society of Medical Oncology 2017 Congress in Madrid, Spain."
PBYI,PBYI:UW,BBG002NFCGM3,4 Biotech Stocks That More Than Doubled This Year,2017-09-05 18:49:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MKeRpA6t2eo/4-biotech-stocks-that-more-than-doubled-this-year-cm841184,InvestorPlace Stock Market News Stock Advice amp Trading Tips The second quarter reporting cycle has almost ended with only nine S amp P 500 stocks left to report as of Aug 25 2017 All the sectors excluding Auto and Conglomerates have recorded earnings growth in
PBYI,PBYI:US,BBG0018YXYX7,4 Biotech Stocks That More Than Doubled This Year,2017-09-05 18:49:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MKeRpA6t2eo/4-biotech-stocks-that-more-than-doubled-this-year-cm841184,InvestorPlace Stock Market News Stock Advice amp Trading Tips The second quarter reporting cycle has almost ended with only nine S amp P 500 stocks left to report as of Aug 25 2017 All the sectors excluding Auto and Conglomerates have recorded earnings growth in
PBYI,PBYI:US,BBG0018YXYX7,4 Biotech Stocks That More Than Doubled This Year,2017-09-01 17:51:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TjlzxDn0C5c/4-biotech-stocks-that-more-than-doubled-this-year-cm840378,The second quarter reporting cycle has almost ended with only nine S amp P 500 stocks left to report as of Aug 25 2017 All the sectors excluding Auto and Conglomerates have recorded earnings growth in the quarter Total earnings increased 11 2 in the second quarter on the back of 5 6
PBYI,PBYI:UW,BBG002NFCGM3,4 Biotech Stocks That More Than Doubled This Year,2017-09-01 17:51:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TjlzxDn0C5c/4-biotech-stocks-that-more-than-doubled-this-year-cm840378,The second quarter reporting cycle has almost ended with only nine S amp P 500 stocks left to report as of Aug 25 2017 All the sectors excluding Auto and Conglomerates have recorded earnings growth in the quarter Total earnings increased 11 2 in the second quarter on the back of 5 6
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Participate in Panel Discussion at Citi’s Biotech Conference,2017-08-31 20:15:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-participate-panel-discussion-201500677.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will participate in a panel discussion on breast cancer at 9:00 a.m."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Participate in Panel Discussion at Citi’s Biotech Conference,2017-08-31 20:15:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-participate-panel-discussion-201500677.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will participate in a panel discussion on breast cancer at 9:00 a.m."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces Publication of Abstracts for ESMO 2017,2017-08-30 23:07:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-announces-publication-abstracts-230700762.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced the release of two abstracts on its drug neratinib that will be presented at the European Society for Medical Oncology 2017 Congress, which will be held September 8 – 12 in Madrid, Spain."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces Publication of Abstracts for ESMO 2017,2017-08-30 23:07:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-announces-publication-abstracts-230700762.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced the release of two abstracts on its drug neratinib that will be presented at the European Society for Medical Oncology 2017 Congress, which will be held September 8 – 12 in Madrid, Spain."
PBYI,PBYI:US,BBG0018YXYX7,"ACHV Focuses On Achievement, IMGN Strikes Chord With JAZZ, FDA Snubs ACOR",2017-08-29 23:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NveLk96LAXw/achv-focuses-on-achievement-imgn-strikes-chord-with-jazz-fda-snubs-acor-20170829-01275,"ACHV Focuses On Achievement, IMGN Strikes Chord With JAZZ, FDA Snubs ACOR"
PBYI,PBYI:UW,BBG002NFCGM3,"ACHV Focuses On Achievement, IMGN Strikes Chord With JAZZ, FDA Snubs ACOR",2017-08-29 23:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NveLk96LAXw/achv-focuses-on-achievement-imgn-strikes-chord-with-jazz-fda-snubs-acor-20170829-01275,"ACHV Focuses On Achievement, IMGN Strikes Chord With JAZZ, FDA Snubs ACOR"
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),2017-08-25 20:38:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-reports-inducement-awards-203800006.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, today announced that on August 15, 2017 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 241,250 shares of Puma common stock to 107 new non-executive employees."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),2017-08-25 20:38:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-reports-inducement-awards-203800006.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, today announced that on August 15, 2017 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 241,250 shares of Puma common stock to 107 new non-executive employees."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. – PBYI",2017-08-12 02:50:00 +0000,https://finance.yahoo.com/news/puma-investigation-initiated-former-louisiana-025000316.html?.tsrc=rss,"Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Puma Biotechnology, Inc."
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. – PBYI",2017-08-12 02:50:00 +0000,https://finance.yahoo.com/news/puma-investigation-initiated-former-louisiana-025000316.html?.tsrc=rss,"Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Puma Biotechnology, Inc."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Becomes Oversold (PBYI),2017-08-10 17:34:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MEU284z5_6Y/puma-biotechnology-becomes-oversold-pbyi-cm830349,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Becomes Oversold (PBYI),2017-08-10 17:34:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MEU284z5_6Y/puma-biotechnology-becomes-oversold-pbyi-cm830349,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus",2017-08-10 16:39:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Md5F_PLoFpg/puma-pbyi-q2-loss-narrower-than-expected-nerlynx-in-focus-cm830320,Puma Biotechnology Inc PBYI reported a loss of 2 10 in the second quarter of 2017 including the impact of stock based compensation expenses narrower than the Zacks Consensus Estimate of a loss of 2 82 The company had reported a loss of 2 05 Shares of Puma Biotech were down 1 9
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus",2017-08-10 16:39:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Md5F_PLoFpg/puma-pbyi-q2-loss-narrower-than-expected-nerlynx-in-focus-cm830320,Puma Biotechnology Inc PBYI reported a loss of 2 10 in the second quarter of 2017 including the impact of stock based compensation expenses narrower than the Zacks Consensus Estimate of a loss of 2 82 The company had reported a loss of 2 05 Shares of Puma Biotech were down 1 9
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus",2017-08-10 14:13:02 +0000,https://finance.yahoo.com/news/puma-pbyi-q2-loss-narrower-141302069.html?.tsrc=rss,Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q2. Shares were down in after-hours trading.
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus",2017-08-10 14:13:02 +0000,https://finance.yahoo.com/news/puma-pbyi-q2-loss-narrower-141302069.html?.tsrc=rss,Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q2. Shares were down in after-hours trading.
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech reports 2Q loss,2017-08-10 04:03:10 +0000,https://finance.yahoo.com/news/puma-biotech-reports-2q-loss-223821246.html?.tsrc=rss,"On a per-share basis, the Los Angeles-based company said it had a loss of $2.10. Losses, adjusted for stock option expense, came to $1.38 per share. The results surpassed Wall Street expectations. The ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech reports 2Q loss,2017-08-10 04:03:10 +0000,https://finance.yahoo.com/news/puma-biotech-reports-2q-loss-223821246.html?.tsrc=rss,"On a per-share basis, the Los Angeles-based company said it had a loss of $2.10. Losses, adjusted for stock option expense, came to $1.38 per share. The results surpassed Wall Street expectations. The ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Reports Second Quarter 2017 Financial Results,2017-08-09 20:20:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-reports-second-quarter-202000178.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2017."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Reports Second Quarter 2017 Financial Results,2017-08-09 20:20:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-reports-second-quarter-202000178.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2017."
PBYI,PBYI:UW,BBG002NFCGM3,3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings,2017-08-08 18:36:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NiLnAav5guw/3-drug-stocks-poised-to-surpass-estimates-in-q2-earnings-cm828935,The pharma biotech sector has picked up pace this year after being battered by the drug pricing controversy in 2016 The first half has been pretty strong for companies in the space The sector does have its share of challenges in the form of rising competition high profile pipeline
PBYI,PBYI:US,BBG0018YXYX7,3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings,2017-08-08 18:36:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NiLnAav5guw/3-drug-stocks-poised-to-surpass-estimates-in-q2-earnings-cm828935,The pharma biotech sector has picked up pace this year after being battered by the drug pricing controversy in 2016 The first half has been pretty strong for companies in the space The sector does have its share of challenges in the form of rising competition high profile pipeline
PBYI,PBYI:US,BBG0018YXYX7,What's in Store for BioDelivery (BDSI) This Earnings Season?,2017-08-08 05:35:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2O_GaR9OxOc/whats-in-store-for-biodelivery-bdsi-this-earnings-season-cm828462,BioDelivery Sciences International Inc BDSI is scheduled to report second quarter 2017 results on Aug 9 after market close Last quarter the company s earnings surpassed expectations Year to date BioDelivery s shares have outperformed the industry In fact the stock has gained 82
PBYI,PBYI:UW,BBG002NFCGM3,What's in Store for BioDelivery (BDSI) This Earnings Season?,2017-08-08 05:35:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2O_GaR9OxOc/whats-in-store-for-biodelivery-bdsi-this-earnings-season-cm828462,BioDelivery Sciences International Inc BDSI is scheduled to report second quarter 2017 results on Aug 9 after market close Last quarter the company s earnings surpassed expectations Year to date BioDelivery s shares have outperformed the industry In fact the stock has gained 82
PBYI,PBYI:UW,BBG002NFCGM3,What's in Store for Catalyst (CPRX) This Earnings Season?,2017-08-08 05:34:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mh2vVqcsbz4/whats-in-store-for-catalyst-cprx-this-earnings-season-cm828459,Catalyst Pharmaceuticals Inc CPRX is expected to report second quarter 2017 results on Aug 9 160 Last quarter the company recorded in line earnings It topped expectations in three of the last four quarters with average positive surprise of 14 59 Catalyst s share price has
PBYI,PBYI:US,BBG0018YXYX7,What's in Store for Catalyst (CPRX) This Earnings Season?,2017-08-08 05:34:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mh2vVqcsbz4/whats-in-store-for-catalyst-cprx-this-earnings-season-cm828459,Catalyst Pharmaceuticals Inc CPRX is expected to report second quarter 2017 results on Aug 9 160 Last quarter the company recorded in line earnings It topped expectations in three of the last four quarters with average positive surprise of 14 59 Catalyst s share price has
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. - PBYI",2017-08-05 02:50:00 +0000,https://finance.yahoo.com/news/puma-investigation-initiated-former-louisiana-025000238.html?.tsrc=rss,"NEW ORLEANS, La. , Aug. 4, 2017 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC (""KSF""), announces that ..."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. - PBYI",2017-08-05 02:50:00 +0000,https://finance.yahoo.com/news/puma-investigation-initiated-former-louisiana-025000238.html?.tsrc=rss,"NEW ORLEANS, La. , Aug. 4, 2017 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC (""KSF""), announces that ..."
PBYI,PBYI:UW,BBG002NFCGM3,What's in the Cards for Kite Pharma (KITE) in Q2 Earnings,2017-08-04 16:05:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p_Ncxc1vWrU/whats-in-the-cards-for-kite-pharma-kite-in-q2-earnings-cm827307,Kite Pharma Inc KITE is expected to report second quarter 2017 results on Aug 8 before market opens Last quarter the company delivered a negative earnings surprise of 3 57 Kite Pharma s shares are up 146 5 so far this year This compares favorably with the 9 3 increase registered by
PBYI,PBYI:US,BBG0018YXYX7,What's in the Cards for Kite Pharma (KITE) in Q2 Earnings,2017-08-04 16:05:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p_Ncxc1vWrU/whats-in-the-cards-for-kite-pharma-kite-in-q2-earnings-cm827307,Kite Pharma Inc KITE is expected to report second quarter 2017 results on Aug 8 before market opens Last quarter the company delivered a negative earnings surprise of 3 57 Kite Pharma s shares are up 146 5 so far this year This compares favorably with the 9 3 increase registered by
PBYI,PBYI:US,BBG0018YXYX7,Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings?,2017-08-04 15:05:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GU4Bd6IDv4c/should-you-buy-puma-biotechnology-pbyi-ahead-of-earnings-cm827169,Investors are always looking for stocks that are poised to beat at earnings season and Puma Biotechnology Inc PBYI may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because Puma Biotechnology is
PBYI,PBYI:UW,BBG002NFCGM3,Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings?,2017-08-04 15:05:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GU4Bd6IDv4c/should-you-buy-puma-biotechnology-pbyi-ahead-of-earnings-cm827169,Investors are always looking for stocks that are poised to beat at earnings season and Puma Biotechnology Inc PBYI may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because Puma Biotechnology is
PBYI,PBYI:UW,BBG002NFCGM3,Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings?,2017-08-04 12:53:12 +0000,https://finance.yahoo.com/news/buy-puma-biotechnology-pbyi-ahead-125312925.html?.tsrc=rss,"Puma Biotechnology (PBYI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat."
PBYI,PBYI:US,BBG0018YXYX7,Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings?,2017-08-04 12:53:12 +0000,https://finance.yahoo.com/news/buy-puma-biotechnology-pbyi-ahead-125312925.html?.tsrc=rss,"Puma Biotechnology (PBYI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat."
PBYI,PBYI:US,BBG0018YXYX7,Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?,2017-08-03 22:59:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K5z3a--Zfgs/can-jazz-pharma-jazz-spring-a-surprise-in-q2-earnings-cm826910,Jazz Pharmaceuticals plc JAZZ is scheduled to report second quarter 2017 results on Aug 8 after the market closes Jazz s shares have significantly outperformed the industry so far this year The stock has surged 37 9 compared with the industry s 1 7 increase during the
PBYI,PBYI:UW,BBG002NFCGM3,Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?,2017-08-03 22:59:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K5z3a--Zfgs/can-jazz-pharma-jazz-spring-a-surprise-in-q2-earnings-cm826910,Jazz Pharmaceuticals plc JAZZ is scheduled to report second quarter 2017 results on Aug 8 after the market closes Jazz s shares have significantly outperformed the industry so far this year The stock has surged 37 9 compared with the industry s 1 7 increase during the
PBYI,PBYI:US,BBG0018YXYX7,"FDA Panel Snubs JNJ, CHMP Seeks More Data From PBYI, TBPH On Watch, AGRX Slumps",2017-08-03 00:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KOyym_iFjbQ/fda-panel-snubs-jnj-chmp-seeks-more-data-from-pbyi-tbph-on-watch-agrx-slumps-20170803-00017,"FDA Panel Snubs JNJ, CHMP Seeks More Data From PBYI, TBPH On Watch, AGRX Slumps"
PBYI,PBYI:UW,BBG002NFCGM3,"FDA Panel Snubs JNJ, CHMP Seeks More Data From PBYI, TBPH On Watch, AGRX Slumps",2017-08-03 00:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KOyym_iFjbQ/fda-panel-snubs-jnj-chmp-seeks-more-data-from-pbyi-tbph-on-watch-agrx-slumps-20170803-00017,"FDA Panel Snubs JNJ, CHMP Seeks More Data From PBYI, TBPH On Watch, AGRX Slumps"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP),2017-08-02 20:20:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-receives-day-180-202000976.html?.tsrc=rss,"Puma Biotechnology, Inc. announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has issued its Day-180 List of Outstanding Issues in the process of their ongoing regulatory review of Puma’s Marketing Authorisation Application for neratinib for the extended adjuvant treatment of HER2-positive early stage breast cancer in patients ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP),2017-08-02 20:20:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-receives-day-180-202000976.html?.tsrc=rss,"Puma Biotechnology, Inc. announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has issued its Day-180 List of Outstanding Issues in the process of their ongoing regulatory review of Puma’s Marketing Authorisation Application for neratinib for the extended adjuvant treatment of HER2-positive early stage breast cancer in patients ..."
PBYI,PBYI:UW,BBG002NFCGM3,What's in Store for Arena (ARNA) this Earnings Season?,2017-08-02 18:55:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uCQQ0qYoZjA/whats-in-store-for-arena-arna-this-earnings-season-cm825957,We expect Arena Pharmaceuticals Inc ARNA to beat estimates when it reports second quarter 2017 earnings on Aug 7 after the market closes Year to date Arena s shares have significantly soared 69 7 compared with the industry s 9 increase Arena s earnings performance is a
PBYI,PBYI:US,BBG0018YXYX7,What's in Store for Arena (ARNA) this Earnings Season?,2017-08-02 18:55:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uCQQ0qYoZjA/whats-in-store-for-arena-arna-this-earnings-season-cm825957,We expect Arena Pharmaceuticals Inc ARNA to beat estimates when it reports second quarter 2017 earnings on Aug 7 after the market closes Year to date Arena s shares have significantly soared 69 7 compared with the industry s 9 increase Arena s earnings performance is a
PBYI,PBYI:US,BBG0018YXYX7,What's in Store for Puma (PBYI) this Earnings Season?,2017-08-02 18:54:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hb_Wv4ZEzlk/whats-in-store-for-puma-pbyi-this-earnings-season-cm825949,We expect Puma Biotechnology Inc PBYI to beat estimates when it will likely report second quarter 2017 results on Aug 8 The company s earnings track record has been mixed so far as it missed estimates in two of the trailing four quarters and met expectations in the other two The
PBYI,PBYI:UW,BBG002NFCGM3,What's in Store for Puma (PBYI) this Earnings Season?,2017-08-02 18:54:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hb_Wv4ZEzlk/whats-in-store-for-puma-pbyi-this-earnings-season-cm825949,We expect Puma Biotechnology Inc PBYI to beat estimates when it will likely report second quarter 2017 results on Aug 8 The company s earnings track record has been mixed so far as it missed estimates in two of the trailing four quarters and met expectations in the other two The
PBYI,PBYI:US,BBG0018YXYX7,Inovio (INO) Q2 Earnings: What Lies Ahead for the Stock?,2017-08-02 18:54:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8NjdvypUYSU/inovio-ino-q2-earnings-what-lies-ahead-for-the-stock-cm825946,Inovio Pharmaceuticals Inc INO is scheduled to report second quarter 2017 results on Aug 8 after market close This year so far Inovio s shares have underperformed the industry The stock has lost 19 9 during the period while the industry recorded an increase of 9 Inovio
PBYI,PBYI:UW,BBG002NFCGM3,Inovio (INO) Q2 Earnings: What Lies Ahead for the Stock?,2017-08-02 18:54:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8NjdvypUYSU/inovio-ino-q2-earnings-what-lies-ahead-for-the-stock-cm825946,Inovio Pharmaceuticals Inc INO is scheduled to report second quarter 2017 results on Aug 8 after market close This year so far Inovio s shares have underperformed the industry The stock has lost 19 9 during the period while the industry recorded an increase of 9 Inovio
PBYI,PBYI:US,BBG0018YXYX7,What&apos;s in Store for Puma (PBYI) this Earnings Season?,2017-08-02 16:45:04 +0000,https://finance.yahoo.com/news/apos-store-puma-pbyi-earnings-164504705.html?.tsrc=rss,"Recent approval of Puma&apos;s (PBYI) lead candidate, neratinib, by the FDA might offer a huge boost to the company in Q2, though no sales from the drug will be recorded during the same."
PBYI,PBYI:UW,BBG002NFCGM3,What&apos;s in Store for Puma (PBYI) this Earnings Season?,2017-08-02 16:45:04 +0000,https://finance.yahoo.com/news/apos-store-puma-pbyi-earnings-164504705.html?.tsrc=rss,"Recent approval of Puma&apos;s (PBYI) lead candidate, neratinib, by the FDA might offer a huge boost to the company in Q2, though no sales from the drug will be recorded during the same."
PBYI,PBYI:UW,BBG002NFCGM3,Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season?,2017-08-02 14:59:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5Z2ksbbbCx4/will-acadia-acad-pull-off-a-surprise-this-earnings-season-cm825687,ACADIA Pharmaceuticals Inc ACAD is scheduled to report second quarter 2017 results on Aug 8 after the closing bell The company s track record has been dismal Evidently ACADIA missed estimates in two of the trailing four quarters beat it once and matched the same in the remaining
PBYI,PBYI:US,BBG0018YXYX7,Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season?,2017-08-02 14:59:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5Z2ksbbbCx4/will-acadia-acad-pull-off-a-surprise-this-earnings-season-cm825687,ACADIA Pharmaceuticals Inc ACAD is scheduled to report second quarter 2017 results on Aug 8 after the closing bell The company s track record has been dismal Evidently ACADIA missed estimates in two of the trailing four quarters beat it once and matched the same in the remaining
PBYI,PBYI:UW,BBG002NFCGM3,What's in the Cards for Celldex (CLDX) this Earnings Season?,2017-08-02 14:58:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LQa1v-n6hFY/whats-in-the-cards-for-celldex-cldx-this-earnings-season-cm825634,Celldex Therapeutics Inc CLDX is scheduled to report second quarter 2017 results on Aug 8 after market close Celldex s performance has been encouraging as it delivered positive surprise in three of the trailing four quarters and met estimates in one delivering an average positive surprise
PBYI,PBYI:US,BBG0018YXYX7,What's in the Cards for Celldex (CLDX) this Earnings Season?,2017-08-02 14:58:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LQa1v-n6hFY/whats-in-the-cards-for-celldex-cldx-this-earnings-season-cm825634,Celldex Therapeutics Inc CLDX is scheduled to report second quarter 2017 results on Aug 8 after market close Celldex s performance has been encouraging as it delivered positive surprise in three of the trailing four quarters and met estimates in one delivering an average positive surprise
PBYI,PBYI:US,BBG0018YXYX7,Today's Research Reports on Trending Tickers: CombiMatrix Corporation and Puma Biotechnology,2017-08-02 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000345.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 2, 2017 / A strong earnings season continued to push U.S. markets higher Tuesday. The Dow Jones Industrial Average closed at a new record high for the 5th consecutive ..."
PBYI,PBYI:UW,BBG002NFCGM3,Today's Research Reports on Trending Tickers: CombiMatrix Corporation and Puma Biotechnology,2017-08-02 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000345.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 2, 2017 / A strong earnings season continued to push U.S. markets higher Tuesday. The Dow Jones Industrial Average closed at a new record high for the 5th consecutive ..."
PBYI,PBYI:US,BBG0018YXYX7,Repros (RPRX) Q2 Earnings: What's in Store for the Stock?,2017-08-01 22:55:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2KHwPVjdthU/repros-rprx-q2-earnings-whats-in-store-for-the-stock-cm825330,Repros Therapeutics Inc RPRX is expected to report second quarter 2017 results on Aug 8 Let s see how things are shaping up for this quarter Repros Therapeutics share price has plunged 73 8 year to date while the industry has gained 9 9 With no approved products in its
PBYI,PBYI:UW,BBG002NFCGM3,Repros (RPRX) Q2 Earnings: What's in Store for the Stock?,2017-08-01 22:55:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2KHwPVjdthU/repros-rprx-q2-earnings-whats-in-store-for-the-stock-cm825330,Repros Therapeutics Inc RPRX is expected to report second quarter 2017 results on Aug 8 Let s see how things are shaping up for this quarter Repros Therapeutics share price has plunged 73 8 year to date while the industry has gained 9 9 With no approved products in its
PBYI,PBYI:US,BBG0018YXYX7,"Health Care Sector Update for 08/01/2017: PBYI,CBMX,NVTA,PRPO",2017-08-01 17:34:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W8tVwB8svcM/health-care-sector-update-for-08012017-pbyicbmxnvtaprpo-cm825182,Top Health Care StocksTop Health Care Stocks JNJ 0 09 JNJ 0 09 PFE 0 06 PFE 0 06 ABT 0 41 ABT 0 41 MRK 0 43 MRK 0 43 AMGN 0 05 AMGN 0 05 Health care stocks were largely sitting out Tuesday s market gains with the NYSE Health Care Index rising nearly 0 1 while shares of health
PBYI,PBYI:UW,BBG002NFCGM3,"Health Care Sector Update for 08/01/2017: PBYI,CBMX,NVTA,PRPO",2017-08-01 17:34:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W8tVwB8svcM/health-care-sector-update-for-08012017-pbyicbmxnvtaprpo-cm825182,Top Health Care StocksTop Health Care Stocks JNJ 0 09 JNJ 0 09 PFE 0 06 PFE 0 06 ABT 0 41 ABT 0 41 MRK 0 43 MRK 0 43 AMGN 0 05 AMGN 0 05 Health care stocks were largely sitting out Tuesday s market gains with the NYSE Health Care Index rising nearly 0 1 while shares of health
PBYI,PBYI:UW,BBG002NFCGM3,Can Mallinckrodt (MNK) Deliver a Beat this Earnings Season?,2017-08-01 14:59:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/09JJrkWojsw/can-mallinckrodt-mnk-deliver-a-beat-this-earnings-season-cm825022,Mallinckrodt plc MNK is set to report second quarter 2017 results on Aug 8 Mallinckrodt has delivered an average positive earnings surprise of 5 27 for the four trailing quarters Let s see how things are shaping up for this announcement Mallinckrodt PLC Price and EPS
PBYI,PBYI:US,BBG0018YXYX7,Can Mallinckrodt (MNK) Deliver a Beat this Earnings Season?,2017-08-01 14:59:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/09JJrkWojsw/can-mallinckrodt-mnk-deliver-a-beat-this-earnings-season-cm825022,Mallinckrodt plc MNK is set to report second quarter 2017 results on Aug 8 Mallinckrodt has delivered an average positive earnings surprise of 5 27 for the four trailing quarters Let s see how things are shaping up for this announcement Mallinckrodt PLC Price and EPS
PBYI,PBYI:US,BBG0018YXYX7,GW Pharmaceuticals (GWPH) Q3 Earnings: What Lies in Store?,2017-08-01 14:58:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Lup1OnECHlI/gw-pharmaceuticals-gwph-q3-earnings-what-lies-in-store-cm825017,GW Pharmaceuticals plc GWPH is scheduled to report fiscal third quarter 2017 results on Aug 7 after market hours GW Pharma s share price has decreased 3 1 in the past six months while the industry declined 12 6 in the same time frame Factors at Play GW Pharma s growth is
PBYI,PBYI:UW,BBG002NFCGM3,GW Pharmaceuticals (GWPH) Q3 Earnings: What Lies in Store?,2017-08-01 14:58:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Lup1OnECHlI/gw-pharmaceuticals-gwph-q3-earnings-what-lies-in-store-cm825017,GW Pharmaceuticals plc GWPH is scheduled to report fiscal third quarter 2017 results on Aug 7 after market hours GW Pharma s share price has decreased 3 1 in the past six months while the industry declined 12 6 in the same time frame Factors at Play GW Pharma s growth is
PBYI,PBYI:UW,BBG002NFCGM3,Puma Announces Availability of NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in the United States,2017-07-31 20:20:00 +0000,https://finance.yahoo.com/news/puma-announces-availability-nerlynx-neratinib-202000865.html?.tsrc=rss,"Puma Biotechnology, Inc. announced that NERLYNX™ tablets, formerly known as PB272, is now commercially available by prescription in the United States. The U.S."
PBYI,PBYI:US,BBG0018YXYX7,Puma Announces Availability of NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in the United States,2017-07-31 20:20:00 +0000,https://finance.yahoo.com/news/puma-announces-availability-nerlynx-neratinib-202000865.html?.tsrc=rss,"Puma Biotechnology, Inc. announced that NERLYNX™ tablets, formerly known as PB272, is now commercially available by prescription in the United States. The U.S."
PBYI,PBYI:UW,BBG002NFCGM3,Biotech Stocks Facing FDA Decision In August,2017-07-31 01:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T6SiGP_nfTo/biotech-stocks-facing-fda-decision-in-august-20170731-00044,Biotech Stocks Facing FDA Decision In August
PBYI,PBYI:US,BBG0018YXYX7,Biotech Stocks Facing FDA Decision In August,2017-07-31 01:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T6SiGP_nfTo/biotech-stocks-facing-fda-decision-in-august-20170731-00044,Biotech Stocks Facing FDA Decision In August
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. – PBYI",2017-07-29 02:50:00 +0000,https://finance.yahoo.com/news/puma-investigation-initiated-former-louisiana-025000624.html?.tsrc=rss,"Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Puma Biotechnology, Inc."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. – PBYI",2017-07-29 02:50:00 +0000,https://finance.yahoo.com/news/puma-investigation-initiated-former-louisiana-025000624.html?.tsrc=rss,"Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Puma Biotechnology, Inc."
PBYI,PBYI:US,BBG0018YXYX7,"Commit To Purchase Puma Biotechnology At $65, Earn 13.4% Using Options",2017-07-28 16:59:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T2LCWa1HSf0/commit-to-purchase-puma-biotechnology-at-65-earn-134-using-options-cm823393,Investors considering a purchase of Puma Biotechnology Inc Symbol PBYI shares but cautious about paying the going market price of 97 85 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
PBYI,PBYI:UW,BBG002NFCGM3,"Commit To Purchase Puma Biotechnology At $65, Earn 13.4% Using Options",2017-07-28 16:59:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T2LCWa1HSf0/commit-to-purchase-puma-biotechnology-at-65-earn-134-using-options-cm823393,Investors considering a purchase of Puma Biotechnology Inc Symbol PBYI shares but cautious about paying the going market price of 97 85 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
PBYI,PBYI:US,BBG0018YXYX7,Can BioMarin (BMRN) Keep the Earnings Streak Alive in Q2?,2017-07-27 15:04:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hPxLMZHV4EQ/can-biomarin-bmrn-keep-the-earnings-streak-alive-in-q2-cm822387,We expect BioMarin Pharmaceutical Inc BMRN to beat expectations when it reports second quarter 2017 results on Aug 2 after the market closes BioMarin delivered a positive earnings surprise of 110 in the last quarter BioMarin s shares are up 7 7 so far this year This
PBYI,PBYI:UW,BBG002NFCGM3,Can BioMarin (BMRN) Keep the Earnings Streak Alive in Q2?,2017-07-27 15:04:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hPxLMZHV4EQ/can-biomarin-bmrn-keep-the-earnings-streak-alive-in-q2-cm822387,We expect BioMarin Pharmaceutical Inc BMRN to beat expectations when it reports second quarter 2017 results on Aug 2 after the market closes BioMarin delivered a positive earnings surprise of 110 in the last quarter BioMarin s shares are up 7 7 so far this year This
PBYI,PBYI:US,BBG0018YXYX7,3 Been-There-Done-That Biotech CEOs Who Are Doing it Again,2017-07-21 18:42:00 +0000,http://finance.yahoo.com/r/cf0e630a-a6f4-3f93-89fa-641f68b44687/3-been-there-done-that-biotech-ceos-that-are-doing.aspx?yptr=yahoo&.tsrc=rss,"After Puma Biotech&apos;s recent success, the search is on for other clinical-stage biotechs being run by proven CEOs. Could leadership experience turn Aurinia Pharmaceuticals, Axovant Sciences, and Esperion Therapeutics into winners too?"
PBYI,PBYI:UW,BBG002NFCGM3,3 Been-There-Done-That Biotech CEOs Who Are Doing it Again,2017-07-21 18:42:00 +0000,http://finance.yahoo.com/r/cf0e630a-a6f4-3f93-89fa-641f68b44687/3-been-there-done-that-biotech-ceos-that-are-doing.aspx?yptr=yahoo&.tsrc=rss,"After Puma Biotech&apos;s recent success, the search is on for other clinical-stage biotechs being run by proven CEOs. Could leadership experience turn Aurinia Pharmaceuticals, Axovant Sciences, and Esperion Therapeutics into winners too?"
PBYI,PBYI:UW,BBG002NFCGM3,Does Puma Biotechnology's Approval Make It Worth More?,2017-07-19 03:02:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ykZb6YCCgws/does-puma-biotechnologys-approval-make-it-worth-more-cm817834,Puma Biotechnology s NASDAQ PBYI roller coaster ride to approval is finally over After fits and starts in clinical trials 160 the FDA gave the company s breast cancer drug Nerlynx a green light clearing the way to its commercialization later this year The decision is
PBYI,PBYI:US,BBG0018YXYX7,Does Puma Biotechnology's Approval Make It Worth More?,2017-07-19 03:02:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ykZb6YCCgws/does-puma-biotechnologys-approval-make-it-worth-more-cm817834,Puma Biotechnology s NASDAQ PBYI roller coaster ride to approval is finally over After fits and starts in clinical trials 160 the FDA gave the company s breast cancer drug Nerlynx a green light clearing the way to its commercialization later this year The decision is
PBYI,PBYI:UW,BBG002NFCGM3,Does Puma Biotechnology&apos;s Approval Make It Worth More?,2017-07-19 01:00:00 +0000,http://finance.yahoo.com/r/cb1c5dec-390b-3bf8-ae18-304b53bd58bd/does-puma-biotechnologys-approval-make-it-worth-mo.aspx?yptr=yahoo&.tsrc=rss,"The company has secured an FDA go-ahead for its new breast cancer drug, but should investors still be buying its shares?"
PBYI,PBYI:US,BBG0018YXYX7,Does Puma Biotechnology&apos;s Approval Make It Worth More?,2017-07-19 01:00:00 +0000,http://finance.yahoo.com/r/cb1c5dec-390b-3bf8-ae18-304b53bd58bd/does-puma-biotechnologys-approval-make-it-worth-mo.aspx?yptr=yahoo&.tsrc=rss,"The company has secured an FDA go-ahead for its new breast cancer drug, but should investors still be buying its shares?"
PBYI,PBYI:UW,BBG002NFCGM3,Puma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval,2017-07-19 00:02:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xaMjkjRGb40/pumas-pbyi-breast-cancer-drug-neratinib-gets-fda-approval-cm817798,Puma Biotechnology Inc PBYI shares rose more than 7 in after hours trading on Monday after the company announced that the FDA has approved of its lead breast cancer candidate neratinib Puma Biotech expects to make the drug commercially available in September under the brand name
PBYI,PBYI:US,BBG0018YXYX7,Puma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval,2017-07-19 00:02:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xaMjkjRGb40/pumas-pbyi-breast-cancer-drug-neratinib-gets-fda-approval-cm817798,Puma Biotechnology Inc PBYI shares rose more than 7 in after hours trading on Monday after the company announced that the FDA has approved of its lead breast cancer candidate neratinib Puma Biotech expects to make the drug commercially available in September under the brand name
PBYI,PBYI:US,BBG0018YXYX7,"Gainers & Losers Of July 18: CAPR, NVAX, TTOO, IMUC, SBPH...",2017-07-18 22:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/87QxJ7oXNTk/gainers--losers-of-july-18-capr-nvax-ttoo-imuc-sbph-20170718-01422,"Gainers & Losers Of July 18: CAPR, NVAX, TTOO, IMUC, SBPH..."
PBYI,PBYI:UW,BBG002NFCGM3,"Gainers & Losers Of July 18: CAPR, NVAX, TTOO, IMUC, SBPH...",2017-07-18 22:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/87QxJ7oXNTk/gainers--losers-of-july-18-capr-nvax-ttoo-imuc-sbph-20170718-01422,"Gainers & Losers Of July 18: CAPR, NVAX, TTOO, IMUC, SBPH..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma&apos;s (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval,2017-07-18 22:10:10 +0000,https://finance.yahoo.com/news/puma-apos-pbyi-breast-cancer-221010136.html?.tsrc=rss,"Puma Biotechnology, Inc&apos;s (PBYI) lead breast cancer candidate neratinib is approved by FDA and is set to be commercially available in September under the brand name, Nerlynx."
PBYI,PBYI:US,BBG0018YXYX7,Puma&apos;s (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval,2017-07-18 22:10:10 +0000,https://finance.yahoo.com/news/puma-apos-pbyi-breast-cancer-221010136.html?.tsrc=rss,"Puma Biotechnology, Inc&apos;s (PBYI) lead breast cancer candidate neratinib is approved by FDA and is set to be commercially available in September under the brand name, Nerlynx."
PBYI,PBYI:US,BBG0018YXYX7,Could This Biotech Stir Takeover Interest After Cancer Drug Approval?,2017-07-18 20:21:22 +0000,http://finance.yahoo.com/r/5f628fca-08eb-3907-9ad8-c6c201648f6b/could-this-biotech-stir-takeover-interest-after-cancer-drug-approval?src=A00220&yptr=yahoo&.tsrc=rss,"Puma stock rocketed to a 22-month high Tuesday on takeover speculation after the FDA approved the firm&apos;s breast cancer drug, Nerlynx."
PBYI,PBYI:UW,BBG002NFCGM3,Could This Biotech Stir Takeover Interest After Cancer Drug Approval?,2017-07-18 20:21:22 +0000,http://finance.yahoo.com/r/5f628fca-08eb-3907-9ad8-c6c201648f6b/could-this-biotech-stir-takeover-interest-after-cancer-drug-approval?src=A00220&yptr=yahoo&.tsrc=rss,"Puma stock rocketed to a 22-month high Tuesday on takeover speculation after the FDA approved the firm&apos;s breast cancer drug, Nerlynx."
PBYI,PBYI:US,BBG0018YXYX7,Tuesday's ETF with Unusual Volume: PTH,2017-07-18 19:03:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h8d_PPDAzas/tuesdays-etf-with-unusual-volume-pth-cm817662,The PowerShares DWA Healthcare Momentum Portfolio ETF PTH is seeing unusually high volume in afternoon trading Tuesday with over 83 000 shares traded versus three month average volume of about 27 000 Shares of PTH were up about 0 2 on the day Components of that ETF with the
PBYI,PBYI:UW,BBG002NFCGM3,Tuesday's ETF with Unusual Volume: PTH,2017-07-18 19:03:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h8d_PPDAzas/tuesdays-etf-with-unusual-volume-pth-cm817662,The PowerShares DWA Healthcare Momentum Portfolio ETF PTH is seeing unusually high volume in afternoon trading Tuesday with over 83 000 shares traded versus three month average volume of about 27 000 Shares of PTH were up about 0 2 on the day Components of that ETF with the
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Inc (PBYI) Drug Nerlynx Set To Hit The Market; J.P. Morgan Chimes In,2017-07-18 17:14:58 +0000,https://finance.yahoo.com/news/puma-biotechnology-inc-pbyi-drug-171458652.html?.tsrc=rss,"Puma Biotechnology Inc (NASDAQ:PBYI) has won FDA approval for its lead candidate Nerlynx (neratinib), sending shares up 9% in Tuesday's trading session. The drug treats breast cancer patients that are HER2 positive and reduces the risk of a relapse. According to the NCI, nearly 40,000 breast cancer patients across the United States are HER2-positive, accounting for 15% of all cancer patients."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Inc (PBYI) Drug Nerlynx Set To Hit The Market; J.P. Morgan Chimes In,2017-07-18 17:14:58 +0000,https://finance.yahoo.com/news/puma-biotechnology-inc-pbyi-drug-171458652.html?.tsrc=rss,"Puma Biotechnology Inc (NASDAQ:PBYI) has won FDA approval for its lead candidate Nerlynx (neratinib), sending shares up 9% in Tuesday's trading session. The drug treats breast cancer patients that are HER2 positive and reduces the risk of a relapse. According to the NCI, nearly 40,000 breast cancer patients across the United States are HER2-positive, accounting for 15% of all cancer patients."
PBYI,PBYI:UW,BBG002NFCGM3,"Notable Tuesday Option Activity: CASY, NYLD, PBYI",2017-07-18 17:02:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IvdkJin3jVk/notable-tuesday-option-activity-casy-nyld-pbyi-cm817584,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Casey s General Stores Inc Symbol CASY where a total volume of 3 200 contracts has been traded thus far today a contract volume which is representative of
PBYI,PBYI:US,BBG0018YXYX7,"Notable Tuesday Option Activity: CASY, NYLD, PBYI",2017-07-18 17:02:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IvdkJin3jVk/notable-tuesday-option-activity-casy-nyld-pbyi-cm817584,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Casey s General Stores Inc Symbol CASY where a total volume of 3 200 contracts has been traded thus far today a contract volume which is representative of
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech Wins Big on FDA Approval of Breast Cancer Treatment,2017-07-18 15:31:10 +0000,https://finance.yahoo.com/news/puma-biotech-wins-big-fda-153110235.html?.tsrc=rss,"Puma Biotechnology, Inc. (NASDAQ: PBYI) saw its shares touch a multiyear high on Tuesday after the firm reported a key approval by the U.S. Food and Drug Administration (FDA). Specifically, the agency ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech Wins Big on FDA Approval of Breast Cancer Treatment,2017-07-18 15:31:10 +0000,https://finance.yahoo.com/news/puma-biotech-wins-big-fda-153110235.html?.tsrc=rss,"Puma Biotechnology, Inc. (NASDAQ: PBYI) saw its shares touch a multiyear high on Tuesday after the firm reported a key approval by the U.S. Food and Drug Administration (FDA). Specifically, the agency ..."
PBYI,PBYI:UW,BBG002NFCGM3,Today's Research Reports on Trending Tickers: Puma Biotechnology Inc. and Novavax Inc.,2017-07-18 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000331.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / July 18, 2017 / U.S. markets were relatively quiet Monday as investors eagerly await the latest batch of corporate earnings. Bank of America Corp., General Electric Co., Goldman ..."
PBYI,PBYI:US,BBG0018YXYX7,Today's Research Reports on Trending Tickers: Puma Biotechnology Inc. and Novavax Inc.,2017-07-18 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000331.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / July 18, 2017 / U.S. markets were relatively quiet Monday as investors eagerly await the latest batch of corporate earnings. Bank of America Corp., General Electric Co., Goldman ..."
PBYI,PBYI:US,BBG0018YXYX7,"FDA Nod For PBYI, ANIK Sees 23-26% Revenue Growth, CBAY Abuzz, RPRX Plunges",2017-07-18 03:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ehAY7mKbIFs/fda-nod-for-pbyi-anik-sees-2326-revenue-growth-cbay-abuzz-rprx-plunges-20170718-00099,"FDA Nod For PBYI, ANIK Sees 23-26% Revenue Growth, CBAY Abuzz, RPRX Plunges"
PBYI,PBYI:UW,BBG002NFCGM3,"FDA Nod For PBYI, ANIK Sees 23-26% Revenue Growth, CBAY Abuzz, RPRX Plunges",2017-07-18 03:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d6iX_VkeCJo/fda-nod-for-pbyi-anik-sees-2326%25-revenue-growth-cbay-abuzz-rprx-plunges-20170718-00099,"FDA Nod For PBYI, ANIK Sees 23-26% Revenue Growth, CBAY Abuzz, RPRX Plunges"
PBYI,PBYI:US,BBG0018YXYX7,"FDA Nod For PBYI, ANIK Sees 23-26% Revenue Growth, CBAY Abuzz, RPRX Plunges",2017-07-18 03:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d6iX_VkeCJo/fda-nod-for-pbyi-anik-sees-2326%25-revenue-growth-cbay-abuzz-rprx-plunges-20170718-00099,"FDA Nod For PBYI, ANIK Sees 23-26% Revenue Growth, CBAY Abuzz, RPRX Plunges"
PBYI,PBYI:UW,BBG002NFCGM3,"FDA Nod For PBYI, ANIK Sees 23-26% Revenue Growth, CBAY Abuzz, RPRX Plunges",2017-07-18 03:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ehAY7mKbIFs/fda-nod-for-pbyi-anik-sees-2326-revenue-growth-cbay-abuzz-rprx-plunges-20170718-00099,"FDA Nod For PBYI, ANIK Sees 23-26% Revenue Growth, CBAY Abuzz, RPRX Plunges"
PBYI,PBYI:US,BBG0018YXYX7,Puma jumps after FDA approval of breast-cancer treatment,2017-07-17 23:17:08 +0000,http://finance.yahoo.com/r/4b42e951-6489-389b-9a43-b6816f0d3744/Story.aspx?guid=51B4BF6C-8BFC-407A-9E59-1A309BD1C4BD&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Puma Biotechnology Inc. jumped as much as 11.5% in late trading Monday after the company announced that the Food and Drug Administration had approved a breast-cancer treatment for medical use. The medicine, ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma jumps after FDA approval of breast-cancer treatment,2017-07-17 23:17:08 +0000,http://finance.yahoo.com/r/4b42e951-6489-389b-9a43-b6816f0d3744/Story.aspx?guid=51B4BF6C-8BFC-407A-9E59-1A309BD1C4BD&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Puma Biotechnology Inc. jumped as much as 11.5% in late trading Monday after the company announced that the Food and Drug Administration had approved a breast-cancer treatment for medical use. The medicine, ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma : FDA Okays New Treatment To Reduce Risk Of Breast Cancer Returning,2017-07-17 23:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oqxW_qcB-kY/puma--fda-okays-new-treatment-to-reduce-risk-of-breast-cancer-returning-20170717-01277,Puma : FDA Okays New Treatment To Reduce Risk Of Breast Cancer Returning
PBYI,PBYI:UW,BBG002NFCGM3,Puma : FDA Okays New Treatment To Reduce Risk Of Breast Cancer Returning,2017-07-17 23:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oqxW_qcB-kY/puma--fda-okays-new-treatment-to-reduce-risk-of-breast-cancer-returning-20170717-01277,Puma : FDA Okays New Treatment To Reduce Risk Of Breast Cancer Returning
PBYI,PBYI:US,BBG0018YXYX7,InPlay from Briefing.com,2017-07-17 21:52:47 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
PBYI,PBYI:UW,BBG002NFCGM3,InPlay from Briefing.com,2017-07-17 21:52:47 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
PBYI,PBYI:US,BBG0018YXYX7,U.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,2017-07-17 21:36:00 +0000,https://finance.yahoo.com/news/u-food-drug-administration-approves-213600322.html?.tsrc=rss,"Puma Biotechnology, Inc. today announced that the U.S. Food and Drug Administration has approved NERLYNX™ , formerly known as PB272, a once-daily oral tyrosine kinase inhibitor for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy."
PBYI,PBYI:UW,BBG002NFCGM3,U.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,2017-07-17 21:36:00 +0000,https://finance.yahoo.com/news/u-food-drug-administration-approves-213600322.html?.tsrc=rss,"Puma Biotechnology, Inc. today announced that the U.S. Food and Drug Administration has approved NERLYNX™ , formerly known as PB272, a once-daily oral tyrosine kinase inhibitor for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech Is up 181% This Year; Here's Why It Can Still Go Higher,2017-07-10 14:57:00 +0000,http://finance.yahoo.com/r/1fa19480-69ba-308a-b36c-b8bafcfc7abf/puma-biotech-is-up-181-this-year-heres-why-it-can-still-go-higher-1499698685?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Puma Biotechnology (PBYI) is up more than 181% since the start of the year, but that doesn't mean that the rally is over, argues Leerink.  Analyst Michael Schmidt resumed coverage of the stock with an Outperform rating and $115 price target on Monday.  Detail from the note:  Based on our analysis we believe regulatory approval of neratinib in the extended adjuvant treatment setting is highly likely."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech Is up 181% This Year; Here's Why It Can Still Go Higher,2017-07-10 14:57:00 +0000,http://finance.yahoo.com/r/1fa19480-69ba-308a-b36c-b8bafcfc7abf/puma-biotech-is-up-181-this-year-heres-why-it-can-still-go-higher-1499698685?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Puma Biotechnology (PBYI) is up more than 181% since the start of the year, but that doesn't mean that the rally is over, argues Leerink.  Analyst Michael Schmidt resumed coverage of the stock with an Outperform rating and $115 price target on Monday.  Detail from the note:  Based on our analysis we believe regulatory approval of neratinib in the extended adjuvant treatment setting is highly likely."
PBYI,PBYI:UW,BBG002NFCGM3,Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial,2017-07-07 13:30:01 +0000,https://finance.yahoo.com/news/puma-pbyi-ends-patient-enrollment-133001841.html?.tsrc=rss,"Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer."
PBYI,PBYI:US,BBG0018YXYX7,Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial,2017-07-07 13:30:01 +0000,https://finance.yahoo.com/news/puma-pbyi-ends-patient-enrollment-133001841.html?.tsrc=rss,"Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer."
PBYI,PBYI:US,BBG0018YXYX7,"BMY's Orencia Scores Another FDA Nod, Janssen Ends Deal With CAPR, PBYI On Track",2017-07-07 01:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/grM11UAzP9M/bmys-orencia-scores-another-fda-nod-janssen-ends-deal-with-capr-pbyi-on-track-20170707-00017,"BMY's Orencia Scores Another FDA Nod, Janssen Ends Deal With CAPR, PBYI On Track"
PBYI,PBYI:UW,BBG002NFCGM3,"BMY's Orencia Scores Another FDA Nod, Janssen Ends Deal With CAPR, PBYI On Track",2017-07-07 01:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/grM11UAzP9M/bmys-orencia-scores-another-fda-nod-janssen-ends-deal-with-capr-pbyi-on-track-20170707-00017,"BMY's Orencia Scores Another FDA Nod, Janssen Ends Deal With CAPR, PBYI On Track"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial,2017-07-06 20:15:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-completes-targeted-enrollment-201500297.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that targeted patient enrollment in the Phase III NALA trial of the Company's lead drug candidate PB272 in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments in the setting of metastatic disease has been completed."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial,2017-07-06 20:15:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-completes-targeted-enrollment-201500297.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that targeted patient enrollment in the Phase III NALA trial of the Company's lead drug candidate PB272 in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments in the setting of metastatic disease has been completed."
PBYI,PBYI:UW,BBG002NFCGM3,Key FDA Events to Watch Out for in Jul 2017,2017-07-03 13:47:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/so-gVBAE_RE/key-fda-events-to-watch-out-for-in-jul-2017-cm811144,Halfway into the year and the FDA has already crossed its total tally of 22 approvals in 2016 So far in 2017 the FDA has given its nod to 23 novel drugs including 2 in June Key approvals so far in 2017 include Regeneron Sanofi s Kevzara rheumatoid arthritis Roche s multiple
PBYI,PBYI:US,BBG0018YXYX7,Key FDA Events to Watch Out for in Jul 2017,2017-07-03 13:47:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/so-gVBAE_RE/key-fda-events-to-watch-out-for-in-jul-2017-cm811144,Halfway into the year and the FDA has already crossed its total tally of 22 approvals in 2016 So far in 2017 the FDA has given its nod to 23 novel drugs including 2 in June Key approvals so far in 2017 include Regeneron Sanofi s Kevzara rheumatoid arthritis Roche s multiple
PBYI,PBYI:UW,BBG002NFCGM3,Are Options Traders Betting on a Big Move in Puma Biotechnology (PBYI) Stock?,2017-07-03 12:43:12 +0000,https://finance.yahoo.com/news/options-traders-betting-big-move-124312043.html?.tsrc=rss,"Investors in Puma Biotechnology, Inc. (PBYI) need to pay close attention to the stock based on moves in the options market lately."
PBYI,PBYI:US,BBG0018YXYX7,Are Options Traders Betting on a Big Move in Puma Biotechnology (PBYI) Stock?,2017-07-03 12:43:12 +0000,https://finance.yahoo.com/news/options-traders-betting-big-move-124312043.html?.tsrc=rss,"Investors in Puma Biotechnology, Inc. (PBYI) need to pay close attention to the stock based on moves in the options market lately."
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Puma Biotechnology, Inc. to Contact the Firm",2017-06-29 20:30:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-lead-plaintiff-deadline-203000448.html?.tsrc=rss,"Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors Puma Biotechnology, Inc. of the July 7, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Puma Biotechnology, Inc. to Contact the Firm",2017-06-29 20:30:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-lead-plaintiff-deadline-203000448.html?.tsrc=rss,"Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors Puma Biotechnology, Inc. of the July 7, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company."
PBYI,PBYI:US,BBG0018YXYX7,Biotech Stocks Facing FDA Decision In July,2017-06-29 00:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pgpziX5aPwc/biotech-stocks-facing-fda-decision-in-july-20170629-00014,Biotech Stocks Facing FDA Decision In July
PBYI,PBYI:UW,BBG002NFCGM3,Biotech Stocks Facing FDA Decision In July,2017-06-29 00:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pgpziX5aPwc/biotech-stocks-facing-fda-decision-in-july-20170629-00014,Biotech Stocks Facing FDA Decision In July
PBYI,PBYI:UW,BBG002NFCGM3,5 Biotech Stocks With Major Catalysts in July,2017-06-28 20:22:00 +0000,http://finance.yahoo.com/r/66aab481-87c1-3787-a38f-26ad86dee364/5-biotech-stocks-with-major-catalysts-in-july.aspx?yptr=yahoo&.tsrc=rss,"Big news is on the way soon for AcelRx, Alnylam, Amgen, Dynavax, and Merck."
PBYI,PBYI:US,BBG0018YXYX7,5 Biotech Stocks With Major Catalysts in July,2017-06-28 20:22:00 +0000,http://finance.yahoo.com/r/66aab481-87c1-3787-a38f-26ad86dee364/5-biotech-stocks-with-major-catalysts-in-july.aspx?yptr=yahoo&.tsrc=rss,"Big news is on the way soon for AcelRx, Alnylam, Amgen, Dynavax, and Merck."
PBYI,PBYI:UW,BBG002NFCGM3,AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use,2017-06-27 16:52:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fpC77U1mUg8/astrazenecas-faslodex-recommended-by-chmp-for-1st-line-use-cm808905,AstraZeneca PLC AZN announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has adopted a positive opinion recommending the marketing authorisation of Faslodex fulvestrant for 1st line treatment for postmenopausal women with HR
PBYI,PBYI:US,BBG0018YXYX7,AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use,2017-06-27 16:52:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fpC77U1mUg8/astrazenecas-faslodex-recommended-by-chmp-for-1st-line-use-cm808905,AstraZeneca PLC AZN announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has adopted a positive opinion recommending the marketing authorisation of Faslodex fulvestrant for 1st line treatment for postmenopausal women with HR
PBYI,PBYI:UW,BBG002NFCGM3,5 Best Biotech Stocks of 2017 So Far,2017-06-25 18:01:00 +0000,http://finance.yahoo.com/r/87deddbe-1f8b-3e81-8ff4-c80467e2f63f/5-best-biotech-stocks-of-2017-so-far.aspx?yptr=yahoo&.tsrc=rss,"How Alnylam, Puma, Immunogen, Sangamo, and Calithera beat all others to be the best biotech stocks of the year so far."
PBYI,PBYI:US,BBG0018YXYX7,5 Best Biotech Stocks of 2017 So Far,2017-06-25 18:01:00 +0000,http://finance.yahoo.com/r/87deddbe-1f8b-3e81-8ff4-c80467e2f63f/5-best-biotech-stocks-of-2017-so-far.aspx?yptr=yahoo&.tsrc=rss,"How Alnylam, Puma, Immunogen, Sangamo, and Calithera beat all others to be the best biotech stocks of the year so far."
PBYI,PBYI:UW,BBG002NFCGM3,3 Biotech Stocks That More than Doubled Year to Date,2017-06-19 15:25:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8kKdR_t4FAE/3-biotech-stocks-that-more-than-doubled-year-to-date-cm805064,We are almost half way through 2017 and the biotech sector which had a rough and challenging 2016 has been showing signs of recovery despite some ups and downs Year to date YTD the NASDAQ Biotechnology Index is up 10 4 providing a glimmer of hope to biotech investors who saw the
PBYI,PBYI:US,BBG0018YXYX7,3 Biotech Stocks That More than Doubled Year to Date,2017-06-19 15:25:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8kKdR_t4FAE/3-biotech-stocks-that-more-than-doubled-year-to-date-cm805064,We are almost half way through 2017 and the biotech sector which had a rough and challenging 2016 has been showing signs of recovery despite some ups and downs Year to date YTD the NASDAQ Biotechnology Index is up 10 4 providing a glimmer of hope to biotech investors who saw the
PBYI,PBYI:UW,BBG002NFCGM3,10 Stocks Ready for a BIG Move – In Either Direction,2017-06-16 01:07:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aUg2cvK_5O8/10-stocks-ready-for-a-big-move-in-either-direction-cm804174,InvestorPlace Stock Market News Stock Advice amp Trading Tips Despite what headlines might otherwise indicate 2017 has been a quiet albeit positive year for the stock market so far Volatility as measured by the CBOE Volatility Index aka the VIX has been at multiyear lows
PBYI,PBYI:US,BBG0018YXYX7,10 Stocks Ready for a BIG Move – In Either Direction,2017-06-16 01:07:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aUg2cvK_5O8/10-stocks-ready-for-a-big-move-in-either-direction-cm804174,InvestorPlace Stock Market News Stock Advice amp Trading Tips Despite what headlines might otherwise indicate 2017 has been a quiet albeit positive year for the stock market so far Volatility as measured by the CBOE Volatility Index aka the VIX has been at multiyear lows
PBYI,PBYI:US,BBG0018YXYX7,Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval,2017-06-15 21:24:09 +0000,https://finance.yahoo.com/news/puma-pbyi-stock-surges-neratinib-212409083.html?.tsrc=rss,Puma&apos;s stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry in the year so far after an FDA advisory committee recommended approval for neratinib in May this year.
PBYI,PBYI:UW,BBG002NFCGM3,Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval,2017-06-15 21:24:09 +0000,https://finance.yahoo.com/news/puma-pbyi-stock-surges-neratinib-212409083.html?.tsrc=rss,Puma&apos;s stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry in the year so far after an FDA advisory committee recommended approval for neratinib in May this year.
PBYI,PBYI:UW,BBG002NFCGM3,"The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017",2017-06-13 15:57:00 +0000,https://finance.yahoo.com/news/klein-law-firm-reminds-investors-155700014.html?.tsrc=rss,"The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Puma Biotechnology, Inc. who purchased shares between February 29, 2016 and May 4, 2017."
PBYI,PBYI:US,BBG0018YXYX7,"The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017",2017-06-13 15:57:00 +0000,https://finance.yahoo.com/news/klein-law-firm-reminds-investors-155700014.html?.tsrc=rss,"The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Puma Biotechnology, Inc. who purchased shares between February 29, 2016 and May 4, 2017."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Puma Biotechnology, Inc. to Contact the Firm",2017-06-12 20:10:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-lead-plaintiff-deadline-201000504.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 12, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors Puma Biotechnology, Inc. (""Puma Biotechnology"" or the ""Company"") ..."
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Puma Biotechnology, Inc. to Contact the Firm",2017-06-12 20:10:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-lead-plaintiff-deadline-201000504.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 12, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors Puma Biotechnology, Inc. (""Puma Biotechnology"" or the ""Company"") ..."
PBYI,PBYI:US,BBG0018YXYX7,"The Klein Law Firm Announces a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017",2017-06-12 15:56:00 +0000,https://finance.yahoo.com/news/klein-law-firm-announces-class-155600980.html?.tsrc=rss,"The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Puma Biotechnology, Inc. who purchased shares between February 29, 2016 and May 4, 2017."
PBYI,PBYI:UW,BBG002NFCGM3,"The Klein Law Firm Announces a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017",2017-06-12 15:56:00 +0000,https://finance.yahoo.com/news/klein-law-firm-announces-class-155600980.html?.tsrc=rss,"The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Puma Biotechnology, Inc. who purchased shares between February 29, 2016 and May 4, 2017."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI",2017-06-09 23:35:00 +0000,https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-233500904.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 9, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Puma Biotechnology, Inc. (""Puma"" or the ""Company"") (NASDAQ: PBYI) ..."
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI",2017-06-09 23:35:00 +0000,https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-233500904.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 9, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Puma Biotechnology, Inc. (""Puma"" or the ""Company"") (NASDAQ: PBYI) ..."
PBYI,PBYI:US,BBG0018YXYX7,"PBYI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017",2017-06-08 15:47:00 +0000,https://finance.yahoo.com/news/pbyi-shareholder-alert-law-offices-154700981.html?.tsrc=rss,"The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc."
PBYI,PBYI:UW,BBG002NFCGM3,"PBYI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017",2017-06-08 15:47:00 +0000,https://finance.yahoo.com/news/pbyi-shareholder-alert-law-offices-154700981.html?.tsrc=rss,"The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc."
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017",2017-06-07 14:39:00 +0000,https://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-143900855.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 7, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Puma Biotechnology, Inc. (""Puma"" or the ""Company"") ..."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017",2017-06-07 14:39:00 +0000,https://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-143900855.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 7, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Puma Biotechnology, Inc. (""Puma"" or the ""Company"") ..."
PBYI,PBYI:US,BBG0018YXYX7,Finish Line Inc (FINL) and Puma Biotech Inc (PBYI) Lead 15 Notable Investor Filings,2017-06-06 21:16:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9IepgF-mZuY/finish-line-inc-finl-and-puma-biotech-inc-pbyi-lead-15-notable-investor-filings-cm799678,InvestorPlace Stock Market News Stock Advice amp Trading Tips There were 15 notable investor filings today and 160 Finish Line Inc NASDAQ FINL is the largest company of interest When a person or group of persons acquires beneficial
PBYI,PBYI:UW,BBG002NFCGM3,Finish Line Inc (FINL) and Puma Biotech Inc (PBYI) Lead 15 Notable Investor Filings,2017-06-06 21:16:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9IepgF-mZuY/finish-line-inc-finl-and-puma-biotech-inc-pbyi-lead-15-notable-investor-filings-cm799678,InvestorPlace Stock Market News Stock Advice amp Trading Tips There were 15 notable investor filings today and 160 Finish Line Inc NASDAQ FINL is the largest company of interest When a person or group of persons acquires beneficial
PBYI,PBYI:US,BBG0018YXYX7,"3 Takeaways From Monday's ASCO Meetings: Puma Biotech, Incyte, Celgene",2017-06-06 20:34:08 +0000,https://finance.yahoo.com/news/3-takeaways-mondays-asco-meetings-203408835.html?.tsrc=rss,The American Society of Clinical Oncology’s annual meeting ended Tuesday. The event was filled with updates on clinical trials and research. Credit Suisse analyst Alethia Young released her key findings ...
PBYI,PBYI:UW,BBG002NFCGM3,"3 Takeaways From Monday's ASCO Meetings: Puma Biotech, Incyte, Celgene",2017-06-06 20:34:08 +0000,https://finance.yahoo.com/news/3-takeaways-mondays-asco-meetings-203408835.html?.tsrc=rss,The American Society of Clinical Oncology’s annual meeting ended Tuesday. The event was filled with updates on clinical trials and research. Credit Suisse analyst Alethia Young released her key findings ...
PBYI,PBYI:UW,BBG002NFCGM3,"Tesla Seen Rising 26% In Model 3 &apos;Bull Case&apos;; Puma, Microchip, Ulta Price Targets Hiked",2017-06-06 20:04:24 +0000,http://finance.yahoo.com/r/ff89e9c7-cedc-3245-96ab-20a300e640e3/tesla-rates-bull-case-on-model-3-puma-microchip-price-targets-hiked?src=A00220&yptr=yahoo&.tsrc=rss,"Tesla shares could rise 26%, Pacific Crest said, assuming that Model 3 demand will top estimates. Analysts raised price targets on Puma Biotech, Microchip and Ulta Beauty."
PBYI,PBYI:US,BBG0018YXYX7,"Tesla Seen Rising 26% In Model 3 &apos;Bull Case&apos;; Puma, Microchip, Ulta Price Targets Hiked",2017-06-06 20:04:24 +0000,http://finance.yahoo.com/r/ff89e9c7-cedc-3245-96ab-20a300e640e3/tesla-rates-bull-case-on-model-3-puma-microchip-price-targets-hiked?src=A00220&yptr=yahoo&.tsrc=rss,"Tesla shares could rise 26%, Pacific Crest said, assuming that Model 3 demand will top estimates. Analysts raised price targets on Puma Biotech, Microchip and Ulta Beauty."
PBYI,PBYI:US,BBG0018YXYX7,"Company News for June 06, 2017",2017-06-06 15:18:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xw7032RNlUI/company-news-for-june-06-2017-cm799397,160 160 160 Shares of Herbalife Ltd HLF declined 6 6 after the company projected revenues to decline between 2 and 6 for the second quarter higher than its previous projected declines of 0 5 to 4 5 160 160 160 Pandora Media Inc s P shares gained 1 9 after reports
PBYI,PBYI:UW,BBG002NFCGM3,"Company News for June 06, 2017",2017-06-06 15:18:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xw7032RNlUI/company-news-for-june-06-2017-cm799397,160 160 160 Shares of Herbalife Ltd HLF declined 6 6 after the company projected revenues to decline between 2 and 6 for the second quarter higher than its previous projected declines of 0 5 to 4 5 160 160 160 Pandora Media Inc s P shares gained 1 9 after reports
PBYI,PBYI:US,BBG0018YXYX7,"Corporate News Blog - Puma Biotech Announced Positive Results from PB272 Phase-II Data at the ASCO, 2017",2017-06-06 12:15:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-puma-biotech-121500287.html?.tsrc=rss,"Research Desk Line-up: Tesaro Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 6, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for biopharmaceutical ..."
PBYI,PBYI:UW,BBG002NFCGM3,"Corporate News Blog - Puma Biotech Announced Positive Results from PB272 Phase-II Data at the ASCO, 2017",2017-06-06 12:15:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-puma-biotech-121500287.html?.tsrc=rss,"Research Desk Line-up: Tesaro Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 6, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for biopharmaceutical ..."
PBYI,PBYI:US,BBG0018YXYX7,"INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017",2017-06-05 18:14:00 +0000,https://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-181400590.html?.tsrc=rss,"The following statement is being issued by Levi & Korsinsky, LLP:"
PBYI,PBYI:UW,BBG002NFCGM3,"INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017",2017-06-05 18:14:00 +0000,https://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-181400590.html?.tsrc=rss,"The following statement is being issued by Levi & Korsinsky, LLP:"
PBYI,PBYI:US,BBG0018YXYX7,Pfizer Provides Final Update on Phase II Talazoparib Study,2017-06-05 17:03:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vf13TjdWlh8/pfizer-provides-final-update-on-phase-ii-talazoparib-study-cm798793,Pfizer Inc PFE announced data from its phase II study ABRAZO which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1 2 positive gBRCA mutations showing anti tumor activity The results were presented at the Annual Meeting of the American Society of
PBYI,PBYI:UW,BBG002NFCGM3,Pfizer Provides Final Update on Phase II Talazoparib Study,2017-06-05 17:03:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vf13TjdWlh8/pfizer-provides-final-update-on-phase-ii-talazoparib-study-cm798793,Pfizer Inc PFE announced data from its phase II study ABRAZO which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1 2 positive gBRCA mutations showing anti tumor activity The results were presented at the Annual Meeting of the American Society of
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Holding On To Strong Gain In Afternoon Trading,2017-06-05 13:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NEtHz7T_LkY/puma-biotechnology-holding-on-to-strong-gain-in-afternoon-trading-20170605-00955,Puma Biotechnology Holding On To Strong Gain In Afternoon Trading
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Holding On To Strong Gain In Afternoon Trading,2017-06-05 13:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NEtHz7T_LkY/puma-biotechnology-holding-on-to-strong-gain-in-afternoon-trading-20170605-00955,Puma Biotechnology Holding On To Strong Gain In Afternoon Trading
PBYI,PBYI:UW,BBG002NFCGM3,Lawsuit for Investors in (NASDAQ: PBYI) Shares Against Puma Biotechnology Inc. Announced by Shareholders Foundation,2017-06-05 13:20:00 +0000,https://finance.yahoo.com/news/lawsuit-investors-nasdaq-pbyi-shares-132000482.html?.tsrc=rss,"SAN DIEGO, CA / ACCESSWIRE / June 5, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for investors who purchased (NASDAQ: PBYI) shares against Puma Biotechnology Inc. over alleged ..."
PBYI,PBYI:US,BBG0018YXYX7,Lawsuit for Investors in (NASDAQ: PBYI) Shares Against Puma Biotechnology Inc. Announced by Shareholders Foundation,2017-06-05 13:20:00 +0000,https://finance.yahoo.com/news/lawsuit-investors-nasdaq-pbyi-shares-132000482.html?.tsrc=rss,"SAN DIEGO, CA / ACCESSWIRE / June 5, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for investors who purchased (NASDAQ: PBYI) shares against Puma Biotechnology Inc. over alleged ..."
PBYI,PBYI:US,BBG0018YXYX7,"Pre-Market Most Active for Jun 5, 2017 :  FOR, SMFG, TOT, NOK, AAPL, PBYI, BABA, JCP, TLT, LOXO, QQQ, GLYC",2017-06-05 12:59:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fID82DnjtzY/pre-market-most-active-for-jun-5-2017-for-smfg-tot-nok-aapl-pbyi-baba-jcp-tlt-loxo-qqq-glyc-cm798535,The NASDAQ 100 Pre Market Indicator is down 4 61 to 5 876 85 The total Pre Market volume is currently 7 901 646 shares traded The following are the most active stocks for the pre market session Forestar Group Inc FOR is 1 85 at 16 05 with 2 192 385 shares traded
PBYI,PBYI:UW,BBG002NFCGM3,"Pre-Market Most Active for Jun 5, 2017 :  FOR, SMFG, TOT, NOK, AAPL, PBYI, BABA, JCP, TLT, LOXO, QQQ, GLYC",2017-06-05 12:59:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fID82DnjtzY/pre-market-most-active-for-jun-5-2017-for-smfg-tot-nok-aapl-pbyi-baba-jcp-tlt-loxo-qqq-glyc-cm798535,The NASDAQ 100 Pre Market Indicator is down 4 61 to 5 876 85 The total Pre Market volume is currently 7 901 646 shares traded The following are the most active stocks for the pre market session Forestar Group Inc FOR is 1 85 at 16 05 with 2 192 385 shares traded
PBYI,PBYI:UW,BBG002NFCGM3,"'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio",2017-06-05 11:30:00 +0000,http://finance.yahoo.com/r/d5438cff-ab8c-301f-9334-97f32647c24c/aphinity-study-spells-trouble-for-roche-another-win-for-puma-bio.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,This will be the investors' verdict on the results of Roche's APHINITY study of Perjeta in adjuvant breast cancer treatment that were released Monday morning.
PBYI,PBYI:US,BBG0018YXYX7,"'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio",2017-06-05 11:30:00 +0000,http://finance.yahoo.com/r/d5438cff-ab8c-301f-9334-97f32647c24c/aphinity-study-spells-trouble-for-roche-another-win-for-puma-bio.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,This will be the investors' verdict on the results of Roche's APHINITY study of Perjeta in adjuvant breast cancer treatment that were released Monday morning.
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting,2017-06-03 19:50:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-announces-positive-pb272-195000373.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced the presentation of positive results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 for the treatment of HER2-positive metastatic breast cancer that has metastasized to the brain."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting,2017-06-03 19:50:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-announces-positive-pb272-195000373.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced the presentation of positive results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 for the treatment of HER2-positive metastatic breast cancer that has metastasized to the brain."
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI",2017-06-03 00:00:00 +0000,https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-000000651.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 2, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Puma Biotechnology, Inc. (""Puma"" or the ""Company"") (NASDAQ: PBYI) ..."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI",2017-06-03 00:00:00 +0000,https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-000000651.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 2, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Puma Biotechnology, Inc. (""Puma"" or the ""Company"") (NASDAQ: PBYI) ..."
PBYI,PBYI:US,BBG0018YXYX7,"PBYI INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017",2017-06-02 16:52:00 +0000,https://finance.yahoo.com/news/pbyi-investor-alert-law-offices-165200950.html?.tsrc=rss,"The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc."
PBYI,PBYI:UW,BBG002NFCGM3,"PBYI INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017",2017-06-02 16:52:00 +0000,https://finance.yahoo.com/news/pbyi-investor-alert-law-offices-165200950.html?.tsrc=rss,"The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc."
PBYI,PBYI:UW,BBG002NFCGM3,"Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day",2017-06-02 15:34:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pCN4L1oo3ZA/universal-display-hewlett-packard-regeneron-pharmaceuticals-sangamo-therapeutics-and-puma-biotechnology-highlighted-as-zacks-bull-and-bear-of-the-day-cm798056,For Immediate Release Chicago IL June 02 2017 Zacks Equity Research highlights Universal Display Corporation NASDAQ OLED Free Report as the Bull of the Day Hewlett Packard Enterprise NYSE HPE Free Report as the Bear of the Day In addition Zacks Equity Research
PBYI,PBYI:US,BBG0018YXYX7,"Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day",2017-06-02 15:34:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pCN4L1oo3ZA/universal-display-hewlett-packard-regeneron-pharmaceuticals-sangamo-therapeutics-and-puma-biotechnology-highlighted-as-zacks-bull-and-bear-of-the-day-cm798056,For Immediate Release Chicago IL June 02 2017 Zacks Equity Research highlights Universal Display Corporation NASDAQ OLED Free Report as the Bull of the Day Hewlett Packard Enterprise NYSE HPE Free Report as the Bear of the Day In addition Zacks Equity Research
PBYI,PBYI:US,BBG0018YXYX7,"Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day",2017-06-02 13:30:01 +0000,https://finance.yahoo.com/news/universal-display-hewlett-packard-regeneron-133001659.html?.tsrc=rss,"Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day"
PBYI,PBYI:UW,BBG002NFCGM3,"Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day",2017-06-02 13:30:01 +0000,https://finance.yahoo.com/news/universal-display-hewlett-packard-regeneron-133001659.html?.tsrc=rss,"Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day"
PBYI,PBYI:UW,BBG002NFCGM3,"Notable Thursday Option Activity: XBIT, BOX, PBYI",2017-06-01 21:32:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/okjc-ogV8Xc/notable-thursday-option-activity-xbit-box-pbyi-cm797689,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in XBiotech Inc Symbol XBIT where a total volume of 657 contracts has been traded thus far today a contract volume which is representative of approximately 65 700
PBYI,PBYI:US,BBG0018YXYX7,"Notable Thursday Option Activity: XBIT, BOX, PBYI",2017-06-01 21:32:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/okjc-ogV8Xc/notable-thursday-option-activity-xbit-box-pbyi-cm797689,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in XBiotech Inc Symbol XBIT where a total volume of 657 contracts has been traded thus far today a contract volume which is representative of approximately 65 700
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm",2017-06-01 20:29:36 +0000,https://finance.yahoo.com/news/puma-biotechnology-lead-plaintiff-deadline-202936366.html?.tsrc=rss,"NEW YORK, June 01, 2017-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Puma Biotechnology, Inc. of the July 7, 2017 deadline to seek the role of lead plaintiff in ..."
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm",2017-06-01 20:29:36 +0000,https://finance.yahoo.com/news/puma-biotechnology-lead-plaintiff-deadline-202936366.html?.tsrc=rss,"NEW YORK, June 01, 2017-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Puma Biotechnology, Inc. of the July 7, 2017 deadline to seek the role of lead plaintiff in ..."
PBYI,PBYI:UW,BBG002NFCGM3,3 Hot Biotech Stocks to Buy in June,2017-06-01 15:36:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P8ADeZVIerw/3-hot-biotech-stocks-to-buy-in-june-cm797435,The biotech sector which started the year on a strong note has been witnessing a decline especially from March year to date YTD the Zacks categorized Medical Biomedical Genetics industry is down 1 1 while the overall market is up 8 2 A key concern for the sector remains the drug
PBYI,PBYI:US,BBG0018YXYX7,3 Hot Biotech Stocks to Buy in June,2017-06-01 15:36:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P8ADeZVIerw/3-hot-biotech-stocks-to-buy-in-june-cm797435,The biotech sector which started the year on a strong note has been witnessing a decline especially from March year to date YTD the Zacks categorized Medical Biomedical Genetics industry is down 1 1 while the overall market is up 8 2 A key concern for the sector remains the drug
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Present at the Jefferies 2017 Healthcare Conference,2017-05-31 20:17:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-present-jefferies-2017-201700851.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:00 a.m."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Present at the Jefferies 2017 Healthcare Conference,2017-05-31 20:17:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-present-jefferies-2017-201700851.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:00 a.m."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017",2017-05-30 14:59:00 +0000,https://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-145900877.html?.tsrc=rss,"The following statement is being issued by Levi & Korsinsky, LLP:"
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017",2017-05-30 14:59:00 +0000,https://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-145900877.html?.tsrc=rss,"The following statement is being issued by Levi & Korsinsky, LLP:"
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI",2017-05-26 23:00:00 +0000,https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-230000050.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 26, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Puma Biotechnology, Inc. (""Puma"" or the ""Company"") (NASDAQ: PBYI) ..."
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI",2017-05-26 23:00:00 +0000,https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-230000050.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 26, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Puma Biotechnology, Inc. (""Puma"" or the ""Company"") (NASDAQ: PBYI) ..."
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Soaring After Neratinib FDA Panel Win, Time to Buy?",2017-05-26 15:35:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yaybNYrEbpk/puma-soaring-after-neratinib-fda-panel-win-time-to-buy-cm795230,Shares of 160 Puma Biotechnology Inc PBYI have risen 35 since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate neratinib for the treatment of some breast cancers In fact on Thursday the stock hit a new 52 week high of 80 00
PBYI,PBYI:US,BBG0018YXYX7,"Puma Soaring After Neratinib FDA Panel Win, Time to Buy?",2017-05-26 15:35:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yaybNYrEbpk/puma-soaring-after-neratinib-fda-panel-win-time-to-buy-cm795230,Shares of 160 Puma Biotechnology Inc PBYI have risen 35 since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate neratinib for the treatment of some breast cancers In fact on Thursday the stock hit a new 52 week high of 80 00
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Soaring After Neratinib FDA Panel Win, Time to Buy?",2017-05-26 13:48:01 +0000,https://finance.yahoo.com/news/puma-soaring-neratinib-fda-panel-134801014.html?.tsrc=rss,"Shares of Puma Biotechnology, Inc. (PBYI) have risen 35% since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate, neratinib for the treatment of some breast cancers."
PBYI,PBYI:US,BBG0018YXYX7,"Puma Soaring After Neratinib FDA Panel Win, Time to Buy?",2017-05-26 13:48:01 +0000,https://finance.yahoo.com/news/puma-soaring-neratinib-fda-panel-134801014.html?.tsrc=rss,"Shares of Puma Biotechnology, Inc. (PBYI) have risen 35% since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate, neratinib for the treatment of some breast cancers."
PBYI,PBYI:US,BBG0018YXYX7,Will Puma Biotechnology (PBYI) Continue to Surge Higher?,2017-05-26 13:35:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k3ZjYv0eGZE/will-puma-biotechnology-pbyi-continue-to-surge-higher-cm795030,As of late it has definitely been a great time to be an investor in Puma Biotechnology Inc PBYI The stock has moved higher by 97 2 in the past month while it is also above its 20 Day SMA too This combination of strong price performance and favorable technical could suggest that the
PBYI,PBYI:UW,BBG002NFCGM3,Will Puma Biotechnology (PBYI) Continue to Surge Higher?,2017-05-26 13:35:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k3ZjYv0eGZE/will-puma-biotechnology-pbyi-continue-to-surge-higher-cm795030,As of late it has definitely been a great time to be an investor in Puma Biotechnology Inc PBYI The stock has moved higher by 97 2 in the past month while it is also above its 20 Day SMA too This combination of strong price performance and favorable technical could suggest that the
PBYI,PBYI:US,BBG0018YXYX7,Will Puma Biotechnology (PBYI) Continue to Surge Higher?,2017-05-26 11:11:11 +0000,https://finance.yahoo.com/news/puma-biotechnology-pbyi-continue-surge-111111956.html?.tsrc=rss,"As of late, it has definitely been a great time to be an investor in Puma Biotechnology Inc (PBYI)."
PBYI,PBYI:UW,BBG002NFCGM3,Will Puma Biotechnology (PBYI) Continue to Surge Higher?,2017-05-26 11:11:11 +0000,https://finance.yahoo.com/news/puma-biotechnology-pbyi-continue-surge-111111956.html?.tsrc=rss,"As of late, it has definitely been a great time to be an investor in Puma Biotechnology Inc (PBYI)."
PBYI,PBYI:UW,BBG002NFCGM3,"Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential",2017-05-25 15:18:00 +0000,http://finance.yahoo.com/r/9155ac3a-c955-37f6-88a2-f2f47c1c0240/bullish-puma-investor-talks-neratinb-fda-panel-win-next-steps-and-takeout-potential.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.
PBYI,PBYI:US,BBG0018YXYX7,"Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential",2017-05-25 15:18:00 +0000,http://finance.yahoo.com/r/9155ac3a-c955-37f6-88a2-f2f47c1c0240/bullish-puma-investor-talks-neratinb-fda-panel-win-next-steps-and-takeout-potential.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.
PBYI,PBYI:UW,BBG002NFCGM3,"INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 - PBYI",2017-05-25 14:36:00 +0000,https://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-143600577.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 25, 2017 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, ..."
PBYI,PBYI:US,BBG0018YXYX7,"INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 - PBYI",2017-05-25 14:36:00 +0000,https://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-143600577.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 25, 2017 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, ..."
PBYI,PBYI:US,BBG0018YXYX7,Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring,2017-05-25 13:37:00 +0000,http://finance.yahoo.com/r/4ca490ff-7b9e-3b6d-82f5-b5b737589f5d/biotech-movers-positive-phase-three-results-for-roclatan-send-aerie-shares-soaring.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Aerie Pharmaceuticals, BioCryst Pharmaceuticals and GW Pharmaceuticals were among the biotech movers in premarket trading on Thursday."
PBYI,PBYI:UW,BBG002NFCGM3,Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring,2017-05-25 13:37:00 +0000,http://finance.yahoo.com/r/4ca490ff-7b9e-3b6d-82f5-b5b737589f5d/biotech-movers-positive-phase-three-results-for-roclatan-send-aerie-shares-soaring.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Aerie Pharmaceuticals, BioCryst Pharmaceuticals and GW Pharmaceuticals were among the biotech movers in premarket trading on Thursday."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session,2017-05-25 13:34:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c-U1fF4ppFY/puma-biotechnology-pbyi-jumps-stock-adds-297-in-session-cm794508,Puma Biotechnology Inc PBYI was a big mover last session as its shares rose over 30 on the day The move came after the Food and Drug Administration FDA advisory committee voted 12 4 recommending that Puma s breast cancer drug neratinib be approved This also led to far more shares
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session,2017-05-25 13:34:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c-U1fF4ppFY/puma-biotechnology-pbyi-jumps-stock-adds-297-in-session-cm794508,Puma Biotechnology Inc PBYI was a big mover last session as its shares rose over 30 on the day The move came after the Food and Drug Administration FDA advisory committee voted 12 4 recommending that Puma s breast cancer drug neratinib be approved This also led to far more shares
PBYI,PBYI:UW,BBG002NFCGM3,Biotech And Pharma Industry And Stock News,2017-05-25 12:43:44 +0000,http://finance.yahoo.com/r/d95a9140-bcb4-38ab-b942-e0c45662051a/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead?src=A00220&yptr=yahoo&.tsrc=rss,Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
PBYI,PBYI:US,BBG0018YXYX7,Biotech And Pharma Industry And Stock News,2017-05-25 12:43:44 +0000,http://finance.yahoo.com/r/d95a9140-bcb4-38ab-b942-e0c45662051a/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead?src=A00220&yptr=yahoo&.tsrc=rss,Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session,2017-05-25 12:15:12 +0000,https://finance.yahoo.com/news/puma-biotechnology-pbyi-jumps-stock-121512392.html?.tsrc=rss,"Puma Biotechnology, Inc. (PBYI) moved big last session, as its shares rose over 30% on the day."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session,2017-05-25 12:15:12 +0000,https://finance.yahoo.com/news/puma-biotechnology-pbyi-jumps-stock-121512392.html?.tsrc=rss,"Puma Biotechnology, Inc. (PBYI) moved big last session, as its shares rose over 30% on the day."
PBYI,PBYI:UW,BBG002NFCGM3,"AERI Is Awesome, GWPH Abuzz, FDA Panel Nod For PBYI",2017-05-25 01:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ofrEaaE3wzk/aeri-is-awesome-gwph-abuzz-fda-panel-nod-for-pbyi-20170525-00028,"AERI Is Awesome, GWPH Abuzz, FDA Panel Nod For PBYI"
PBYI,PBYI:US,BBG0018YXYX7,"AERI Is Awesome, GWPH Abuzz, FDA Panel Nod For PBYI",2017-05-25 01:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ofrEaaE3wzk/aeri-is-awesome-gwph-abuzz-fda-panel-nod-for-pbyi-20170525-00028,"AERI Is Awesome, GWPH Abuzz, FDA Panel Nod For PBYI"
PBYI,PBYI:US,BBG0018YXYX7,"Gainers & Losers Of May 24: PBYI, INO, NVCR, AKAO, NBIX...",2017-05-24 21:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fKol1YRRM_4/gainers--losers-of-may-24-pbyi-ino-nvcr-akao-nbix-20170524-01409,"Gainers & Losers Of May 24: PBYI, INO, NVCR, AKAO, NBIX..."
PBYI,PBYI:UW,BBG002NFCGM3,"Gainers & Losers Of May 24: PBYI, INO, NVCR, AKAO, NBIX...",2017-05-24 21:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fKol1YRRM_4/gainers--losers-of-may-24-pbyi-ino-nvcr-akao-nbix-20170524-01409,"Gainers & Losers Of May 24: PBYI, INO, NVCR, AKAO, NBIX..."
PBYI,PBYI:US,BBG0018YXYX7,Why Puma Biotechnology Inc Jumped Higher Today,2017-05-24 21:32:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lCKElcn5GOA/why-puma-biotechnology-inc-jumped-higher-today-cm794208,What happened Shares of Puma Biotechnology NASDAQ PBYI are up 28 at 3 20 p m EDT after the Food and Drug Administration FDA advisory committee voted 12 4 recommending that Puma s breast cancer drug neratinib be approved So what Puma Biotechnology is trying to
PBYI,PBYI:UW,BBG002NFCGM3,Why Puma Biotechnology Inc Jumped Higher Today,2017-05-24 21:32:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lCKElcn5GOA/why-puma-biotechnology-inc-jumped-higher-today-cm794208,What happened Shares of Puma Biotechnology NASDAQ PBYI are up 28 at 3 20 p m EDT after the Food and Drug Administration FDA advisory committee voted 12 4 recommending that Puma s breast cancer drug neratinib be approved So what Puma Biotechnology is trying to
PBYI,PBYI:US,BBG0018YXYX7,"Why Abercrombie & Fitch, Triumph Group, and Puma Biotechnology Jumped Today",2017-05-24 21:32:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9P5C9t4agZM/why-abercrombie-fitch-triumph-group-and-puma-biotechnology-jumped-today-cm794195,Wednesday was a good day for stocks and the Dow Jones Industrials and S amp P 500 both climbed through milestone levels Most market participants attributed the positive sentiment to the Federal Reserve which released the minutes of its latest monetary policy meeting during
PBYI,PBYI:UW,BBG002NFCGM3,"Why Abercrombie & Fitch, Triumph Group, and Puma Biotechnology Jumped Today",2017-05-24 21:32:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9P5C9t4agZM/why-abercrombie-fitch-triumph-group-and-puma-biotechnology-jumped-today-cm794195,Wednesday was a good day for stocks and the Dow Jones Industrials and S amp P 500 both climbed through milestone levels Most market participants attributed the positive sentiment to the Federal Reserve which released the minutes of its latest monetary policy meeting during
PBYI,PBYI:UW,BBG002NFCGM3,This Biotech Stock Has Soared 84% This Week On Breast-Cancer Drug News,2017-05-24 20:38:23 +0000,http://finance.yahoo.com/r/7205b5b8-b232-318e-b7a8-8723d6c8d73f/puma-breast-cancer-drug-hurdles-fda-committee-on-way-to-approval?src=A00220&yptr=yahoo&.tsrc=rss,"Puma stock leapt midday Wednesday after an FDA committee voted to recommend approval of its drug, neratinib, for the treatment of some breast cancers."
PBYI,PBYI:US,BBG0018YXYX7,This Biotech Stock Has Soared 84% This Week On Breast-Cancer Drug News,2017-05-24 20:38:23 +0000,http://finance.yahoo.com/r/7205b5b8-b232-318e-b7a8-8723d6c8d73f/puma-breast-cancer-drug-hurdles-fda-committee-on-way-to-approval?src=A00220&yptr=yahoo&.tsrc=rss,"Puma stock leapt midday Wednesday after an FDA committee voted to recommend approval of its drug, neratinib, for the treatment of some breast cancers."
PBYI,PBYI:US,BBG0018YXYX7,"Noteworthy Wednesday Option Activity: TCO, PBYI, PEP",2017-05-24 20:31:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3H4Amg4pTGA/noteworthy-wednesday-option-activity-tco-pbyi-pep-cm794149,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Taubman Centers Inc Symbol TCO where a total volume of 7 551 contracts has been traded thus far today a contract volume which is representative of approximately 755
PBYI,PBYI:UW,BBG002NFCGM3,"Noteworthy Wednesday Option Activity: TCO, PBYI, PEP",2017-05-24 20:31:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3H4Amg4pTGA/noteworthy-wednesday-option-activity-tco-pbyi-pep-cm794149,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Taubman Centers Inc Symbol TCO where a total volume of 7 551 contracts has been traded thus far today a contract volume which is representative of approximately 755
PBYI,PBYI:UW,BBG002NFCGM3,"Health Care Sector Update for 05/24/2017: PBYI,INO,NBIX",2017-05-24 20:30:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TgB-UFQG_4E/health-care-sector-update-for-05242017-pbyiinonbix-cm794177,Top Health Care StocksTop Health Care Stocks JNJ 0 01 JNJ 0 01 PFE 0 14 PFE 0 14 ABT 0 37 ABT 0 37 MRK 0 77 MRK 0 77 AMGN 0 32 AMGN 0 32 Health care stocks were in the middle of Wednesday s leaderboard this afternoon with the NYSE Health Care Index climbing over 0 3 while shares
PBYI,PBYI:US,BBG0018YXYX7,"Health Care Sector Update for 05/24/2017: PBYI,INO,NBIX",2017-05-24 20:30:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TgB-UFQG_4E/health-care-sector-update-for-05242017-pbyiinonbix-cm794177,Top Health Care StocksTop Health Care Stocks JNJ 0 01 JNJ 0 01 PFE 0 14 PFE 0 14 ABT 0 37 ABT 0 37 MRK 0 77 MRK 0 77 AMGN 0 32 AMGN 0 32 Health care stocks were in the middle of Wednesday s leaderboard this afternoon with the NYSE Health Care Index climbing over 0 3 while shares
PBYI,PBYI:US,BBG0018YXYX7,"Why Abercrombie & Fitch, Triumph Group, and Puma Biotechnology Jumped Today",2017-05-24 20:17:04 +0000,http://finance.yahoo.com/r/5fcf1f00-b646-3e48-a7f6-f3e6ed92963b/why-abercrombie-fitch-triumph-group-and-puma-biote.aspx?yptr=yahoo&.tsrc=rss,"On a strong day for the market, these stocks led the way higher. Find out why."
PBYI,PBYI:UW,BBG002NFCGM3,"Why Abercrombie & Fitch, Triumph Group, and Puma Biotechnology Jumped Today",2017-05-24 20:17:04 +0000,http://finance.yahoo.com/r/5fcf1f00-b646-3e48-a7f6-f3e6ed92963b/why-abercrombie-fitch-triumph-group-and-puma-biote.aspx?yptr=yahoo&.tsrc=rss,"On a strong day for the market, these stocks led the way higher. Find out why."
PBYI,PBYI:UW,BBG002NFCGM3,Why Puma Biotechnology Inc Jumped Higher Today,2017-05-24 19:49:00 +0000,http://finance.yahoo.com/r/12e103d8-9953-36f5-8d3b-3b43bd2cc19e/why-puma-biotechnology-inc-jumped-higher-today.aspx?yptr=yahoo&.tsrc=rss,A positive FDA advisory committee meeting makes approval of Puma&apos;s breast-cancer drug likely.
PBYI,PBYI:US,BBG0018YXYX7,Why Puma Biotechnology Inc Jumped Higher Today,2017-05-24 19:49:00 +0000,http://finance.yahoo.com/r/12e103d8-9953-36f5-8d3b-3b43bd2cc19e/why-puma-biotechnology-inc-jumped-higher-today.aspx?yptr=yahoo&.tsrc=rss,A positive FDA advisory committee meeting makes approval of Puma&apos;s breast-cancer drug likely.
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech shares surge 20% after FDA advisory committee votes in favor of approving breast cancer drug,2017-05-24 18:54:00 +0000,http://finance.yahoo.com/r/34900b25-2c48-3230-9d66-70661b1c7b1c/Story.aspx?guid=58646EA7-F27A-4251-B140-516C0D34A2BF&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Puma Biotechnology Inc. shares surged 20% in afternoon trade Wednesday, after the company said an advisory committee for the U.S. Food and Drug Administration has voted 12 to 4 in favor of recommending ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech shares surge 20% after FDA advisory committee votes in favor of approving breast cancer drug,2017-05-24 18:54:00 +0000,http://finance.yahoo.com/r/34900b25-2c48-3230-9d66-70661b1c7b1c/Story.aspx?guid=58646EA7-F27A-4251-B140-516C0D34A2BF&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Puma Biotechnology Inc. shares surged 20% in afternoon trade Wednesday, after the company said an advisory committee for the U.S. Food and Drug Administration has voted 12 to 4 in favor of recommending ..."
PBYI,PBYI:UW,BBG002NFCGM3,InPlay from Briefing.com,2017-05-24 17:57:10 +0000,https://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
PBYI,PBYI:US,BBG0018YXYX7,InPlay from Briefing.com,2017-05-24 17:57:10 +0000,https://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech Gets Favorable FDA Vote On Neratinib,2017-05-24 17:36:21 +0000,https://finance.yahoo.com/news/puma-biotech-gets-favorable-fda-173621607.html?.tsrc=rss,Puma Biotechnology Inc (NASDAQ: PBYI ) traders are eagerly-anticipating the end of the trading halt for Puma on Wednesday after the company received a positive recommendation for approval of neratinib ...
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech Gets Favorable FDA Vote On Neratinib,2017-05-24 17:36:21 +0000,https://finance.yahoo.com/news/puma-biotech-gets-favorable-fda-173621607.html?.tsrc=rss,Puma Biotechnology Inc (NASDAQ: PBYI ) traders are eagerly-anticipating the end of the trading halt for Puma on Wednesday after the company received a positive recommendation for approval of neratinib ...
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib,2017-05-24 17:29:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-receives-fda-advisory-172900463.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, today announced that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted 12 - 4 to recommend approval of PB272 for the extended adjuvant treatment of HER2-positive early stage breast cancer based on finding that the risk-benefit profile of neratinib is favorable."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib,2017-05-24 17:29:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-receives-fda-advisory-172900463.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, today announced that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted 12 - 4 to recommend approval of PB272 for the extended adjuvant treatment of HER2-positive early stage breast cancer based on finding that the risk-benefit profile of neratinib is favorable."
PBYI,PBYI:US,BBG0018YXYX7,FDA Panel Votes 12 To 4 to Approve Puma's Breast Cancer Drug,2017-05-24 16:32:00 +0000,http://finance.yahoo.com/r/3a053dc2-f103-39c6-bc62-3eb23191bb1c/fda-panel-votes-12-to-4-to-approve-pumas-breast-cancer-drug?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"A panel of experts convened by the Food and Drug Administration says that a drug for breast cancer developed by Puma Biotechnology should be approved, but argued for more limits on which women should get the medicine."
PBYI,PBYI:UW,BBG002NFCGM3,FDA Panel Votes 12 To 4 to Approve Puma's Breast Cancer Drug,2017-05-24 16:32:00 +0000,http://finance.yahoo.com/r/3a053dc2-f103-39c6-bc62-3eb23191bb1c/fda-panel-votes-12-to-4-to-approve-pumas-breast-cancer-drug?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"A panel of experts convened by the Food and Drug Administration says that a drug for breast cancer developed by Puma Biotechnology should be approved, but argued for more limits on which women should get the medicine."
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017",2017-05-24 14:38:00 +0000,https://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-143800274.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 24, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Puma Biotechnology, Inc. (""Puma"" or the ""Company"") ..."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017",2017-05-24 14:38:00 +0000,https://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-143800274.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 24, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Puma Biotechnology, Inc. (""Puma"" or the ""Company"") ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology FDA Live Blog,2017-05-24 12:12:00 +0000,http://finance.yahoo.com/r/933c61d3-837d-382a-bc05-b4a2d23804a7/puma-biotechnology-fda-live-blo?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"A live blog of the FDA's deliberations on neratinib, a breast cancer drug developed by Puma Biotechnology."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology FDA Live Blog,2017-05-24 12:12:00 +0000,http://finance.yahoo.com/r/933c61d3-837d-382a-bc05-b4a2d23804a7/puma-biotechnology-fda-live-blo?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"A live blog of the FDA's deliberations on neratinib, a breast cancer drug developed by Puma Biotechnology."
PBYI,PBYI:UW,BBG002NFCGM3,"Gainers & Losers Of May 23: GLYC, PBYI, SGMO, CERS, AGLE...",2017-05-23 21:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t5IyzUfbJZ8/gainers--losers-of-may-23-glyc-pbyi-sgmo-cers-agle-20170523-01429,"Gainers & Losers Of May 23: GLYC, PBYI, SGMO, CERS, AGLE..."
PBYI,PBYI:US,BBG0018YXYX7,"Gainers & Losers Of May 23: GLYC, PBYI, SGMO, CERS, AGLE...",2017-05-23 21:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t5IyzUfbJZ8/gainers--losers-of-may-23-glyc-pbyi-sgmo-cers-agle-20170523-01429,"Gainers & Losers Of May 23: GLYC, PBYI, SGMO, CERS, AGLE..."
PBYI,PBYI:US,BBG0018YXYX7,The Current State Of The Breast Cancer Treatment Space,2017-05-23 12:59:04 +0000,https://finance.yahoo.com/news/current-state-breast-cancer-treatment-125904515.html?.tsrc=rss,"Puma Biotechnology Inc (NASDAQ: PBYI ) popped 88 percent Monday on news that its neratinib candidate , an early-stage breast cancer treatment for human epidermal growth factor receptor-2 (HER2) positive ..."
PBYI,PBYI:UW,BBG002NFCGM3,The Current State Of The Breast Cancer Treatment Space,2017-05-23 12:59:04 +0000,https://finance.yahoo.com/news/current-state-breast-cancer-treatment-125904515.html?.tsrc=rss,"Puma Biotechnology Inc (NASDAQ: PBYI ) popped 88 percent Monday on news that its neratinib candidate , an early-stage breast cancer treatment for human epidermal growth factor receptor-2 (HER2) positive ..."
PBYI,PBYI:UW,BBG002NFCGM3,"FDA Approves 1st Drug For GCA, Puma Leaps, Will SBPH Spring A Surprise?",2017-05-23 00:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jnC0MpKk-uY/fda-approves-1st-drug-for-gca-puma-leaps-will-sbph-spring-a-surprise-20170523-00002,"FDA Approves 1st Drug For GCA, Puma Leaps, Will SBPH Spring A Surprise?"
PBYI,PBYI:US,BBG0018YXYX7,"FDA Approves 1st Drug For GCA, Puma Leaps, Will SBPH Spring A Surprise?",2017-05-23 00:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jnC0MpKk-uY/fda-approves-1st-drug-for-gca-puma-leaps-will-sbph-spring-a-surprise-20170523-00002,"FDA Approves 1st Drug For GCA, Puma Leaps, Will SBPH Spring A Surprise?"
PBYI,PBYI:US,BBG0018YXYX7,"Sorl Auto Parts, Inc. (SORL) Stock Pops 22% as Buzz Grows",2017-05-22 22:12:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CeH06Z4bT7k/sorl-auto-parts-inc-sorl-stock-pops-22-as-buzz-grows-cm792965,InvestorPlace Stock Market News Stock Advice amp Trading Tips It s fairly unusual for a publication to move a stock unless the publication posts a take down piece exposing some horrid misdeed For 160 Sorl Auto Parts Inc NASDAQ SORL it was simply
PBYI,PBYI:UW,BBG002NFCGM3,"Sorl Auto Parts, Inc. (SORL) Stock Pops 22% as Buzz Grows",2017-05-22 22:12:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CeH06Z4bT7k/sorl-auto-parts-inc-sorl-stock-pops-22-as-buzz-grows-cm792965,InvestorPlace Stock Market News Stock Advice amp Trading Tips It s fairly unusual for a publication to move a stock unless the publication posts a take down piece exposing some horrid misdeed For 160 Sorl Auto Parts Inc NASDAQ SORL it was simply
PBYI,PBYI:US,BBG0018YXYX7,"Why Puma Biotechnology, Applied Optoelectronics, and Ferroglobe Jumped Today",2017-05-22 22:12:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X3NItOl8Mys/why-puma-biotechnology-applied-optoelectronics-and-ferroglobe-jumped-today-cm792938,Monday was a good start to the week for stocks with major benchmarks climbing around half a percent on the day Most market participants pointed to a lack of bad news over the weekend and anticipation about expected favorable economic data in the coming days as drivers of the
PBYI,PBYI:UW,BBG002NFCGM3,"Why Puma Biotechnology, Applied Optoelectronics, and Ferroglobe Jumped Today",2017-05-22 22:12:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X3NItOl8Mys/why-puma-biotechnology-applied-optoelectronics-and-ferroglobe-jumped-today-cm792938,Monday was a good start to the week for stocks with major benchmarks climbing around half a percent on the day Most market participants pointed to a lack of bad news over the weekend and anticipation about expected favorable economic data in the coming days as drivers of the
PBYI,PBYI:US,BBG0018YXYX7,Buy Alibaba Group Holding Ltd (BABA) Stock at Your Own Risk,2017-05-22 21:13:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VfMp8JeEPC8/buy-alibaba-group-holding-ltd-baba-stock-at-your-own-risk-cm792950,InvestorPlace Stock Market News Stock Advice amp Trading Tips Alibaba Group Holding Ltd 160 NYSE BABA delivered some pretty stellar earnings recently and the momentum keeps pushing shares to new all time highs I m going to run through the numbers quickly but before we
PBYI,PBYI:UW,BBG002NFCGM3,Buy Alibaba Group Holding Ltd (BABA) Stock at Your Own Risk,2017-05-22 21:13:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VfMp8JeEPC8/buy-alibaba-group-holding-ltd-baba-stock-at-your-own-risk-cm792950,InvestorPlace Stock Market News Stock Advice amp Trading Tips Alibaba Group Holding Ltd 160 NYSE BABA delivered some pretty stellar earnings recently and the momentum keeps pushing shares to new all time highs I m going to run through the numbers quickly but before we
PBYI,PBYI:US,BBG0018YXYX7,"Why Puma Biotechnology, Applied Optoelectronics, and Ferroglobe Jumped Today",2017-05-22 20:23:26 +0000,http://finance.yahoo.com/r/9fba9e0e-6074-325d-94b4-c005d9e550a9/why-puma-biotechnology-applied-optoelectronics-and.aspx?yptr=yahoo&.tsrc=rss,These stocks helped lead the market higher. Find out why.
PBYI,PBYI:UW,BBG002NFCGM3,"Why Puma Biotechnology, Applied Optoelectronics, and Ferroglobe Jumped Today",2017-05-22 20:23:26 +0000,http://finance.yahoo.com/r/9fba9e0e-6074-325d-94b4-c005d9e550a9/why-puma-biotechnology-applied-optoelectronics-and.aspx?yptr=yahoo&.tsrc=rss,These stocks helped lead the market higher. Find out why.
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Inc (PBYI) Pops 60% on FDA Review,2017-05-22 20:13:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Mr-TqOKaOow/puma-biotechnology-inc-pbyi-pops-60-on-fda-review-cm792926,InvestorPlace Stock Market News Stock Advice amp Trading Tips Puma Biotechnology Inc NASDAQ PBYI jolted as much as 80 higher on Monday morning on news that the 160 U S Food amp Drug Administration posted a seemingly positive review of Puma s
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Inc (PBYI) Pops 60% on FDA Review,2017-05-22 20:13:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Mr-TqOKaOow/puma-biotechnology-inc-pbyi-pops-60-on-fda-review-cm792926,InvestorPlace Stock Market News Stock Advice amp Trading Tips Puma Biotechnology Inc NASDAQ PBYI jolted as much as 80 higher on Monday morning on news that the 160 U S Food amp Drug Administration posted a seemingly positive review of Puma s
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech Surges To 6-Month High On Likely Cancer Drug Approval,2017-05-22 20:09:21 +0000,http://finance.yahoo.com/r/70aa347d-0c13-36b4-b10f-099e859b239f/puma-biotech-surges-to-6-month-high-on-likely-cancer-drug-approval?src=A00220&yptr=yahoo&.tsrc=rss,Puma stock rocketed to a six-month high Monday on speculation that a key FDA panel will recommend its breast cancer drug be approved.
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech Surges To 6-Month High On Likely Cancer Drug Approval,2017-05-22 20:09:21 +0000,http://finance.yahoo.com/r/70aa347d-0c13-36b4-b10f-099e859b239f/puma-biotech-surges-to-6-month-high-on-likely-cancer-drug-approval?src=A00220&yptr=yahoo&.tsrc=rss,Puma stock rocketed to a six-month high Monday on speculation that a key FDA panel will recommend its breast cancer drug be approved.
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech Shares Are Roaring On An FDA Review. Here's What Could Still Go Wrong,2017-05-22 18:14:00 +0000,http://finance.yahoo.com/r/9429eced-6e2c-3082-bd8a-652e8e0ce44c/puma-biotech-shares-are-roaring-on-an-fda-review-heres-what-could-still-go-wrong?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Puma's having a great day, with its stock up 35%. Is it time to pounce? Take a look at what could go wrong at the company's FDA hearing on Wednesday, first."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech Shares Are Roaring On An FDA Review. Here's What Could Still Go Wrong,2017-05-22 18:14:00 +0000,http://finance.yahoo.com/r/9429eced-6e2c-3082-bd8a-652e8e0ce44c/puma-biotech-shares-are-roaring-on-an-fda-review-heres-what-could-still-go-wrong?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Puma's having a great day, with its stock up 35%. Is it time to pounce? Take a look at what could go wrong at the company's FDA hearing on Wednesday, first."
PBYI,PBYI:US,BBG0018YXYX7,Why Puma Biotechnology Inc Jumped Higher Today,2017-05-22 17:05:00 +0000,http://finance.yahoo.com/r/100ff70f-8fa4-37cf-bd48-8853d4661287/why-puma-biotechnology-inc-jumped-higher-today.aspx?yptr=yahoo&.tsrc=rss,Documents from the FDA suggest the agency is open to the possibility of approving neratinib.
PBYI,PBYI:UW,BBG002NFCGM3,Why Puma Biotechnology Inc Jumped Higher Today,2017-05-22 17:05:00 +0000,http://finance.yahoo.com/r/100ff70f-8fa4-37cf-bd48-8853d4661287/why-puma-biotechnology-inc-jumped-higher-today.aspx?yptr=yahoo&.tsrc=rss,Documents from the FDA suggest the agency is open to the possibility of approving neratinib.
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 - PBYI",2017-05-22 15:17:00 +0000,https://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-151700552.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 22, 2017 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, ..."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 - PBYI",2017-05-22 15:17:00 +0000,https://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-151700552.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 22, 2017 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, ..."
PBYI,PBYI:US,BBG0018YXYX7,"Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote",2017-05-22 14:41:00 +0000,http://finance.yahoo.com/r/2f1f91df-beca-3063-896f-83e3011c95a2/puma-bio-bulls-win-monday-s-fda-neratinib-review-ahead-of-wednesday-s-advisory-panel-vote.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"The lack of ""OMG"" bombshells in the FDA's neratinib review are a Monday win for Puma bulls, and the stock is soaring."
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote",2017-05-22 14:41:00 +0000,http://finance.yahoo.com/r/2f1f91df-beca-3063-896f-83e3011c95a2/puma-bio-bulls-win-monday-s-fda-neratinib-review-ahead-of-wednesday-s-advisory-panel-vote.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"The lack of ""OMG"" bombshells in the FDA's neratinib review are a Monday win for Puma bulls, and the stock is soaring."
PBYI,PBYI:UW,BBG002NFCGM3,Are Options Traders Betting on a Big Move in Puma (PBYI) Stock?,2017-05-22 14:16:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ICfcVT1FuwY/are-options-traders-betting-on-a-big-move-in-puma-pbyi-stock-cm792495,Investors in Puma Biotechnology Inc PBYI need to pay close attention to the stock based on moves in the options market lately That is because the May 26 th 2017 20 Put had some of the highest implied volatility of all equity options today What is Implied Volatility
PBYI,PBYI:US,BBG0018YXYX7,Are Options Traders Betting on a Big Move in Puma (PBYI) Stock?,2017-05-22 14:16:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ICfcVT1FuwY/are-options-traders-betting-on-a-big-move-in-puma-pbyi-stock-cm792495,Investors in Puma Biotechnology Inc PBYI need to pay close attention to the stock based on moves in the options market lately That is because the May 26 th 2017 20 Put had some of the highest implied volatility of all equity options today What is Implied Volatility
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting,2017-05-22 14:08:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-announces-posting-fda-140800507.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the U.S. Food and Drug Administration posted briefing documents on its website in preparation for the May 24 Oncologic Drugs Advisory Committee meeting scheduled to review PB272 for the extended adjuvant treatment of HER2-positive early stage breast cancer."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting,2017-05-22 14:08:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-announces-posting-fda-140800507.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the U.S. Food and Drug Administration posted briefing documents on its website in preparation for the May 24 Oncologic Drugs Advisory Committee meeting scheduled to review PB272 for the extended adjuvant treatment of HER2-positive early stage breast cancer."
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline – PBYI",2017-05-22 13:00:00 +0000,https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-130000378.html?.tsrc=rss,"NEW YORK, May 22, 2017-- Pomerantz LLP announces that a class action lawsuit has been filed against Puma Biotechnology, Inc. and certain of its officers. The class action, filed in United States District ..."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline – PBYI",2017-05-22 13:00:00 +0000,https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-130000378.html?.tsrc=rss,"NEW YORK, May 22, 2017-- Pomerantz LLP announces that a class action lawsuit has been filed against Puma Biotechnology, Inc. and certain of its officers. The class action, filed in United States District ..."
PBYI,PBYI:UW,BBG002NFCGM3,Are Options Traders Betting on a Big Move in Puma (PBYI) Stock?,2017-05-22 12:32:12 +0000,https://finance.yahoo.com/news/options-traders-betting-big-move-123212163.html?.tsrc=rss,"Investors in Puma Biotechnology, Inc. (PBYI) need to pay close attention to the stock based on moves in the options market lately."
PBYI,PBYI:US,BBG0018YXYX7,Are Options Traders Betting on a Big Move in Puma (PBYI) Stock?,2017-05-22 12:32:12 +0000,https://finance.yahoo.com/news/options-traders-betting-big-move-123212163.html?.tsrc=rss,"Investors in Puma Biotechnology, Inc. (PBYI) need to pay close attention to the stock based on moves in the options market lately."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology (PBYI) Has Spiked To The Upside,2017-05-22 09:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SnZM_cUtqIM/puma-biotechnology-pbyi-has-spiked-to-the-upside-20170522-00682,Puma Biotechnology (PBYI) Has Spiked To The Upside
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology (PBYI) Has Spiked To The Upside,2017-05-22 09:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SnZM_cUtqIM/puma-biotechnology-pbyi-has-spiked-to-the-upside-20170522-00682,Puma Biotechnology (PBYI) Has Spiked To The Upside
PBYI,PBYI:US,BBG0018YXYX7,"Harwood Feffer LLP Announces Investigation of Puma Biotechnology, Inc.",2017-05-19 20:36:00 +0000,https://finance.yahoo.com/news/harwood-feffer-llp-announces-investigation-203600079.html?.tsrc=rss,"NEW YORK, May 19, 2017 /PRNewswire/ --   Harwood Feffer LLP ( www.hfesq.com ) is investigating potential claims against the board of directors of Puma Biotechnology, Inc. (""Puma"" or the ""Company"") ..."
PBYI,PBYI:UW,BBG002NFCGM3,"Harwood Feffer LLP Announces Investigation of Puma Biotechnology, Inc.",2017-05-19 20:36:00 +0000,https://finance.yahoo.com/news/harwood-feffer-llp-announces-investigation-203600079.html?.tsrc=rss,"NEW YORK, May 19, 2017 /PRNewswire/ --   Harwood Feffer LLP ( www.hfesq.com ) is investigating potential claims against the board of directors of Puma Biotechnology, Inc. (""Puma"" or the ""Company"") ..."
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm",2017-05-18 23:49:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-lead-plaintiff-deadline-234900156.html?.tsrc=rss,"NEW YORK, May 18, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors Puma Biotechnology, Inc. (""Puma Biotechnology"" or the ""Company"") (PBYI) of the July 7, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.  If you invested in Puma Biotechnology stock or options between February 29, 2016 and May 4, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/PBYI There is no cost or obligation to you."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm",2017-05-18 23:49:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-lead-plaintiff-deadline-234900156.html?.tsrc=rss,"NEW YORK, May 18, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors Puma Biotechnology, Inc. (""Puma Biotechnology"" or the ""Company"") (PBYI) of the July 7, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.  If you invested in Puma Biotechnology stock or options between February 29, 2016 and May 4, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/PBYI There is no cost or obligation to you."
PBYI,PBYI:UW,BBG002NFCGM3,"PBYI INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017",2017-05-18 16:01:00 +0000,https://finance.yahoo.com/news/pbyi-investor-alert-law-offices-160100157.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 18, 2017 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California ..."
PBYI,PBYI:US,BBG0018YXYX7,"PBYI INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017",2017-05-18 16:01:00 +0000,https://finance.yahoo.com/news/pbyi-investor-alert-law-offices-160100157.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 18, 2017 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California ..."
PBYI,PBYI:US,BBG0018YXYX7,Today's Research Reports on Biotech Stocks to Watch: Pulmatrix and Puma Biotechnology,2017-05-18 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-biotech-stocks-120000493.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 18, 2017 / Despite the recent sell-off triggered by the recent health-care bill that is meant to take the place of the Affordable Care Act, the Biotech Industry has continued ..."
PBYI,PBYI:UW,BBG002NFCGM3,Today's Research Reports on Biotech Stocks to Watch: Pulmatrix and Puma Biotechnology,2017-05-18 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-biotech-stocks-120000493.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 18, 2017 / Despite the recent sell-off triggered by the recent health-care bill that is meant to take the place of the Affordable Care Act, the Biotech Industry has continued ..."
PBYI,PBYI:UW,BBG002NFCGM3,"Gainers & Losers Of May 17: SNDX, PULM, PBYI, CNCE, XLRN...",2017-05-17 22:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4AXZTg4uS5c/gainers--losers-of-may-17-sndx-pulm-pbyi-cnce-xlrn-20170517-01376,"Gainers & Losers Of May 17: SNDX, PULM, PBYI, CNCE, XLRN..."
PBYI,PBYI:US,BBG0018YXYX7,"Gainers & Losers Of May 17: SNDX, PULM, PBYI, CNCE, XLRN...",2017-05-17 22:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4AXZTg4uS5c/gainers--losers-of-may-17-sndx-pulm-pbyi-cnce-xlrn-20170517-01376,"Gainers & Losers Of May 17: SNDX, PULM, PBYI, CNCE, XLRN..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting,2017-05-17 21:06:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-announces-publication-neratinib-210600400.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 that will be presented at the American Society of Clinical Oncology Annual Meeting, which will be held June 2–6, 2017, in Chicago."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting,2017-05-17 21:06:00 +0000,https://finance.yahoo.com/news/puma-biotechnology-announces-publication-neratinib-210600400.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 that will be presented at the American Society of Clinical Oncology Annual Meeting, which will be held June 2–6, 2017, in Chicago."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Leaps On Report Its Breast Cancer Drug Could Rival Roche,2017-05-17 20:37:51 +0000,http://finance.yahoo.com/r/cf5d10fd-4690-33bb-a5c6-2a5974fafb67/puma-stock-jumps-on-suggestion-it-could-rival-roche-in-breast-cancer?src=A00220&yptr=yahoo&.tsrc=rss,Puma stock popped to a two-week high Wednesday on a bullish report arguing its breast cancer drug could hold up against Roche&apos;s.
PBYI,PBYI:US,BBG0018YXYX7,Puma Leaps On Report Its Breast Cancer Drug Could Rival Roche,2017-05-17 20:37:51 +0000,http://finance.yahoo.com/r/cf5d10fd-4690-33bb-a5c6-2a5974fafb67/puma-stock-jumps-on-suggestion-it-could-rival-roche-in-breast-cancer?src=A00220&yptr=yahoo&.tsrc=rss,Puma stock popped to a two-week high Wednesday on a bullish report arguing its breast cancer drug could hold up against Roche&apos;s.
PBYI,PBYI:UW,BBG002NFCGM3,Wednesday's ETF with Unusual Volume: VBK,2017-05-17 18:12:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qNSrPF2bR_U/wednesdays-etf-with-unusual-volume-vbk-cm790719,The Vanguard Small Cap Growth ETF is seeing unusually high volume in afternoon trading Wednesday with over 1 3 million shares traded versus three month average volume of about 161 000 Shares of VBK were off about 1 5 on the day Components of that ETF with the highest volume on
PBYI,PBYI:US,BBG0018YXYX7,Wednesday's ETF with Unusual Volume: VBK,2017-05-17 18:12:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qNSrPF2bR_U/wednesdays-etf-with-unusual-volume-vbk-cm790719,The Vanguard Small Cap Growth ETF is seeing unusually high volume in afternoon trading Wednesday with over 1 3 million shares traded versus three month average volume of about 161 000 Shares of VBK were off about 1 5 on the day Components of that ETF with the highest volume on
PBYI,PBYI:US,BBG0018YXYX7,Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now,2017-05-17 16:17:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8F5e0S9c4tU/reasons-to-add-puma-biotechnology-pbyi-to-portfolio-now-cm790633,On May 16 2017 we issued an updated report on Puma Biotechnology Inc PBYI Puma Biotechnology is a development stage biopharmaceutical company focused on the development and commercialization of innovative treatments that enhance cancer care The company posted narrower than
PBYI,PBYI:UW,BBG002NFCGM3,Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now,2017-05-17 16:17:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8F5e0S9c4tU/reasons-to-add-puma-biotechnology-pbyi-to-portfolio-now-cm790633,On May 16 2017 we issued an updated report on Puma Biotechnology Inc PBYI Puma Biotechnology is a development stage biopharmaceutical company focused on the development and commercialization of innovative treatments that enhance cancer care The company posted narrower than
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017",2017-05-17 14:10:00 +0000,https://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-141000270.html?.tsrc=rss,"NEW YORK, May 17, 2017-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Puma Biotechnology, Inc. and certain of its officers, ..."
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017",2017-05-17 14:10:00 +0000,https://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-141000270.html?.tsrc=rss,"NEW YORK, May 17, 2017-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Puma Biotechnology, Inc. and certain of its officers, ..."
PBYI,PBYI:UW,BBG002NFCGM3,Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now,2017-05-17 13:48:01 +0000,https://finance.yahoo.com/news/reasons-add-puma-biotechnology-pbyi-134801639.html?.tsrc=rss,"On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI)."
PBYI,PBYI:US,BBG0018YXYX7,Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now,2017-05-17 13:48:01 +0000,https://finance.yahoo.com/news/reasons-add-puma-biotechnology-pbyi-134801639.html?.tsrc=rss,"On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI)."
PBYI,PBYI:US,BBG0018YXYX7,"INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 - PBYI",2017-05-16 12:57:00 +0000,https://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-125700231.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 16, 2017 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, ..."
PBYI,PBYI:UW,BBG002NFCGM3,"INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 - PBYI",2017-05-16 12:57:00 +0000,https://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-125700231.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 16, 2017 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, ..."
PBYI,PBYI:UW,BBG002NFCGM3,"Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Puma Biotechnology, Inc.",2017-05-15 18:34:32 +0000,https://finance.yahoo.com/news/federman-sherwood-announces-filing-securities-183432311.html?.tsrc=rss,"OKLAHOMA CITY, May 15, 2017-- Federman & Sherwood announces that on May 8, 2017, a class action lawsuit was filed in the United States District Court for the Central District of California against Puma ..."
PBYI,PBYI:US,BBG0018YXYX7,"Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Puma Biotechnology, Inc.",2017-05-15 18:34:32 +0000,https://finance.yahoo.com/news/federman-sherwood-announces-filing-securities-183432311.html?.tsrc=rss,"OKLAHOMA CITY, May 15, 2017-- Federman & Sherwood announces that on May 8, 2017, a class action lawsuit was filed in the United States District Court for the Central District of California against Puma ..."
PBYI,PBYI:US,BBG0018YXYX7,"The Klein Law Firm Announces a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017 (PBYI)",2017-05-15 18:18:30 +0000,https://finance.yahoo.com/news/klein-law-firm-announces-class-181830344.html?.tsrc=rss,"NEW YORK, May 15, 2017-- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Puma Biotechnology, Inc. who purchased shares between February 29, 2016 and ..."
PBYI,PBYI:UW,BBG002NFCGM3,"The Klein Law Firm Announces a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017 (PBYI)",2017-05-15 18:18:30 +0000,https://finance.yahoo.com/news/klein-law-firm-announces-class-181830344.html?.tsrc=rss,"NEW YORK, May 15, 2017-- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Puma Biotechnology, Inc. who purchased shares between February 29, 2016 and ..."
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI",2017-05-12 22:45:00 +0000,https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-224500424.html?.tsrc=rss,"NEW YORK, May 12, 2017 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Puma Biotechnology, Inc. (""Puma"" or the ""Company"") (PBYI) and certain of its officers.  The class action, filed in United States District Court, Central District of California, and docketed under 17-cv-03455, is on behalf of a class consisting of investors who purchased or otherwise acquired Puma securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934.  If you are a shareholder who purchased Puma securities between February 29, 2016 and May 4, 2017, both dates inclusive, you have until July 7, 2017 to ask the Court to appoint you as Lead Plaintiff for the class."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI",2017-05-12 22:45:00 +0000,https://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-224500424.html?.tsrc=rss,"NEW YORK, May 12, 2017 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Puma Biotechnology, Inc. (""Puma"" or the ""Company"") (PBYI) and certain of its officers.  The class action, filed in United States District Court, Central District of California, and docketed under 17-cv-03455, is on behalf of a class consisting of investors who purchased or otherwise acquired Puma securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934.  If you are a shareholder who purchased Puma securities between February 29, 2016 and May 4, 2017, both dates inclusive, you have until July 7, 2017 to ask the Court to appoint you as Lead Plaintiff for the class."
PBYI,PBYI:US,BBG0018YXYX7,"PBYI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017",2017-05-12 12:45:00 +0000,http://finance.yahoo.com/news/pbyi-shareholder-alert-law-offices-124500149.html?.tsrc=rss,"NEW YORK, May 12, 2017-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of ..."
PBYI,PBYI:UW,BBG002NFCGM3,"PBYI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017",2017-05-12 12:45:00 +0000,http://finance.yahoo.com/news/pbyi-shareholder-alert-law-offices-124500149.html?.tsrc=rss,"NEW YORK, May 12, 2017-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of ..."
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017",2017-05-11 17:53:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-175300086.html?.tsrc=rss,"NEW YORK, May 11, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Puma Biotechnology, Inc. (""Puma"" ..."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017",2017-05-11 17:53:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-175300086.html?.tsrc=rss,"NEW YORK, May 11, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Puma Biotechnology, Inc. (""Puma"" ..."
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 – PBYI",2017-05-11 15:32:30 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-153230360.html?.tsrc=rss,"NEW YORK, May 11, 2017-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, Inc. between ..."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 – PBYI",2017-05-11 15:32:30 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-153230360.html?.tsrc=rss,"NEW YORK, May 11, 2017-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, Inc. between ..."
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib",2017-05-11 14:04:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HBcnbf_v7a0/puma-pbyi-q1-loss-narrows-focus-remains-on-neratinib-cm787800,Puma Biotechnology Inc PBYI reported a first quarter 2017 loss of 1 97 per share including the impact of stock based compensation expenses narrower than the Zacks Consensus Estimate of a loss of 2 08 and the year ago loss of 2 19 So far this year Puma s shares have underperformed
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib",2017-05-11 14:04:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HBcnbf_v7a0/puma-pbyi-q1-loss-narrows-focus-remains-on-neratinib-cm787800,Puma Biotechnology Inc PBYI reported a first quarter 2017 loss of 1 97 per share including the impact of stock based compensation expenses narrower than the Zacks Consensus Estimate of a loss of 2 08 and the year ago loss of 2 19 So far this year Puma s shares have underperformed
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib",2017-05-11 12:44:12 +0000,http://finance.yahoo.com/news/puma-pbyi-q1-loss-narrows-124412456.html?.tsrc=rss,"Puma Biotechnology, Inc. (PBYI) reported a first-quarter 2017 loss of $1.97 per share, narrower than the Zacks Consensus Estimate of a loss of $2.08 and the year-ago loss of $2.19."
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib",2017-05-11 12:44:12 +0000,http://finance.yahoo.com/news/puma-pbyi-q1-loss-narrows-124412456.html?.tsrc=rss,"Puma Biotechnology, Inc. (PBYI) reported a first-quarter 2017 loss of $1.97 per share, narrower than the Zacks Consensus Estimate of a loss of $2.08 and the year-ago loss of $2.19."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Puma Biotechnology, Inc. (Nasdaq: PBYI) To Contact Brower Piven Before The Lead Plaintiff Deadline",2017-05-11 00:30:00 +0000,http://finance.yahoo.com/news/shareholder-alert-brower-piven-notifies-003000354.html?.tsrc=rss,"STEVENSON, Md., May 10, 2017-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ..."
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Puma Biotechnology, Inc. (Nasdaq: PBYI) To Contact Brower Piven Before The Lead Plaintiff Deadline",2017-05-11 00:30:00 +0000,http://finance.yahoo.com/news/shareholder-alert-brower-piven-notifies-003000354.html?.tsrc=rss,"STEVENSON, Md., May 10, 2017-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ..."
PBYI,PBYI:UW,BBG002NFCGM3,"Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Misled Shareholders According to a Recently Filed Class Action",2017-05-10 23:36:00 +0000,http://finance.yahoo.com/news/robbins-arroyo-llp-puma-biotechnology-233600470.html?.tsrc=rss,"Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Puma Biotechnology, Inc. in the United States District Court for the Central District of California."
PBYI,PBYI:US,BBG0018YXYX7,"Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Misled Shareholders According to a Recently Filed Class Action",2017-05-10 23:36:00 +0000,http://finance.yahoo.com/news/robbins-arroyo-llp-puma-biotechnology-233600470.html?.tsrc=rss,"Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Puma Biotechnology, Inc. in the United States District Court for the Central District of California."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech reports 1Q loss,2017-05-10 21:54:28 +0000,http://finance.yahoo.com/news/puma-biotech-reports-1q-loss-215428216.html?.tsrc=rss,"On a per-share basis, the Los Angeles-based company said it had a loss of $1.97. Losses, adjusted for stock option expense, came to $1.16 per share. The results surpassed Wall Street expectations. The ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech reports 1Q loss,2017-05-10 21:54:28 +0000,http://finance.yahoo.com/news/puma-biotech-reports-1q-loss-215428216.html?.tsrc=rss,"On a per-share basis, the Los Angeles-based company said it had a loss of $1.97. Losses, adjusted for stock option expense, came to $1.16 per share. The results surpassed Wall Street expectations. The ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Reports First Quarter 2017 Financial Results,2017-05-10 20:20:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-reports-first-quarter-202000488.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2017."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Reports First Quarter 2017 Financial Results,2017-05-10 20:20:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-reports-first-quarter-202000488.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2017."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Present at Bank of America Merrill Lynch 2017 Health Care Conference,2017-05-09 20:20:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-present-bank-america-202000196.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:20 a.m."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Present at Bank of America Merrill Lynch 2017 Health Care Conference,2017-05-09 20:20:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-present-bank-america-202000196.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:20 a.m."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm",2017-05-09 03:23:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-lead-plaintiff-deadline-032300735.html?.tsrc=rss,"Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors Puma Biotechnology, Inc. of the July 7, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company."
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm",2017-05-09 03:23:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-lead-plaintiff-deadline-032300735.html?.tsrc=rss,"Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors Puma Biotechnology, Inc. of the July 7, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm",2017-05-08 20:05:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-investor-alert-faruqi-200500719.html?.tsrc=rss,"Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Puma Biotechnology, Inc. ."
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm",2017-05-08 20:05:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-investor-alert-faruqi-200500719.html?.tsrc=rss,"Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Puma Biotechnology, Inc. ."
PBYI,PBYI:UW,BBG002NFCGM3,"Pomerantz Law Firm Announces the Filing of a Class Action against Puma Biotechnology, Inc. and Certain Officers – PBYI",2017-05-08 19:16:01 +0000,http://finance.yahoo.com/news/pomerantz-law-firm-announces-filing-191601178.html?.tsrc=rss,"NEW YORK, May 08, 2017-- Pomerantz LLP announces that a class action lawsuit has been filed against Puma Biotechnology, Inc. and certain of its officers. The class action, filed in United States District ..."
PBYI,PBYI:US,BBG0018YXYX7,"Pomerantz Law Firm Announces the Filing of a Class Action against Puma Biotechnology, Inc. and Certain Officers – PBYI",2017-05-08 19:16:01 +0000,http://finance.yahoo.com/news/pomerantz-law-firm-announces-filing-191601178.html?.tsrc=rss,"NEW YORK, May 08, 2017-- Pomerantz LLP announces that a class action lawsuit has been filed against Puma Biotechnology, Inc. and certain of its officers. The class action, filed in United States District ..."
PBYI,PBYI:UW,BBG002NFCGM3,"Why Puma Biotechnology, Trex, and National CineMedia Slumped Today",2017-05-05 22:26:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1Tb5dYHSe0Y/why-puma-biotechnology-trex-and-national-cinemedia-slumped-today-cm785309,The stock market performed reasonably well on Friday sending major benchmarks to gains of 0 25 to 0 5 on the day Favorable news from the U S economy outweighed any concerns about geopolitical events occurring this weekend including the much awaited final phase of the French
PBYI,PBYI:US,BBG0018YXYX7,"Why Puma Biotechnology, Trex, and National CineMedia Slumped Today",2017-05-05 22:26:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1Tb5dYHSe0Y/why-puma-biotechnology-trex-and-national-cinemedia-slumped-today-cm785309,The stock market performed reasonably well on Friday sending major benchmarks to gains of 0 25 to 0 5 on the day Favorable news from the U S economy outweighed any concerns about geopolitical events occurring this weekend including the much awaited final phase of the French
PBYI,PBYI:UW,BBG002NFCGM3,"Why Puma Biotechnology, Trex, and National CineMedia Slumped Today",2017-05-05 21:00:34 +0000,http://finance.yahoo.com/r/7054e9c9-a7cf-3a3a-a01a-75e345894d90/why-puma-biotechnology-trex-and-national-cinemedia.aspx?yptr=yahoo&.tsrc=rss,"Despite a strong day for the market, these stocks fell. Find out why."
PBYI,PBYI:US,BBG0018YXYX7,"Why Puma Biotechnology, Trex, and National CineMedia Slumped Today",2017-05-05 21:00:34 +0000,http://finance.yahoo.com/r/7054e9c9-a7cf-3a3a-a01a-75e345894d90/why-puma-biotechnology-trex-and-national-cinemedia.aspx?yptr=yahoo&.tsrc=rss,"Despite a strong day for the market, these stocks fell. Find out why."
PBYI,PBYI:UW,BBG002NFCGM3,"Friday's ETF Movers: FXN, XBI",2017-05-05 19:26:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2xmLpGBbpFM/fridays-etf-movers-fxn-xbi-cm785180,In trading on Friday the First Trust Energy AlphaDEX Fund ETF FXN is outperforming other ETFs up about 2 8 on the day Components of that ETF showing particular strength include shares of Noble NE up about 10 2 and shares of Diamond Offshore Drilling DO up about 8 5 on
PBYI,PBYI:US,BBG0018YXYX7,"Friday's ETF Movers: FXN, XBI",2017-05-05 19:26:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2xmLpGBbpFM/fridays-etf-movers-fxn-xbi-cm785180,In trading on Friday the First Trust Energy AlphaDEX Fund ETF FXN is outperforming other ETFs up about 2 8 on the day Components of that ETF showing particular strength include shares of Noble NE up about 10 2 and shares of Diamond Offshore Drilling DO up about 8 5 on
PBYI,PBYI:UW,BBG002NFCGM3,Why Puma Biotechnology Shares Are Crashing 18.2% Today,2017-05-05 18:26:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PUP0gxc65kE/why-puma-biotechnology-shares-are-crashing-182-today-cm785139,What happened Puma Biotechnology NASDAQ PBYI stock has plummeted 18 2 as of 12 53 p m EDT following news that Dr Robert Charnas its head of regulatory affairs and project management is hitting the exits ahead of a scheduled Food and Drug Administration FDA advisory
PBYI,PBYI:US,BBG0018YXYX7,Why Puma Biotechnology Shares Are Crashing 18.2% Today,2017-05-05 18:26:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PUP0gxc65kE/why-puma-biotechnology-shares-are-crashing-182-today-cm785139,What happened Puma Biotechnology NASDAQ PBYI stock has plummeted 18 2 as of 12 53 p m EDT following news that Dr Robert Charnas its head of regulatory affairs and project management is hitting the exits ahead of a scheduled Food and Drug Administration FDA advisory
PBYI,PBYI:US,BBG0018YXYX7,Oversold Conditions For Puma Biotechnology (PBYI),2017-05-05 17:27:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/25uuwRdkNwc/oversold-conditions-for-puma-biotechnology-pbyi-cm785102,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
PBYI,PBYI:UW,BBG002NFCGM3,Oversold Conditions For Puma Biotechnology (PBYI),2017-05-05 17:27:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/25uuwRdkNwc/oversold-conditions-for-puma-biotechnology-pbyi-cm785102,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
PBYI,PBYI:UW,BBG002NFCGM3,Why Puma Biotechnology Shares Are Crashing 18.2% Today,2017-05-05 17:10:33 +0000,http://finance.yahoo.com/r/b51bb33b-c46f-37c9-89f4-ee99a444cd1d/why-puma-biotechnology-shares-are-crashing-182-tod.aspx?yptr=yahoo&.tsrc=rss,The departure of a key executive ahead of an important FDA advisory committee meeting is raising questions.
PBYI,PBYI:US,BBG0018YXYX7,Why Puma Biotechnology Shares Are Crashing 18.2% Today,2017-05-05 17:10:33 +0000,http://finance.yahoo.com/r/b51bb33b-c46f-37c9-89f4-ee99a444cd1d/why-puma-biotechnology-shares-are-crashing-182-tod.aspx?yptr=yahoo&.tsrc=rss,The departure of a key executive ahead of an important FDA advisory committee meeting is raising questions.
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology, Inc. (PBYI)",2017-05-05 16:19:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-161900258.html?.tsrc=rss,"NEW YORK, May 5, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Puma Biotechnology, Inc. (""Puma"" ..."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology, Inc. (PBYI)",2017-05-05 16:19:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-161900258.html?.tsrc=rss,"NEW YORK, May 5, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Puma Biotechnology, Inc. (""Puma"" ..."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm",2017-05-05 16:08:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-investor-alert-faruqi-160800941.html?.tsrc=rss,"NEW YORK, May 5, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Puma Biotechnology, Inc. (""Puma Biotechnology"" ..."
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm",2017-05-05 16:08:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-investor-alert-faruqi-160800941.html?.tsrc=rss,"NEW YORK, May 5, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Puma Biotechnology, Inc. (""Puma Biotechnology"" ..."
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Puma Biotechnology, Inc. - PBYI",2017-05-05 14:19:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-141900543.html?.tsrc=rss,"NEW YORK, May 5, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Puma Biotechnology, Inc. (""Puma"" or the ""Company"") (NASDAQ: PBYI) (ISIN: US74587V1070). ..."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Puma Biotechnology, Inc. - PBYI",2017-05-05 14:19:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-141900543.html?.tsrc=rss,"NEW YORK, May 5, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Puma Biotechnology, Inc. (""Puma"" or the ""Company"") (NASDAQ: PBYI) (ISIN: US74587V1070). ..."
PBYI,PBYI:US,BBG0018YXYX7,"A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories",2017-05-05 10:53:00 +0000,http://finance.yahoo.com/r/b996c217-f9d9-35e4-b32d-c9348ea3fbae/a-top-puma-bio-exec-resigns-ahead-of-fda-panel-analysts-defend-with-conflicting-stories.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The surprise exit of Puma's regulatory chief is sparking fears the FDA will deal harshly with the company's breast cancer drug neratinib.
PBYI,PBYI:UW,BBG002NFCGM3,"A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories",2017-05-05 10:53:00 +0000,http://finance.yahoo.com/r/b996c217-f9d9-35e4-b32d-c9348ea3fbae/a-top-puma-bio-exec-resigns-ahead-of-fda-panel-analysts-defend-with-conflicting-stories.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The surprise exit of Puma's regulatory chief is sparking fears the FDA will deal harshly with the company's breast cancer drug neratinib.
PBYI,PBYI:UW,BBG002NFCGM3,4 Biotech Stocks That Could Be Rocked and Rolled This Month,2017-05-04 23:11:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A_fDod2CHMQ/4-biotech-stocks-that-could-be-rocked-and-rolled-this-month-cm784671,InvestorPlace Stock Market News Stock Advice amp Trading Tips The month of May isn t usually a good one for the overall market Though a handful of familiar names somehow muster bullishness in the month the S amp P 500 s average performance for the May is a loss of 0 2
PBYI,PBYI:US,BBG0018YXYX7,4 Biotech Stocks That Could Be Rocked and Rolled This Month,2017-05-04 23:11:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A_fDod2CHMQ/4-biotech-stocks-that-could-be-rocked-and-rolled-this-month-cm784671,InvestorPlace Stock Market News Stock Advice amp Trading Tips The month of May isn t usually a good one for the overall market Though a handful of familiar names somehow muster bullishness in the month the S amp P 500 s average performance for the May is a loss of 0 2
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?,2017-05-03 19:51:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zb9GA9O8h08/puma-biotechnology-pbyi-q1-earnings-stock-to-disappoint-cm783680,Puma Biotechnology Inc PBYI is expected to report first quarter 2017 results later this month The company s earnings track record is disappointing as it missed estimates in three of the trailing four quarters and met expectations in one The company had an average negative surprise of 3 23
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?,2017-05-03 19:51:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zb9GA9O8h08/puma-biotechnology-pbyi-q1-earnings-stock-to-disappoint-cm783680,Puma Biotechnology Inc PBYI is expected to report first quarter 2017 results later this month The company s earnings track record is disappointing as it missed estimates in three of the trailing four quarters and met expectations in one The company had an average negative surprise of 3 23
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?,2017-05-03 14:44:02 +0000,http://finance.yahoo.com/news/puma-biotechnology-pbyi-q1-earnings-144402538.html?.tsrc=rss,"Puma Biotechnology, Inc. (PBYI) is expected to report first-quarter 2017 results later this month."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?,2017-05-03 14:44:02 +0000,http://finance.yahoo.com/news/puma-biotechnology-pbyi-q1-earnings-144402538.html?.tsrc=rss,"Puma Biotechnology, Inc. (PBYI) is expected to report first-quarter 2017 results later this month."
PBYI,PBYI:US,BBG0018YXYX7,"Noteworthy Friday Option Activity: PBYI, ENVA, MSFT",2017-04-28 16:28:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H_b-Isy1Yac/noteworthy-friday-option-activity-pbyi-enva-msft-cm781182,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Puma Biotechnology Inc Symbol PBYI where a total volume of 6 240 contracts has been traded thus far today a contract volume which is representative of approximately 624
PBYI,PBYI:UW,BBG002NFCGM3,"Noteworthy Friday Option Activity: PBYI, ENVA, MSFT",2017-04-28 16:28:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H_b-Isy1Yac/noteworthy-friday-option-activity-pbyi-enva-msft-cm781182,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Puma Biotechnology Inc Symbol PBYI where a total volume of 6 240 contracts has been traded thus far today a contract volume which is representative of approximately 624
PBYI,PBYI:US,BBG0018YXYX7,Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug,2017-04-18 17:31:00 +0000,http://finance.yahoo.com/r/3933092d-b0bd-3f99-8add-1ff507bd1b27/shortened-fda-advisory-panel-is-bad-omen-for-puma-bio-s-controversial-breast-cancer-drug.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Over the past five years, the FDA has often used half-day sessions of the Oncologic Drugs Advisory Committee (ODAC) to administer public floggings to flawed cancer drugs."
PBYI,PBYI:UW,BBG002NFCGM3,Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug,2017-04-18 17:31:00 +0000,http://finance.yahoo.com/r/3933092d-b0bd-3f99-8add-1ff507bd1b27/shortened-fda-advisory-panel-is-bad-omen-for-puma-bio-s-controversial-breast-cancer-drug.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Over the past five years, the FDA has often used half-day sessions of the Oncologic Drugs Advisory Committee (ODAC) to administer public floggings to flawed cancer drugs."
PBYI,PBYI:US,BBG0018YXYX7,"OMED Disappoints, PBYI Soars, AMAG Seeks Expanded Approval For Makena",2017-04-18 01:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YiuoSwN88zw/omed-disappoints-pbyi-soars-amag-seeks-expanded-approval-for-makena-20170418-00035,"OMED Disappoints, PBYI Soars, AMAG Seeks Expanded Approval For Makena"
PBYI,PBYI:UW,BBG002NFCGM3,"OMED Disappoints, PBYI Soars, AMAG Seeks Expanded Approval For Makena",2017-04-18 01:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YiuoSwN88zw/omed-disappoints-pbyi-soars-amag-seeks-expanded-approval-for-makena-20170418-00035,"OMED Disappoints, PBYI Soars, AMAG Seeks Expanded Approval For Makena"
PBYI,PBYI:US,BBG0018YXYX7,"Gainers & Losers Of Apr.17: CBLI, INFI, PBYI, OMED, INCY...",2017-04-17 21:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hMfSMx6z5us/gainers--losers-of-apr17-cbli-infi-pbyi-omed-incy-20170417-00923,"Gainers & Losers Of Apr.17: CBLI, INFI, PBYI, OMED, INCY..."
PBYI,PBYI:UW,BBG002NFCGM3,"Gainers & Losers Of Apr.17: CBLI, INFI, PBYI, OMED, INCY...",2017-04-17 21:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hMfSMx6z5us/gainers--losers-of-apr17-cbli-infi-pbyi-omed-incy-20170417-00923,"Gainers & Losers Of Apr.17: CBLI, INFI, PBYI, OMED, INCY..."
PBYI,PBYI:US,BBG0018YXYX7,"Noteworthy Monday Option Activity: NFLX, PBYI, ALR",2017-04-17 16:55:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JhUZEzaHL7I/noteworthy-monday-option-activity-nflx-pbyi-alr-cm774696,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Netflix Inc Symbol NFLX where a total of 65 186 contracts have traded so far representing approximately 6 5 million underlying shares That amounts to about 143 1 of NFLX s
PBYI,PBYI:UW,BBG002NFCGM3,"Noteworthy Monday Option Activity: NFLX, PBYI, ALR",2017-04-17 16:55:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JhUZEzaHL7I/noteworthy-monday-option-activity-nflx-pbyi-alr-cm774696,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Netflix Inc Symbol NFLX where a total of 65 186 contracts have traded so far representing approximately 6 5 million underlying shares That amounts to about 143 1 of NFLX s
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,2017-04-17 12:03:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-announces-fda-advisory-120300748.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, today announced that the U.S. Food and Drug Administration has scheduled the New Drug Application for neratinib for discussion by the Oncologic Drugs Advisory Committee on May 24, 2017."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,2017-04-17 12:03:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-announces-fda-advisory-120300748.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, today announced that the U.S. Food and Drug Administration has scheduled the New Drug Application for neratinib for discussion by the Oncologic Drugs Advisory Committee on May 24, 2017."
PBYI,PBYI:UW,BBG002NFCGM3,InPlay from Briefing.com,2017-04-12 14:53:19 +0000,http://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
PBYI,PBYI:US,BBG0018YXYX7,InPlay from Briefing.com,2017-04-12 14:53:19 +0000,http://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting,2017-04-04 17:05:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-interim-results-170500987.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that interim results from a Phase II clinical trial of Puma’s investigational drug PB272 were presented at the 2017 American Association for Cancer Research Annual Meeting that is currently taking place in Washington, D.C."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting,2017-04-04 17:05:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-interim-results-170500987.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that interim results from a Phase II clinical trial of Puma’s investigational drug PB272 were presented at the 2017 American Association for Cancer Research Annual Meeting that is currently taking place in Washington, D.C."
PBYI,PBYI:US,BBG0018YXYX7,"3:14 am Puma Biotech initiates expanded access program in US to provide PB272 (neratinib), to patients with HER2-positive breast cancer or HER2-mutated cancers; reports Phase II SUMMIT Trial of PB272",2017-04-03 07:14:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#pbyi,"3:14 am Puma Biotech initiates expanded access program in US to provide PB272 (neratinib), to patients with HER2-positive breast cancer or HER2-mutated cancers; reports Phase II SUMMIT Trial of PB272"
PBYI,PBYI:UW,BBG002NFCGM3,"3:14 am Puma Biotech initiates expanded access program in US to provide PB272 (neratinib), to patients with HER2-positive breast cancer or HER2-mutated cancers; reports Phase II SUMMIT Trial of PB272",2017-04-03 07:14:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#pbyi,"3:14 am Puma Biotech initiates expanded access program in US to provide PB272 (neratinib), to patients with HER2-positive breast cancer or HER2-mutated cancers; reports Phase II SUMMIT Trial of PB272"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting,2017-04-02 19:03:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-interim-results-190300789.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma’s investigational drug PB272 given in combination with the antibody drug conjugate T-DM1 were presented at the 2017 American Association for Cancer Research Annual Meeting that is currently taking place in Washington, D.C."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting,2017-04-02 19:03:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-interim-results-190300789.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma’s investigational drug PB272 given in combination with the antibody drug conjugate T-DM1 were presented at the 2017 American Association for Cancer Research Annual Meeting that is currently taking place in Washington, D.C."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting,2017-04-02 19:03:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-interim-results-190300789.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma’s investigational drug PB272 given in combination with the antibody drug conjugate T-DM1 were presented at the 2017 American Association for Cancer Research Annual Meeting that is currently taking place in Washington, D.C."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting,2017-04-02 19:03:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-interim-results-190300789.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma’s investigational drug PB272 given in combination with the antibody drug conjugate T-DM1 were presented at the 2017 American Association for Cancer Research Annual Meeting that is currently taking place in Washington, D.C."
PBYI,PBYI:US,BBG0018YXYX7,"Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting",2017-04-02 15:03:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-results-phase-150300318.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 were presented at the 2017 American Association for Cancer Research Annual Meeting that is currently taking place in Washington, D.C."
PBYI,PBYI:US,BBG0018YXYX7,"Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting",2017-04-02 15:03:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-results-phase-150300318.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 were presented at the 2017 American Association for Cancer Research Annual Meeting that is currently taking place in Washington, D.C."
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting",2017-04-02 15:03:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-results-phase-150300318.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 were presented at the 2017 American Association for Cancer Research Annual Meeting that is currently taking place in Washington, D.C."
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting",2017-04-02 15:03:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-results-phase-150300318.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 were presented at the 2017 American Association for Cancer Research Annual Meeting that is currently taking place in Washington, D.C."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers,2017-04-02 14:30:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-launches-expanded-access-143000042.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, has initiated an expanded access program in the United States to provide its investigational therapy, PB272 , to patients with HER2-positive breast cancer or HER2-mutated cancers."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers,2017-04-02 14:30:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-launches-expanded-access-143000042.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, has initiated an expanded access program in the United States to provide its investigational therapy, PB272 , to patients with HER2-positive breast cancer or HER2-mutated cancers."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers,2017-04-02 14:30:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-launches-expanded-access-143000042.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, has initiated an expanded access program in the United States to provide its investigational therapy, PB272 , to patients with HER2-positive breast cancer or HER2-mutated cancers."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers,2017-04-02 14:30:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-launches-expanded-access-143000042.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, has initiated an expanded access program in the United States to provide its investigational therapy, PB272 , to patients with HER2-positive breast cancer or HER2-mutated cancers."
PBYI,PBYI:US,BBG0018YXYX7,"Adage Capital Partners Gp Llc Buys Wells Fargo, General Dynamics, Puma Biotechnology, Sells ...",2017-03-25 12:58:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rIPY1zUsEeY/adage-capital-partners-gp-llc-buys-wells-fargo-general-dynamics-puma-biotechnology-sells-cm765578,Adage Capital Partners Gp Llc New Purchases PBYI NXPI CC ALB VVC DISH GIS FTS EXC COTY Added Positions WFC GD JCI NEE DIS MOS PKI GS LRCX STJ Reduced Positions SRE AGN HON HDS PG APD APC BURL WMB EW Sold Out PBYI LNKD
PBYI,PBYI:UW,BBG002NFCGM3,"Adage Capital Partners Gp Llc Buys Wells Fargo, General Dynamics, Puma Biotechnology, Sells ...",2017-03-25 12:58:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rIPY1zUsEeY/adage-capital-partners-gp-llc-buys-wells-fargo-general-dynamics-puma-biotechnology-sells-cm765578,Adage Capital Partners Gp Llc New Purchases PBYI NXPI CC ALB VVC DISH GIS FTS EXC COTY Added Positions WFC GD JCI NEE DIS MOS PKI GS LRCX STJ Reduced Positions SRE AGN HON HDS PG APD APC BURL WMB EW Sold Out PBYI LNKD
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and",2017-03-24 21:00:28 +0000,http://biz.yahoo.com/e/170324/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and"
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and",2017-03-24 21:00:28 +0000,http://biz.yahoo.com/e/170324/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and"
PBYI,PBYI:US,BBG0018YXYX7,Finding Bullish and Bearish Market Reversals,2017-03-20 17:00:00 +0000,http://realmoney.thestreet.com/articles/03/20/2017/finding-bullish-and-bearish-market-reversals?puc=yahoo&cm_ven=YAHOO,Finding Bullish and Bearish Market Reversals
PBYI,PBYI:US,BBG0018YXYX7,Finding Bullish and Bearish Market Reversals,2017-03-20 17:00:00 +0000,http://finance.yahoo.com/r/1579d16f-7427-33d7-89bb-0789ac1be0d3/finding-bullish-and-bearish-market-reversals?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,These stocks are showing signs of changing direction.
PBYI,PBYI:UW,BBG002NFCGM3,Finding Bullish and Bearish Market Reversals,2017-03-20 17:00:00 +0000,http://finance.yahoo.com/r/1579d16f-7427-33d7-89bb-0789ac1be0d3/finding-bullish-and-bearish-market-reversals?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,These stocks are showing signs of changing direction.
PBYI,PBYI:UW,BBG002NFCGM3,Finding Bullish and Bearish Market Reversals,2017-03-20 17:00:00 +0000,http://realmoney.thestreet.com/articles/03/20/2017/finding-bullish-and-bearish-market-reversals?puc=yahoo&cm_ven=YAHOO,Finding Bullish and Bearish Market Reversals
PBYI,PBYI:US,BBG0018YXYX7,7 Stocks Trending Up With Monster Volume,2017-03-09 12:00:00 +0000,https://www.thestreet.com/story/14034020/1/7-stocks-trending-up-with-monster-volume.html?puc=yahoo&cm_ven=YAHOO,7 Stocks Trending Up With Monster Volume
PBYI,PBYI:US,BBG0018YXYX7,7 Stocks Trending Up With Monster Volume,2017-03-09 12:00:00 +0000,http://finance.yahoo.com/r/55e3b2dd-5901-3a52-a522-f72a0e36d9f3/7-stocks-trending-up-with-monster-volume.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Here's a technical look at how to play a number of stocks trending higher with strong volume.
PBYI,PBYI:UW,BBG002NFCGM3,7 Stocks Trending Up With Monster Volume,2017-03-09 12:00:00 +0000,http://finance.yahoo.com/r/55e3b2dd-5901-3a52-a522-f72a0e36d9f3/7-stocks-trending-up-with-monster-volume.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Here's a technical look at how to play a number of stocks trending higher with strong volume.
PBYI,PBYI:UW,BBG002NFCGM3,7 Stocks Trending Up With Monster Volume,2017-03-09 12:00:00 +0000,https://www.thestreet.com/story/14034020/1/7-stocks-trending-up-with-monster-volume.html?puc=yahoo&cm_ven=YAHOO,7 Stocks Trending Up With Monster Volume
PBYI,PBYI:UW,BBG002NFCGM3,Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High,2017-03-08 21:26:56 +0000,http://finance.yahoo.com/r/854c6c59-6440-3d2f-a760-5c994a4d9f36/puma-leads-massive-biotech-surge-as-esperion-hits-15-month-high?src=A00220A&yptr=yahoo&.tsrc=rss,"Esperion stock hit a 15-month high Wednesday on a broad biotech surge that saw Puma, AveXis and Bluebird leap."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High,2017-03-08 21:26:56 +0000,http://www.investors.com/news/technology/puma-leads-massive-biotech-surge-as-esperion-hits-15-month-high/?src=A00220A,Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High
PBYI,PBYI:US,BBG0018YXYX7,Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High,2017-03-08 21:26:56 +0000,http://www.investors.com/news/technology/puma-leads-massive-biotech-surge-as-esperion-hits-15-month-high/?src=A00220A,Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High
PBYI,PBYI:US,BBG0018YXYX7,Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High,2017-03-08 21:26:56 +0000,http://finance.yahoo.com/r/854c6c59-6440-3d2f-a760-5c994a4d9f36/puma-leads-massive-biotech-surge-as-esperion-hits-15-month-high?src=A00220A&yptr=yahoo&.tsrc=rss,"Esperion stock hit a 15-month high Wednesday on a broad biotech surge that saw Puma, AveXis and Bluebird leap."
PBYI,PBYI:US,BBG0018YXYX7,"Gainers & Losers Of Mar.8: GBT, CYCC, GNMX, MGCD, TRVN...",2017-03-08 19:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KejySBng75s/gainers--losers-of-mar8-gbt-cycc-gnmx-mgcd-trvn-20170308-01392,"Gainers & Losers Of Mar.8: GBT, CYCC, GNMX, MGCD, TRVN..."
PBYI,PBYI:UW,BBG002NFCGM3,"Gainers & Losers Of Mar.8: GBT, CYCC, GNMX, MGCD, TRVN...",2017-03-08 19:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KejySBng75s/gainers--losers-of-mar8-gbt-cycc-gnmx-mgcd-trvn-20170308-01392,"Gainers & Losers Of Mar.8: GBT, CYCC, GNMX, MGCD, TRVN..."
PBYI,PBYI:UW,BBG002NFCGM3,"Wednesday's ETF Movers: XBI, XOP",2017-03-08 19:13:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VZbeu7YnWXM/wednesdays-etf-movers-xbi-xop-cm758052,In trading on Wednesday the SPDR S amp P Biotech ETF is outperforming other ETFs up about 2 3 on the day Components of that ETF showing particular strength include shares of Puma Biotechnology up about 10 4 and shares of Cytokinetics up about 8 5 on the day And underperforming
PBYI,PBYI:US,BBG0018YXYX7,"Wednesday's ETF Movers: XBI, XOP",2017-03-08 19:13:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VZbeu7YnWXM/wednesdays-etf-movers-xbi-xop-cm758052,In trading on Wednesday the SPDR S amp P Biotech ETF is outperforming other ETFs up about 2 3 on the day Components of that ETF showing particular strength include shares of Puma Biotechnology up about 10 4 and shares of Cytokinetics up about 8 5 on the day And underperforming
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Financials",2017-03-07 18:04:16 +0000,http://finance.yahoo.com/q/is?s=pbyi,"PUMA BIOTECHNOLOGY, INC. Financials"
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Financials",2017-03-07 18:04:16 +0000,http://finance.yahoo.com/q/is?s=pbyi,"PUMA BIOTECHNOLOGY, INC. Financials"
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus",2017-03-03 00:13:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SqdcaLv8OCI/puma-pbyi-q4-loss-wider-than-expected-neratinib-in-focus-cm755715,Puma Biotechnology Inc PBYI reported a fourth quarter 2016 loss of 2 04 per share including the impact of stock based compensation expenses wider than both the Zacks Consensus Estimate of a loss of 2 02 and the year ago loss of 1 90 So far this year Puma s shares
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus",2017-03-03 00:13:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SqdcaLv8OCI/puma-pbyi-q4-loss-wider-than-expected-neratinib-in-focus-cm755715,Puma Biotechnology Inc PBYI reported a fourth quarter 2016 loss of 2 04 per share including the impact of stock based compensation expenses wider than both the Zacks Consensus Estimate of a loss of 2 02 and the year ago loss of 1 90 So far this year Puma s shares
PBYI,PBYI:US,BBG0018YXYX7,Why Puma Biotechnology Inc. Got Hammered Today,2017-03-02 23:13:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3BtpsvfKQqc/why-puma-biotechnology-inc-got-hammered-today-cm755681,What happened Puma Biotechnology NASDAQ PBYI ended the day down 13 8 after Roche NASDAQOTH RHHBY reported that its rival breast cancer drug Perjeta had passed its phase 3 trial dubbed Aphinity Image source Getty Images So what In Roche s
PBYI,PBYI:UW,BBG002NFCGM3,Why Puma Biotechnology Inc. Got Hammered Today,2017-03-02 23:13:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3BtpsvfKQqc/why-puma-biotechnology-inc-got-hammered-today-cm755681,What happened Puma Biotechnology NASDAQ PBYI ended the day down 13 8 after Roche NASDAQOTH RHHBY reported that its rival breast cancer drug Perjeta had passed its phase 3 trial dubbed Aphinity Image source Getty Images So what In Roche s
PBYI,PBYI:US,BBG0018YXYX7,"Kroger, Shake Shack and Puma dip; Monster Beverage gains",2017-03-02 22:31:10 +0000,http://finance.yahoo.com/news/kroger-shake-shack-puma-dip-223110516.html?.tsrc=rss,"Stocks that moved substantially or traded heavily Thursday: Kroger Co., down $1.39 to $30.67 The supermarket chain gave a cautious forecast as it said business conditions will remain difficult in early ..."
PBYI,PBYI:UW,BBG002NFCGM3,"Kroger, Shake Shack and Puma dip; Monster Beverage gains",2017-03-02 22:31:10 +0000,http://finance.yahoo.com/news/kroger-shake-shack-puma-dip-223110516.html?.tsrc=rss,"Stocks that moved substantially or traded heavily Thursday: Kroger Co., down $1.39 to $30.67 The supermarket chain gave a cautious forecast as it said business conditions will remain difficult in early ..."
PBYI,PBYI:US,BBG0018YXYX7,"Kroger, Shake Shack and Puma dip; Monster Beverage gains",2017-03-02 22:31:10 +0000,http://sg.finance.yahoo.com/news/kroger-shake-shack-puma-dip-223110337.html,"Kroger, Shake Shack and Puma dip; Monster Beverage gains"
PBYI,PBYI:UW,BBG002NFCGM3,"Kroger, Shake Shack and Puma dip; Monster Beverage gains",2017-03-02 22:31:10 +0000,http://sg.finance.yahoo.com/news/kroger-shake-shack-puma-dip-223110337.html,"Kroger, Shake Shack and Puma dip; Monster Beverage gains"
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus",2017-03-02 21:53:09 +0000,http://finance.yahoo.com/news/puma-pbyi-q4-loss-wider-215309396.html?.tsrc=rss,"Puma Biotechnology, Inc. (PBYI) reported a fourth-quarter 2016 loss of $2.04 per share (including the impact of stock-based compensation expenses), wider than both the Zacks Consensus Estimate of a loss of $2.02."
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus",2017-03-02 21:53:09 +0000,http://finance.yahoo.com/news/puma-pbyi-q4-loss-wider-215309396.html,"Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus"
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus",2017-03-02 21:53:09 +0000,http://finance.yahoo.com/news/puma-pbyi-q4-loss-wider-215309396.html,"Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus"
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus",2017-03-02 21:53:09 +0000,http://finance.yahoo.com/news/puma-pbyi-q4-loss-wider-215309396.html?.tsrc=rss,"Puma Biotechnology, Inc. (PBYI) reported a fourth-quarter 2016 loss of $2.04 per share (including the impact of stock-based compensation expenses), wider than both the Zacks Consensus Estimate of a loss of $2.02."
PBYI,PBYI:UW,BBG002NFCGM3,Why Puma Biotechnology Inc. Got Hammered Today,2017-03-02 21:43:00 +0000,http://finance.yahoo.com/r/df8ea854-e4fc-3f1e-a3f0-b2bc58d53f1c/why-puma-biotechnology-inc-got-hammered-today.aspx?yptr=yahoo&.tsrc=rss,Competition from rival Roche has the biotech trading lower.
PBYI,PBYI:US,BBG0018YXYX7,Why Puma Biotechnology Inc. Got Hammered Today,2017-03-02 21:43:00 +0000,http://finance.yahoo.com/r/df8ea854-e4fc-3f1e-a3f0-b2bc58d53f1c/why-puma-biotechnology-inc-got-hammered-today.aspx?yptr=yahoo&.tsrc=rss,Competition from rival Roche has the biotech trading lower.
PBYI,PBYI:UW,BBG002NFCGM3,Why Puma Biotechnology Inc. Got Hammered Today,2017-03-02 21:43:00 +0000,http://www.fool.com/investing/2017/03/02/why-puma-biotechnology-inc-got-hammered-today.aspx,Why Puma Biotechnology Inc. Got Hammered Today
PBYI,PBYI:US,BBG0018YXYX7,Why Puma Biotechnology Inc. Got Hammered Today,2017-03-02 21:43:00 +0000,http://www.fool.com/investing/2017/03/02/why-puma-biotechnology-inc-got-hammered-today.aspx,Why Puma Biotechnology Inc. Got Hammered Today
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Present at Cowen’s Health Care Conference,2017-03-02 21:20:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-present-cowen-health-212000959.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:20 p.m."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Present at Cowen’s Health Care Conference,2017-03-02 21:20:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-present-cowen-health-212000959.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:20 p.m."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Present at Cowen’s Health Care Conference,2017-03-02 21:20:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-present-cowen-health-212000959.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:20 p.m."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Present at Cowen’s Health Care Conference,2017-03-02 21:20:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-present-cowen-health-212000959.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:20 p.m."
PBYI,PBYI:US,BBG0018YXYX7,"Health Care Sector Update for 03/02/2017: PBYI,AUPH,ADPT",2017-03-02 18:12:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mgEExCKZi4A/health-care-sector-update-for-03022017-pbyiauphadpt-cm755546,Top Health Care StocksTop Health Care Stocks JNJ 0 13 JNJ 0 13 PFE 0 78 PFE 0 78 MRK 0 25 MRK 0 25 ABT 0 02 ABT 0 02 AMGN 0 22 AMGN 0 22 Health care stocks were little changed on Thursday with the NYSE Health Care Index declining less than 0 1 while shares of health care
PBYI,PBYI:UW,BBG002NFCGM3,"Health Care Sector Update for 03/02/2017: PBYI,AUPH,ADPT",2017-03-02 18:12:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mgEExCKZi4A/health-care-sector-update-for-03022017-pbyiauphadpt-cm755546,Top Health Care StocksTop Health Care Stocks JNJ 0 13 JNJ 0 13 PFE 0 78 PFE 0 78 MRK 0 25 MRK 0 25 ABT 0 02 ABT 0 02 AMGN 0 22 AMGN 0 22 Health care stocks were little changed on Thursday with the NYSE Health Care Index declining less than 0 1 while shares of health care
PBYI,PBYI:UW,BBG002NFCGM3,Puma Plunges on Breast Cancer Drug Update,2017-03-02 17:05:00 +0000,http://www.investopedia.com/news/puma-plunges-breast-cancer-drug-update-pbyi/?partner=YahooSA,Puma Plunges on Breast Cancer Drug Update
PBYI,PBYI:UW,BBG002NFCGM3,Puma Plunges on Breast Cancer Drug Update,2017-03-02 17:05:00 +0000,http://finance.yahoo.com/r/03a94a71-54e0-36c2-9471-259c4f8ed1f0/puma-plunges-breast-cancer-drug-update-pbyi?partner=YahooSA&yptr=yahoo&.tsrc=rss,Puma’s announcement that it will modify its EU marketing application tanked its stock by 25%
PBYI,PBYI:US,BBG0018YXYX7,Puma Plunges on Breast Cancer Drug Update,2017-03-02 17:05:00 +0000,http://finance.yahoo.com/r/03a94a71-54e0-36c2-9471-259c4f8ed1f0/puma-plunges-breast-cancer-drug-update-pbyi?partner=YahooSA&yptr=yahoo&.tsrc=rss,Puma’s announcement that it will modify its EU marketing application tanked its stock by 25%
PBYI,PBYI:US,BBG0018YXYX7,Puma Plunges on Breast Cancer Drug Update,2017-03-02 17:05:00 +0000,http://www.investopedia.com/news/puma-plunges-breast-cancer-drug-update-pbyi/?partner=YahooSA,Puma Plunges on Breast Cancer Drug Update
PBYI,PBYI:UW,BBG002NFCGM3,Top Biotech Stocks With FDA Decisions in 2017,2017-03-02 15:42:00 +0000,http://finance.yahoo.com/r/ff15c78e-b8a4-3cc8-95f3-d928326a20d1/top-biotech-stocks-with-fda-decisions-in-2017.aspx?yptr=yahoo&.tsrc=rss,"Flexion Therapeutics, Puma Biotechnology, and Portola Pharmaceuticals have important FDA decisions coming up this year."
PBYI,PBYI:US,BBG0018YXYX7,Top Biotech Stocks With FDA Decisions in 2017,2017-03-02 15:42:00 +0000,http://www.fool.com/investing/2017/03/02/top-biotech-stocks-with-fda-decisions-in-2017.aspx,Top Biotech Stocks With FDA Decisions in 2017
PBYI,PBYI:UW,BBG002NFCGM3,Top Biotech Stocks With FDA Decisions in 2017,2017-03-02 15:42:00 +0000,http://www.fool.com/investing/2017/03/02/top-biotech-stocks-with-fda-decisions-in-2017.aspx,Top Biotech Stocks With FDA Decisions in 2017
PBYI,PBYI:US,BBG0018YXYX7,Top Biotech Stocks With FDA Decisions in 2017,2017-03-02 15:42:00 +0000,http://finance.yahoo.com/r/ff15c78e-b8a4-3cc8-95f3-d928326a20d1/top-biotech-stocks-with-fda-decisions-in-2017.aspx?yptr=yahoo&.tsrc=rss,"Flexion Therapeutics, Puma Biotechnology, and Portola Pharmaceuticals have important FDA decisions coming up this year."
PBYI,PBYI:UW,BBG002NFCGM3,Wall Street Posts Small Gains as Jobless Claims Shows Surprise Drop; Snap IPO Eyed,2017-03-02 14:32:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GHDnRpIh4Rk/wall-street-posts-small-gains-as-jobless-claims-shows-surprise-drop-snap-ipo-eyed-cm755265,U S stocks were mostly higher ahead of Thursday s open as official data showed a surprise drop in new jobless claims and as traders looked ahead to the much anticipated initial public offering of Snapchat parent Snap Inc U S stocks were mostly higher ahead of Thursday s open as official
PBYI,PBYI:US,BBG0018YXYX7,Wall Street Posts Small Gains as Jobless Claims Shows Surprise Drop; Snap IPO Eyed,2017-03-02 14:32:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GHDnRpIh4Rk/wall-street-posts-small-gains-as-jobless-claims-shows-surprise-drop-snap-ipo-eyed-cm755265,U S stocks were mostly higher ahead of Thursday s open as official data showed a surprise drop in new jobless claims and as traders looked ahead to the much anticipated initial public offering of Snapchat parent Snap Inc U S stocks were mostly higher ahead of Thursday s open as official
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech shares plummet 26% after Roche reports positive results for late-stage breast cancer drug,2017-03-02 14:14:19 +0000,http://finance.yahoo.com/r/98fe1601-d46d-385c-ab41-b4eee91b487f/Story.aspx?guid=1B21BACE-E185-4C5A-AA02-A40292CAD0FF&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Puma Biotechnology Inc. shares dropped 26.3% in pre-market trade Thursday after rival Roche said its drug for early breast cancer had positive results in a late-stage clinical trial. Roche said for post-surgical ...
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech shares plummet 26% after Roche reports positive results for late-stage breast cancer drug,2017-03-02 14:14:19 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=1B21BACE-E185-4C5A-AA02-A40292CAD0FF&siteid=yhoof2,Puma Biotech shares plummet 26% after Roche reports positive results for late-stage breast cancer drug
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech shares plummet 26% after Roche reports positive results for late-stage breast cancer drug,2017-03-02 14:14:19 +0000,http://finance.yahoo.com/r/98fe1601-d46d-385c-ab41-b4eee91b487f/Story.aspx?guid=1B21BACE-E185-4C5A-AA02-A40292CAD0FF&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Puma Biotechnology Inc. shares dropped 26.3% in pre-market trade Thursday after rival Roche said its drug for early breast cancer had positive results in a late-stage clinical trial. Roche said for post-surgical ...
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech shares plummet 26% after Roche reports positive results for late-stage breast cancer drug,2017-03-02 14:14:19 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=1B21BACE-E185-4C5A-AA02-A40292CAD0FF&siteid=yhoof2,Puma Biotech shares plummet 26% after Roche reports positive results for late-stage breast cancer drug
PBYI,PBYI:US,BBG0018YXYX7,"Pre-Market Most Active for Mar 2, 2017 :  AUPH, JD, PTCT, TOT, NOK, BAC, PBYI, SFR, PKX, TVIX, ARES, IBKC",2017-03-02 13:52:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NiRAciN0Hlo/pre-market-most-active-for-mar-2-2017-auph-jd-ptct-tot-nok-bac-pbyi-sfr-pkx-tvix-ares-ibkc-cm755245,The NASDAQ 100 Pre Market Indicator is up 8 84 to 5 399 83 The total Pre Market volume is currently 6 698 994 shares traded The following are the most active stocks for the pre market session Aurinia Pharmaceuticals Inc AUPH is 2 19 at 5 90 with 1 567 075
PBYI,PBYI:UW,BBG002NFCGM3,"Pre-Market Most Active for Mar 2, 2017 :  AUPH, JD, PTCT, TOT, NOK, BAC, PBYI, SFR, PKX, TVIX, ARES, IBKC",2017-03-02 13:52:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NiRAciN0Hlo/pre-market-most-active-for-mar-2-2017-auph-jd-ptct-tot-nok-bac-pbyi-sfr-pkx-tvix-ares-ibkc-cm755245,The NASDAQ 100 Pre Market Indicator is up 8 84 to 5 399 83 The total Pre Market volume is currently 6 698 994 shares traded The following are the most active stocks for the pre market session Aurinia Pharmaceuticals Inc AUPH is 2 19 at 5 90 with 1 567 075
PBYI,PBYI:UW,BBG002NFCGM3,"US Futures in Holding Pattern Ahead of Jobs Data, Snap IPO",2017-03-02 13:32:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JNjZKRtGLUw/us-futures-in-holding-pattern-ahead-of-jobs-data-snap-ipo-cm755230,U S stock futures were practically unchanged on Thursday as traders stayed sidelined ahead of the release of labor market data and the much anticipated initial public offering Snapchat parent Snap Inc U S stock futures were practically unchanged on Thursday as traders stayed sidelined ahead
PBYI,PBYI:US,BBG0018YXYX7,"US Futures in Holding Pattern Ahead of Jobs Data, Snap IPO",2017-03-02 13:32:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JNjZKRtGLUw/us-futures-in-holding-pattern-ahead-of-jobs-data-snap-ipo-cm755230,U S stock futures were practically unchanged on Thursday as traders stayed sidelined ahead of the release of labor market data and the much anticipated initial public offering Snapchat parent Snap Inc U S stock futures were practically unchanged on Thursday as traders stayed sidelined ahead
PBYI,PBYI:US,BBG0018YXYX7,"Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win",2017-03-02 11:36:00 +0000,http://finance.yahoo.com/r/e308b016-8ed2-3b73-86db-016aff6de409/roche-shares-hit-7-month-high-after-successful-breast-cancer-drug-trials.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Roche shares surged in Zurich Thursday after the Swiss drugmaker said trials of its key breast cancer drug showed solid results when compared to chemotherapy.
PBYI,PBYI:US,BBG0018YXYX7,"Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win",2017-03-02 11:36:00 +0000,https://www.thestreet.com/story/14023195/1/roche-shares-hit-7-month-high-after-successful-breast-cancer-drug-trials.html?puc=yahoo&cm_ven=YAHOO,"Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win"
PBYI,PBYI:UW,BBG002NFCGM3,"Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win",2017-03-02 11:36:00 +0000,https://www.thestreet.com/story/14023195/1/roche-shares-hit-7-month-high-after-successful-breast-cancer-drug-trials.html?puc=yahoo&cm_ven=YAHOO,"Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win"
PBYI,PBYI:UW,BBG002NFCGM3,"Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win",2017-03-02 11:36:00 +0000,http://finance.yahoo.com/r/e308b016-8ed2-3b73-86db-016aff6de409/roche-shares-hit-7-month-high-after-successful-breast-cancer-drug-trials.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Roche shares surged in Zurich Thursday after the Swiss drugmaker said trials of its key breast cancer drug showed solid results when compared to chemotherapy.
PBYI,PBYI:US,BBG0018YXYX7,"FDA Approves Odactra, JUNO Abandons Rocket, VRML Abuzz, No Tremors For NDRM",2017-03-02 05:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AeyT2lhQlYg/fda-approves-odactra-juno-abandons-rocket-vrml-abuzz-no-tremors-for-ndrm-20170302-00244,"FDA Approves Odactra, JUNO Abandons Rocket, VRML Abuzz, No Tremors For NDRM"
PBYI,PBYI:UW,BBG002NFCGM3,"FDA Approves Odactra, JUNO Abandons Rocket, VRML Abuzz, No Tremors For NDRM",2017-03-02 05:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AeyT2lhQlYg/fda-approves-odactra-juno-abandons-rocket-vrml-abuzz-no-tremors-for-ndrm-20170302-00244,"FDA Approves Odactra, JUNO Abandons Rocket, VRML Abuzz, No Tremors For NDRM"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech reports 4Q loss,2017-03-01 23:08:53 +0000,http://sg.finance.yahoo.com/news/puma-biotech-reports-4q-loss-230853554.html,Puma Biotech reports 4Q loss
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech reports 4Q loss,2017-03-01 23:08:53 +0000,http://sg.finance.yahoo.com/news/puma-biotech-reports-4q-loss-230853554.html,Puma Biotech reports 4Q loss
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017,2017-03-01 23:02:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-announces-publication-abstracts-230200500.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research Annual Meeting 2017."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017,2017-03-01 23:02:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-announces-publication-abstracts-230200500.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research Annual Meeting 2017."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017,2017-03-01 23:02:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-announces-publication-abstracts-230200500.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research Annual Meeting 2017."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017,2017-03-01 23:02:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-announces-publication-abstracts-230200500.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research Annual Meeting 2017."
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2017-03-01 21:59:21 +0000,http://biz.yahoo.com/e/170301/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2017-03-01 21:59:21 +0000,http://biz.yahoo.com/e/170301/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272,2017-03-01 21:46:00 +0000,http://uk.finance.yahoo.com/news/puma-biotechnology-provides-review-marketing-214600426.html,Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272,2017-03-01 21:46:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-provides-review-marketing-214600725.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that based on its recent meeting with the Rapporteur, Co-Rapporteur and review team members, as well as the European Medicines Agency , the Company plans to modify the summary of product characteristics , sometimes referred to as the European product label, in its Marketing Authorisation Application to restrict the intended population ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272,2017-03-01 21:46:00 +0000,http://uk.finance.yahoo.com/news/puma-biotechnology-provides-review-marketing-214600426.html,Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272,2017-03-01 21:46:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-provides-review-marketing-214600725.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced that based on its recent meeting with the Rapporteur, Co-Rapporteur and review team members, as well as the European Medicines Agency , the Company plans to modify the summary of product characteristics , sometimes referred to as the European product label, in its Marketing Authorisation Application to restrict the intended population ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results,2017-03-01 21:20:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-reports-fourth-quarter-212000802.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2016."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results,2017-03-01 21:20:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-reports-fourth-quarter-212000802.html?.tsrc=rss,"Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2016."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results,2017-03-01 21:20:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-reports-fourth-quarter-212000802.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2016."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results,2017-03-01 21:20:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-reports-fourth-quarter-212000802.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2016."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 10-K, Annual Report",2017-03-01 21:11:33 +0000,http://biz.yahoo.com/e/170301/pbyi10-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 10-K, Annual Report"
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 10-K, Annual Report",2017-03-01 21:11:33 +0000,http://biz.yahoo.com/e/170301/pbyi10-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 10-K, Annual Report"
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?,2017-02-27 14:53:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_zbpHK9kdJ8/puma-biotechnology-pbyi-q4-earnings-whats-in-the-cards-cm753546,Puma Biotechnology Inc PBYI is expected to report fourth quarter 2016 results next month The company has a mixed earnings history It missed estimates in two of the trailing four quarters met expectations in one and surpassed the same in the other The company had an average negative
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?,2017-02-27 14:53:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_zbpHK9kdJ8/puma-biotechnology-pbyi-q4-earnings-whats-in-the-cards-cm753546,Puma Biotechnology Inc PBYI is expected to report fourth quarter 2016 results next month The company has a mixed earnings history It missed estimates in two of the trailing four quarters met expectations in one and surpassed the same in the other The company had an average negative
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?,2017-02-27 13:28:01 +0000,http://finance.yahoo.com/news/puma-biotechnology-pbyi-q4-earnings-132801793.html,Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?,2017-02-27 13:28:01 +0000,http://finance.yahoo.com/news/puma-biotechnology-pbyi-q4-earnings-132801793.html?.tsrc=rss,"Puma Biotechnology, Inc. (PBYI) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?,2017-02-27 13:28:01 +0000,http://finance.yahoo.com/news/puma-biotechnology-pbyi-q4-earnings-132801793.html?.tsrc=rss,"Puma Biotechnology, Inc. (PBYI) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?,2017-02-27 13:28:01 +0000,http://finance.yahoo.com/news/puma-biotechnology-pbyi-q4-earnings-132801793.html,Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?
PBYI,PBYI:US,BBG0018YXYX7,"Notable Friday Option Activity: PBYI, VMI, ASH",2017-02-17 21:51:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uPl58oLi_yc/notable-friday-option-activity-pbyi-vmi-ash-cm749838,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Puma Biotechnology Inc Symbol PBYI where a total volume of 2 998 contracts has been traded thus far today a contract volume which is representative of approximately 299
PBYI,PBYI:UW,BBG002NFCGM3,"Notable Friday Option Activity: PBYI, VMI, ASH",2017-02-17 21:51:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uPl58oLi_yc/notable-friday-option-activity-pbyi-vmi-ash-cm749838,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Puma Biotechnology Inc Symbol PBYI where a total volume of 2 998 contracts has been traded thus far today a contract volume which is representative of approximately 299
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference,2017-02-14 21:15:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-present-rbc-capital-211500716.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 2:05 p.m."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference,2017-02-14 21:15:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-present-rbc-capital-211500716.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 2:05 p.m."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference,2017-02-08 21:15:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-present-leerink-partners-211500119.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:00 a.m."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference,2017-02-08 21:15:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-present-leerink-partners-211500119.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:00 a.m."
PBYI,PBYI:US,BBG0018YXYX7,Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?,2017-02-03 14:19:00 +0000,https://www.thestreet.com/story/13977856/1/biotech-stock-mailbag-do-investors-have-an-aphinity-for-shorting-puma-into-trial-results.html?puc=yahoo&cm_ven=YAHOO,Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?
PBYI,PBYI:UW,BBG002NFCGM3,Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?,2017-02-03 14:19:00 +0000,https://www.thestreet.com/story/13977856/1/biotech-stock-mailbag-do-investors-have-an-aphinity-for-shorting-puma-into-trial-results.html?puc=yahoo&cm_ven=YAHOO,Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?
PBYI,PBYI:UW,BBG002NFCGM3,"Friday Sector Laggards: Biotechnology, Aerospace & Defense Stocks",2017-01-20 20:38:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4h01ZMpKVDQ/friday-sector-laggards-biotechnology-aerospace-defense-stocks-cm736190,In trading on Friday biotechnology shares were relative laggards down on the day by about 0 5 Helping drag down the group were shares of Pluristem Therapeutics PSTI down about 22 1 and shares of Puma Biotechnology PBYI down about 6 9 on the day Also lagging the market
PBYI,PBYI:US,BBG0018YXYX7,"Friday Sector Laggards: Biotechnology, Aerospace & Defense Stocks",2017-01-20 20:38:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4h01ZMpKVDQ/friday-sector-laggards-biotechnology-aerospace-defense-stocks-cm736190,In trading on Friday biotechnology shares were relative laggards down on the day by about 0 5 Helping drag down the group were shares of Pluristem Therapeutics PSTI down about 22 1 and shares of Puma Biotechnology PBYI down about 6 9 on the day Also lagging the market
PBYI,PBYI:UW,BBG002NFCGM3,"Friday's ETF Movers: SOXX, XBI",2017-01-20 20:37:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TbuDev625qk/fridays-etf-movers-soxx-xbi-cm736189,In trading on Friday the iShares PHLX Semiconductor ETF SOXX is outperforming other ETFs up about 1 5 on the day Components of that ETF showing particular strength include shares of Skyworks Solutions SWKS up about 12 9 and shares of Cirrus Logic CRUS up about 5 4 on the
PBYI,PBYI:US,BBG0018YXYX7,"Friday's ETF Movers: SOXX, XBI",2017-01-20 20:37:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TbuDev625qk/fridays-etf-movers-soxx-xbi-cm736189,In trading on Friday the iShares PHLX Semiconductor ETF SOXX is outperforming other ETFs up about 1 5 on the day Components of that ETF showing particular strength include shares of Skyworks Solutions SWKS up about 12 9 and shares of Cirrus Logic CRUS up about 5 4 on the
PBYI,PBYI:US,BBG0018YXYX7,Puma (PBYI) Expands Study Cohort for Lead Candidate PB272,2017-01-10 00:49:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hLuXVzqvq84/puma-pbyi-expands-study-cohort-for-lead-candidate-pb272-cm731358,Puma Biotechnology Inc PBYI has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 neratinib as a single agent in patients with solid tumors who have an activating HER2 mutation basket study The expanded cohort includes patients with
PBYI,PBYI:UW,BBG002NFCGM3,Puma (PBYI) Expands Study Cohort for Lead Candidate PB272,2017-01-10 00:49:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hLuXVzqvq84/puma-pbyi-expands-study-cohort-for-lead-candidate-pb272-cm731358,Puma Biotechnology Inc PBYI has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 neratinib as a single agent in patients with solid tumors who have an activating HER2 mutation basket study The expanded cohort includes patients with
PBYI,PBYI:UW,BBG002NFCGM3,Puma (PBYI) Expands Study Cohort for Lead Candidate PB272,2017-01-09 23:07:11 +0000,http://finance.yahoo.com/news/puma-pbyi-expands-study-cohort-230711782.html,Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
PBYI,PBYI:US,BBG0018YXYX7,Puma (PBYI) Expands Study Cohort for Lead Candidate PB272,2017-01-09 23:07:11 +0000,http://finance.yahoo.com/news/puma-pbyi-expands-study-cohort-230711782.html,Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
PBYI,PBYI:US,BBG0018YXYX7,"Newman Ferrara LLP Announces Corporate Governance Investigation of Puma Biotechnology, Inc. - PBYI",2017-01-09 21:55:00 +0000,http://finance.yahoo.com/news/newman-ferrara-llp-announces-corporate-215500654.html,"[Business Wire] - Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Puma Biotechnology, Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors ."
PBYI,PBYI:UW,BBG002NFCGM3,"Newman Ferrara LLP Announces Corporate Governance Investigation of Puma Biotechnology, Inc. - PBYI",2017-01-09 21:55:00 +0000,http://finance.yahoo.com/news/newman-ferrara-llp-announces-corporate-215500654.html,"[Business Wire] - Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Puma Biotechnology, Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors ."
PBYI,PBYI:UW,BBG002NFCGM3,"Friday Sector Leaders: Trucking, Biotechnology Stocks",2017-01-06 19:49:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FqiFJqcEQlQ/friday-sector-leaders-trucking-biotechnology-stocks-cm730539,In trading on Friday trucking shares were relative leaders up on the day by about 1 3 Leading the group were shares of Celadon Group CGI up about 5 7 and shares of USA Truck USAK up about 5 1 on the day Also showing relative strength are biotechnology shares up on the
PBYI,PBYI:US,BBG0018YXYX7,"Friday Sector Leaders: Trucking, Biotechnology Stocks",2017-01-06 19:49:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FqiFJqcEQlQ/friday-sector-leaders-trucking-biotechnology-stocks-cm730539,In trading on Friday trucking shares were relative leaders up on the day by about 1 3 Leading the group were shares of Celadon Group CGI up about 5 7 and shares of USA Truck USAK up about 5 1 on the day Also showing relative strength are biotechnology shares up on the
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events",2017-01-06 19:13:08 +0000,http://biz.yahoo.com/e/170106/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events"
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events",2017-01-06 19:13:08 +0000,http://biz.yahoo.com/e/170106/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients,2017-01-06 13:25:07 +0000,http://www.publicnow.com/view/9C5F39CAB413026E9AE7CE74C87BA68169D48CAA,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has expanded the fourth cohort from its Phase II SUMMIT clinical trial of its lead drug candidate PB272 ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients,2017-01-06 13:25:07 +0000,http://www.publicnow.com/view/9C5F39CAB413026E9AE7CE74C87BA68169D48CAA,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has expanded the fourth cohort from its Phase II SUMMIT clinical trial of its lead drug candidate PB272 ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Present at J.P. Morgan Healthcare Conference,2017-01-03 21:15:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-present-j-p-211500764.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 8:30 a.m."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Present at J.P. Morgan Healthcare Conference,2017-01-03 21:15:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-present-j-p-211500764.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 8:30 a.m."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Move Stock Exchange Listing to Nasdaq,2016-12-19 21:31:28 +0000,http://www.publicnow.com/view/8D1337124D3B815DA37738A8095D14F5B7450368,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it will voluntarily move its stock exchange listing from the New York Stock Exchange to ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Move Stock Exchange Listing to Nasdaq,2016-12-19 21:31:28 +0000,http://www.publicnow.com/view/8D1337124D3B815DA37738A8095D14F5B7450368,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it will voluntarily move its stock exchange listing from the New York Stock Exchange to ..."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St",2016-12-19 21:27:07 +0000,http://biz.yahoo.com/e/161219/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St"
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St",2016-12-19 21:27:07 +0000,http://biz.yahoo.com/e/161219/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St"
PBYI,PBYI:US,BBG0018YXYX7,"CLVS Gets FDA Nod, PBYI Leaves Big Board, LOXO Hits All-time High, CNAT On Watch",2016-12-19 20:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9I2-LeJFKKM/clvs-gets-fda-nod-pbyi-leaves-big-board-loxo-hits-alltime-high-cnat-on-watch-20161219-01000,"CLVS Gets FDA Nod, PBYI Leaves Big Board, LOXO Hits All-time High, CNAT On Watch"
PBYI,PBYI:UW,BBG002NFCGM3,"CLVS Gets FDA Nod, PBYI Leaves Big Board, LOXO Hits All-time High, CNAT On Watch",2016-12-19 20:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9I2-LeJFKKM/clvs-gets-fda-nod-pbyi-leaves-big-board-loxo-hits-alltime-high-cnat-on-watch-20161219-01000,"CLVS Gets FDA Nod, PBYI Leaves Big Board, LOXO Hits All-time High, CNAT On Watch"
PBYI,PBYI:US,BBG0018YXYX7,Puma Cancer Drug Suffers 'Approvability Risk' On Extreme Side Effect,2016-12-08 17:38:14 +0000,http://www.investors.com/news/technology/puma-cancer-drug-suffers-approvability-risk-on-extreme-side-effect/,Puma Cancer Drug Suffers 'Approvability Risk' On Extreme Side Effect
PBYI,PBYI:UW,BBG002NFCGM3,Puma Cancer Drug Suffers 'Approvability Risk' On Extreme Side Effect,2016-12-08 17:38:14 +0000,http://www.investors.com/news/technology/puma-cancer-drug-suffers-approvability-risk-on-extreme-side-effect/,Puma Cancer Drug Suffers 'Approvability Risk' On Extreme Side Effect
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events",2016-12-08 13:46:29 +0000,http://biz.yahoo.com/e/161208/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events"
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events",2016-12-08 13:46:29 +0000,http://biz.yahoo.com/e/161208/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium,2016-12-08 13:35:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-interim-results-133500928.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that interim results from a Phase II clinical trial of Puma’s investigational drug PB272 were presented at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium,2016-12-08 13:35:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-interim-results-133500928.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that interim results from a Phase II clinical trial of Puma’s investigational drug PB272 were presented at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium,2016-12-07 23:21:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-results-biomarker-232100399.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that a biomarker analysis of the NSABP FB-7 Phase II clinical trial of Puma's investigational drug PB272 was presented at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium,2016-12-07 23:21:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-results-biomarker-232100399.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that a biomarker analysis of the NSABP FB-7 Phase II clinical trial of Puma's investigational drug PB272 was presented at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas."
PBYI,PBYI:US,BBG0018YXYX7,"Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2016 San Antonio Breast Cancer Symposium",2016-12-07 23:07:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-interim-results-230700133.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that updated interim results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 , given as monotherapy and in combination with the anticancer drug fulvestrant, were presented at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas."
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2016 San Antonio Breast Cancer Symposium",2016-12-07 23:07:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-presents-interim-results-230700133.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that updated interim results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 , given as monotherapy and in combination with the anticancer drug fulvestrant, were presented at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas."
PBYI,PBYI:US,BBG0018YXYX7,Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards,2016-12-07 12:00:00 +0000,https://www.thestreet.com/story/13917080/1/cascadian-therapeutics-enlarges-breast-cancer-pill-study-to-meet-fda-registration-standards.html?puc=yahoo&cm_ven=YAHOO,Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards
PBYI,PBYI:UW,BBG002NFCGM3,Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards,2016-12-07 12:00:00 +0000,https://www.thestreet.com/story/13917080/1/cascadian-therapeutics-enlarges-breast-cancer-pill-study-to-meet-fda-registration-standards.html?puc=yahoo&cm_ven=YAHOO,Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards
PBYI,PBYI:US,BBG0018YXYX7,CORRECTING and REPLACING Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States,2016-12-06 23:44:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-initiates-managed-access-211500500.html,"[Business Wire] - The second paragraph, last sentence of the release has changed."
PBYI,PBYI:UW,BBG002NFCGM3,CORRECTING and REPLACING Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States,2016-12-06 23:44:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-initiates-managed-access-211500500.html,"[Business Wire] - The second paragraph, last sentence of the release has changed."
PBYI,PBYI:US,BBG0018YXYX7,PBYI Crosses Below Key Moving Average Level,2016-12-01 18:17:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F-dimCvYuGw/pbyi-crosses-below-key-moving-average-level-cm716457,In trading on Thursday shares of Puma Biotechnology Inc Symbol PBYI crossed below their 200 day moving average of 42 46 changing hands as low as 40 40 per share Puma Biotechnology Inc shares are currently trading off about 5 on the day The chart below shows the one year performance
PBYI,PBYI:UW,BBG002NFCGM3,PBYI Crosses Below Key Moving Average Level,2016-12-01 18:17:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F-dimCvYuGw/pbyi-crosses-below-key-moving-average-level-cm716457,In trading on Thursday shares of Puma Biotechnology Inc Symbol PBYI crossed below their 200 day moving average of 42 46 changing hands as low as 40 40 per share Puma Biotechnology Inc shares are currently trading off about 5 on the day The chart below shows the one year performance
PBYI,PBYI:US,BBG0018YXYX7,Why Did Puma Biotechnology Dilute Shareholders?,2016-11-30 14:33:48 +0000,http://www.fool.com/investing/2016/11/29/why-did-puma-biotechnology-dilute-shareholders.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Did Puma Biotechnology Dilute Shareholders?
PBYI,PBYI:UW,BBG002NFCGM3,Why Did Puma Biotechnology Dilute Shareholders?,2016-11-30 14:33:48 +0000,http://www.fool.com/investing/2016/11/29/why-did-puma-biotechnology-dilute-shareholders.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Did Puma Biotechnology Dilute Shareholders?
PBYI,PBYI:UW,BBG002NFCGM3,Why Did Puma Biotechnology Dilute Shareholders?,2016-11-29 15:55:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ODqyy_oK4Pk/why-did-puma-biotechnology-dilute-shareholders-cm715040,Early stage biotech companies commonly sell more shares in order to raise capital After all when you re pouring money into research and development but don t yet have a product approved to generate revenue your hands are often tied While investors don t like to see their slice of
PBYI,PBYI:US,BBG0018YXYX7,Why Did Puma Biotechnology Dilute Shareholders?,2016-11-29 15:55:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ODqyy_oK4Pk/why-did-puma-biotechnology-dilute-shareholders-cm715040,Early stage biotech companies commonly sell more shares in order to raise capital After all when you re pouring money into research and development but don t yet have a product approved to generate revenue your hands are often tied While investors don t like to see their slice of
PBYI,PBYI:US,BBG0018YXYX7,"Puma Biotechnology, Inc. :PBYI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016",2016-11-28 19:11:03 +0000,http://www.capitalcube.com/blog/index.php/puma-biotechnology-inc-pbyi-us-earnings-analysis-q3-2016-by-the-numbers-november-28-2016/,"Puma Biotechnology, Inc. :PBYI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016"
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Biotechnology, Inc. :PBYI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016",2016-11-28 19:11:03 +0000,http://www.capitalcube.com/blog/index.php/puma-biotechnology-inc-pbyi-us-earnings-analysis-q3-2016-by-the-numbers-november-28-2016/,"Puma Biotechnology, Inc. :PBYI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016"
PBYI,PBYI:US,BBG0018YXYX7,Shareholder Dilution: What Investors Need to Know,2016-11-22 14:19:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c7_L7OOn39I/shareholder-dilution-what-investors-need-to-know-cm712486,Share dilution is rarely met with anything but contempt from shareholders though there are some cases where it can be used for the good of the company and shareholders alike In this week s crossover episode of Industry Focus Healthcare Kristine Harjes talks with guest
PBYI,PBYI:UW,BBG002NFCGM3,Shareholder Dilution: What Investors Need to Know,2016-11-22 14:19:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c7_L7OOn39I/shareholder-dilution-what-investors-need-to-know-cm712486,Share dilution is rarely met with anything but contempt from shareholders though there are some cases where it can be used for the good of the company and shareholders alike In this week s crossover episode of Industry Focus Healthcare Kristine Harjes talks with guest
PBYI,PBYI:UW,BBG002NFCGM3,Shareholder Dilution: What Investors Need to Know,2016-11-22 13:12:32 +0000,http://www.fool.com/investing/2016/11/22/shareholder-dilution-what-investors-need-to-know.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Shareholder Dilution: What Investors Need to Know
PBYI,PBYI:US,BBG0018YXYX7,Shareholder Dilution: What Investors Need to Know,2016-11-22 13:12:32 +0000,http://www.fool.com/investing/2016/11/22/shareholder-dilution-what-investors-need-to-know.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Shareholder Dilution: What Investors Need to Know
PBYI,PBYI:UW,BBG002NFCGM3,4 Companies That Destroyed Shareholders Last Week,2016-11-19 15:15:15 +0000,http://247wallst.com/investing/2016/11/19/4-companies-that-destroyed-shareholders-last-week-9/,4 Companies That Destroyed Shareholders Last Week
PBYI,PBYI:US,BBG0018YXYX7,4 Companies That Destroyed Shareholders Last Week,2016-11-19 15:15:15 +0000,http://247wallst.com/investing/2016/11/19/4-companies-that-destroyed-shareholders-last-week-9/,4 Companies That Destroyed Shareholders Last Week
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Puma Biotechnology, Inc. and Advises Investors with Losses to Contact the Firm",2016-11-15 20:57:00 +0000,http://finance.yahoo.com/news/shareholder-alert-goldberg-law-pc-205700836.html,"[Business Wire] - Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Puma Biotechnology, Inc. concerning possible violations of federal securities laws."
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Puma Biotechnology, Inc. and Advises Investors with Losses to Contact the Firm",2016-11-15 20:57:00 +0000,http://finance.yahoo.com/news/shareholder-alert-goldberg-law-pc-205700836.html,"[Business Wire] - Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Puma Biotechnology, Inc. concerning possible violations of federal securities laws."
PBYI,PBYI:US,BBG0018YXYX7,Here’s Why The Puma Biotechnology Inc (PBYI) Pullback Might Be A Buy-In Opportunity,2016-11-15 20:11:08 +0000,http://www.insidermonkey.com/blog/heres-why-the-puma-biotechnology-inc-pbyi-pullback-might-be-a-buy-in-opportunity-488290/,Here’s Why The Puma Biotechnology Inc (PBYI) Pullback Might Be A Buy-In Opportunity
PBYI,PBYI:UW,BBG002NFCGM3,Here’s Why The Puma Biotechnology Inc (PBYI) Pullback Might Be A Buy-In Opportunity,2016-11-15 20:11:08 +0000,http://www.insidermonkey.com/blog/heres-why-the-puma-biotechnology-inc-pbyi-pullback-might-be-a-buy-in-opportunity-488290/,Here’s Why The Puma Biotechnology Inc (PBYI) Pullback Might Be A Buy-In Opportunity
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology, Inc. (PBYI)",2016-11-15 20:10:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-201000967.html,"[PR Newswire] - NEW YORK, Nov. 15, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the Puma Biotechnology, Inc. (""Puma"" ..."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology, Inc. (PBYI)",2016-11-15 20:10:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-201000967.html,"[PR Newswire] - NEW YORK, Nov. 15, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the Puma Biotechnology, Inc. (""Puma"" ..."
PBYI,PBYI:US,BBG0018YXYX7,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Puma Biotechnology, Inc. - PBYI",2016-11-15 18:00:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-180000482.html,"[PR Newswire] - NEW YORK, Nov. 15, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Puma Biotechnology, Inc. (""Puma"" or the ""Company"") (NYSE: PBYI) (ISIN: US74587V1070). ..."
PBYI,PBYI:UW,BBG002NFCGM3,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Puma Biotechnology, Inc. - PBYI",2016-11-15 18:00:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-180000482.html,"[PR Newswire] - NEW YORK, Nov. 15, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Puma Biotechnology, Inc. (""Puma"" or the ""Company"") (NYSE: PBYI) (ISIN: US74587V1070). ..."
PBYI,PBYI:US,BBG0018YXYX7,What Caused Puma Biotechnology's Shares to Tumble 20.5% Today,2016-11-15 00:28:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WWeg4w74-8o/what-caused-puma-biotechnologys-shares-to-tumble-205-today-cm709063,Image source Getty Images What happened Puma Biotechnology NYSE PBYI shares stumbled 20 5 today on reports that breast cancer patients taking its lead drug candidate neratinib still had stubbornly high diarrhea incidence rates despite the co administration of
PBYI,PBYI:UW,BBG002NFCGM3,What Caused Puma Biotechnology's Shares to Tumble 20.5% Today,2016-11-15 00:28:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WWeg4w74-8o/what-caused-puma-biotechnologys-shares-to-tumble-205-today-cm709063,Image source Getty Images What happened Puma Biotechnology NYSE PBYI shares stumbled 20 5 today on reports that breast cancer patients taking its lead drug candidate neratinib still had stubbornly high diarrhea incidence rates despite the co administration of
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces Presentations of Investigational Data at the San Antonio Breast Cancer Symposium (SABCS),2016-11-15 00:16:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-announces-presentations-investigational-001600170.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that its lead drug candidate PB272 will be featured in 11 poster presentations at the 2016 San Antonio Breast Cancer Symposium , December 6 - 10, 2016, in San Antonio, Texas."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces Presentations of Investigational Data at the San Antonio Breast Cancer Symposium (SABCS),2016-11-15 00:16:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-announces-presentations-investigational-001600170.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that its lead drug candidate PB272 will be featured in 11 poster presentations at the 2016 San Antonio Breast Cancer Symposium , December 6 - 10, 2016, in San Antonio, Texas."
PBYI,PBYI:UW,BBG002NFCGM3,What Caused Puma Biotechnology's Shares to Tumble 20.5% Today,2016-11-14 22:36:46 +0000,http://www.fool.com/investing/general/2016/11/14/what-caused-puma-biotechnologys-shares-to-tumble-2.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,What Caused Puma Biotechnology's Shares to Tumble 20.5% Today
PBYI,PBYI:US,BBG0018YXYX7,What Caused Puma Biotechnology's Shares to Tumble 20.5% Today,2016-11-14 22:36:46 +0000,http://www.fool.com/investing/general/2016/11/14/what-caused-puma-biotechnologys-shares-to-tumble-2.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,What Caused Puma Biotechnology's Shares to Tumble 20.5% Today
PBYI,PBYI:US,BBG0018YXYX7,"Notable Monday Option Activity: PBYI, OCUL, REGN",2016-11-14 22:28:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WUnVjKRfg6o/notable-monday-option-activity-pbyi-ocul-regn-cm709018,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Puma Biotechnology Inc Symbol PBYI where a total volume of 6 622 contracts has been traded thus far today a contract volume which is representative of approximately 662
PBYI,PBYI:UW,BBG002NFCGM3,"Notable Monday Option Activity: PBYI, OCUL, REGN",2016-11-14 22:28:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WUnVjKRfg6o/notable-monday-option-activity-pbyi-ocul-regn-cm709018,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Puma Biotechnology Inc Symbol PBYI where a total volume of 6 622 contracts has been traded thus far today a contract volume which is representative of approximately 662
PBYI,PBYI:US,BBG0018YXYX7,"Credit Suisse Says Gr3 Diarrhea Still A Concern For Puma Biotech, But Pullback Is Overdone",2016-11-14 21:37:00 +0000,http://finance.yahoo.com/news/credit-suisse-says-gr3-diarrhea-213700620.html,"Credit Suisse Says Gr3 Diarrhea Still A Concern For Puma Biotech, But Pullback Is Overdone"
PBYI,PBYI:UW,BBG002NFCGM3,"Credit Suisse Says Gr3 Diarrhea Still A Concern For Puma Biotech, But Pullback Is Overdone",2016-11-14 21:37:00 +0000,http://finance.yahoo.com/news/credit-suisse-says-gr3-diarrhea-213700620.html,"Credit Suisse Says Gr3 Diarrhea Still A Concern For Puma Biotech, But Pullback Is Overdone"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology falls more than 20%,2016-11-14 18:13:12 +0000,http://www.cnbc.com/id/104106355?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104106355,Puma Biotechnology falls more than 20%
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology falls more than 20%,2016-11-14 18:13:12 +0000,http://www.cnbc.com/id/104106355?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104106355,Puma Biotechnology falls more than 20%
PBYI,PBYI:UW,BBG002NFCGM3,January 2019 Options Now Available For Puma Biotechnology (PBYI),2016-11-14 16:27:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3u_Mkiw9GzY/january-2019-options-now-available-for-puma-biotechnology-pbyi-cm708711,Investors in Puma Biotechnology Inc Symbol PBYI saw new options begin trading today for the January 2019 expiration One of the key data points that goes into the price an option buyer is willing to pay is the time value so with 795 days until expiration the newly trading
PBYI,PBYI:US,BBG0018YXYX7,January 2019 Options Now Available For Puma Biotechnology (PBYI),2016-11-14 16:27:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3u_Mkiw9GzY/january-2019-options-now-available-for-puma-biotechnology-pbyi-cm708711,Investors in Puma Biotechnology Inc Symbol PBYI saw new options begin trading today for the January 2019 expiration One of the key data points that goes into the price an option buyer is willing to pay is the time value so with 795 days until expiration the newly trading
PBYI,PBYI:UW,BBG002NFCGM3,Puma Bio Falls on Escalating Concerns About Diarrhea Risk With Breast Cancer Drug,2016-11-14 16:25:00 +0000,https://www.thestreet.com/story/13891919/1/puma-bio-falls-on-escalating-concerns-about-diarrhea-risk-with-breast-cancer-drug.html?puc=yahoo&cm_ven=YAHOO,Puma Bio Falls on Escalating Concerns About Diarrhea Risk With Breast Cancer Drug
PBYI,PBYI:US,BBG0018YXYX7,Puma Bio Falls on Escalating Concerns About Diarrhea Risk With Breast Cancer Drug,2016-11-14 16:25:00 +0000,https://www.thestreet.com/story/13891919/1/puma-bio-falls-on-escalating-concerns-about-diarrhea-risk-with-breast-cancer-drug.html?puc=yahoo&cm_ven=YAHOO,Puma Bio Falls on Escalating Concerns About Diarrhea Risk With Breast Cancer Drug
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. - PBYI",2016-11-12 03:07:00 +0000,http://finance.yahoo.com/news/puma-investigation-initiated-former-louisiana-030700014.html,"[PR Newswire] - NEW ORLEANS, Nov. 11, 2016 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (""KSF""), announces that KSF has ..."
PBYI,PBYI:US,BBG0018YXYX7,"Puma Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. - PBYI",2016-11-12 03:07:00 +0000,http://finance.yahoo.com/news/puma-investigation-initiated-former-louisiana-030700014.html,"[PR Newswire] - NEW ORLEANS, Nov. 11, 2016 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (""KSF""), announces that KSF has ..."
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Posts Wider Loss in Q3, Neratinib in Focus",2016-11-10 14:56:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4X7knO3w5eI/puma-pbyi-posts-wider-loss-in-q3-neratinib-in-focus-cm706997,Puma Biotechnology Inc PBYI reported a third quarter 2016 loss of 2 02 per share including the impact of stock based compensation expense wider than the Zacks Consensus Estimate of a loss of 2 00 and the year ago loss of 1 87 With no approved products in Puma Biotech s portfolio at
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Posts Wider Loss in Q3, Neratinib in Focus",2016-11-10 14:56:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4X7knO3w5eI/puma-pbyi-posts-wider-loss-in-q3-neratinib-in-focus-cm706997,Puma Biotechnology Inc PBYI reported a third quarter 2016 loss of 2 02 per share including the impact of stock based compensation expense wider than the Zacks Consensus Estimate of a loss of 2 00 and the year ago loss of 1 87 With no approved products in Puma Biotech s portfolio at
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Posts Wider Loss in Q3, Neratinib in Focus",2016-11-10 12:50:12 +0000,http://finance.yahoo.com/news/puma-pbyi-posts-wider-loss-125012431.html,"Puma (PBYI) Posts Wider Loss in Q3, Neratinib in Focus"
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Posts Wider Loss in Q3, Neratinib in Focus",2016-11-10 12:50:12 +0000,http://finance.yahoo.com/news/puma-pbyi-posts-wider-loss-125012431.html,"Puma (PBYI) Posts Wider Loss in Q3, Neratinib in Focus"
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology (PBYI) Shares Cross Above 200 DMA,2016-11-09 22:52:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dmp_emNn8g8/puma-biotechnology-pbyi-shares-cross-above-200-dma-cm706783,In trading on Wednesday shares of Puma Biotechnology Inc Symbol PBYI crossed above their 200 day moving average of 42 23 changing hands as high as 47 50 per share Puma Biotechnology Inc shares are currently trading up about 16 2 on the day The chart below shows the one
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology (PBYI) Shares Cross Above 200 DMA,2016-11-09 22:52:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dmp_emNn8g8/puma-biotechnology-pbyi-shares-cross-above-200-dma-cm706783,In trading on Wednesday shares of Puma Biotechnology Inc Symbol PBYI crossed above their 200 day moving average of 42 23 changing hands as high as 47 50 per share Puma Biotechnology Inc shares are currently trading up about 16 2 on the day The chart below shows the one
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech reports 3Q loss,2016-11-09 22:29:27 +0000,http://sg.finance.yahoo.com/news/puma-biotech-reports-3q-loss-222927077.html,Puma Biotech reports 3Q loss
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech reports 3Q loss,2016-11-09 22:29:27 +0000,http://sg.finance.yahoo.com/news/puma-biotech-reports-3q-loss-222927077.html,Puma Biotech reports 3Q loss
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2016-11-09 22:24:46 +0000,http://biz.yahoo.com/e/161109/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2016-11-09 22:24:46 +0000,http://biz.yahoo.com/e/161109/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Reports Third Quarter 2016 Financial Results,2016-11-09 21:21:09 +0000,http://www.publicnow.com/view/0AA4C867D30F347E7D5F60630D2FC3C9B4BC889A,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2016. Unless otherwise stated, all ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Reports Third Quarter 2016 Financial Results,2016-11-09 21:21:09 +0000,http://www.publicnow.com/view/0AA4C867D30F347E7D5F60630D2FC3C9B4BC889A,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2016. Unless otherwise stated, all ..."
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report",2016-11-09 21:11:48 +0000,http://biz.yahoo.com/e/161109/pbyi10-q.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report"
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report",2016-11-09 21:11:48 +0000,http://biz.yahoo.com/e/161109/pbyi10-q.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology (PBYI) Q3 Earnings: What's in Store?,2016-11-04 00:07:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_Ct6Nz9fV04/puma-biotechnology-pbyi-q3-earnings-whats-in-store-cm703729,Puma Biotechnology Inc PBYI is expected to report third quarter 2016 results in November The company s track record has been mostly disappointing While it missed estimates in two of the trailing four quarters it met the same in one and surpassed in the other The company recorded an
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology (PBYI) Q3 Earnings: What's in Store?,2016-11-04 00:07:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_Ct6Nz9fV04/puma-biotechnology-pbyi-q3-earnings-whats-in-store-cm703729,Puma Biotechnology Inc PBYI is expected to report third quarter 2016 results in November The company s track record has been mostly disappointing While it missed estimates in two of the trailing four quarters it met the same in one and surpassed in the other The company recorded an
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology (PBYI) Q3 Earnings: What's in Store?,2016-11-03 22:24:10 +0000,http://finance.yahoo.com/news/puma-biotechnology-pbyi-q3-earnings-222410487.html,Puma Biotechnology (PBYI) Q3 Earnings: What's in Store?
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology (PBYI) Q3 Earnings: What's in Store?,2016-11-03 22:24:10 +0000,http://finance.yahoo.com/news/puma-biotechnology-pbyi-q3-earnings-222410487.html,Puma Biotechnology (PBYI) Q3 Earnings: What's in Store?
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Present at Credit Suisse Healthcare Conference,2016-10-31 20:15:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-present-credit-suisse-201500315.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:30 a.m."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Present at Credit Suisse Healthcare Conference,2016-10-31 20:15:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-present-credit-suisse-201500315.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:30 a.m."
PBYI,PBYI:UW,BBG002NFCGM3,"Lifshitz & Miller Law Firm Announces Investigation of Electronics for Imaging, Inc., Ferrellgas Partners LP, Fusion Pharm, Inc., Humana Inc., KemPharm, Inc., National Beverage Corp., Puma Biotechnology, Inc., and TG Therapeutics, Inc.",2016-10-31 15:38:00 +0000,http://finance.yahoo.com/news/lifshitz-miller-law-firm-announces-153800496.html,"[PR Newswire] - NEW YORK, Oct. 31, 2016 /PRNewswire/ -- Electronics for Imaging, Inc. (EFII) Lifshitz & Miller announces investigation on behalf of EFII investors. The investigation concerns whether EFII adequately disclosed ..."
PBYI,PBYI:US,BBG0018YXYX7,"Lifshitz & Miller Law Firm Announces Investigation of Electronics for Imaging, Inc., Ferrellgas Partners LP, Fusion Pharm, Inc., Humana Inc., KemPharm, Inc., National Beverage Corp., Puma Biotechnology, Inc., and TG Therapeutics, Inc.",2016-10-31 15:38:00 +0000,http://finance.yahoo.com/news/lifshitz-miller-law-firm-announces-153800496.html,"[PR Newswire] - NEW YORK, Oct. 31, 2016 /PRNewswire/ -- Electronics for Imaging, Inc. (EFII) Lifshitz & Miller announces investigation on behalf of EFII investors. The investigation concerns whether EFII adequately disclosed ..."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. – PBYI",2016-10-29 02:07:00 +0000,http://finance.yahoo.com/news/puma-investigation-initiated-former-louisiana-020700967.html,"[Business Wire] - Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Puma Biotechnology, Inc."
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. – PBYI",2016-10-29 02:07:00 +0000,http://finance.yahoo.com/news/puma-investigation-initiated-former-louisiana-020700967.html,"[Business Wire] - Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Puma Biotechnology, Inc."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Closes $172 Million Public Offering of Common Stock,2016-10-25 15:55:04 +0000,http://www.publicnow.com/view/37EB4CA90C0DE9DA7EB8D398C1E5371398E9FBA8,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the closing of an underwritten public offering of 4,312,500 shares of its common stock at a price ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Closes $172 Million Public Offering of Common Stock,2016-10-25 15:55:04 +0000,http://www.publicnow.com/view/37EB4CA90C0DE9DA7EB8D398C1E5371398E9FBA8,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the closing of an underwritten public offering of 4,312,500 shares of its common stock at a price ..."
PBYI,PBYI:US,BBG0018YXYX7,4 Companies That Destroyed Shareholders Last Week,2016-10-23 14:15:45 +0000,http://247wallst.com/investing/2016/10/23/4-companies-that-destroyed-shareholders-last-week-7/,4 Companies That Destroyed Shareholders Last Week
PBYI,PBYI:UW,BBG002NFCGM3,4 Companies That Destroyed Shareholders Last Week,2016-10-23 14:15:45 +0000,http://247wallst.com/investing/2016/10/23/4-companies-that-destroyed-shareholders-last-week-7/,4 Companies That Destroyed Shareholders Last Week
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-10-21 21:04:06 +0000,http://biz.yahoo.com/e/161021/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-10-21 21:04:06 +0000,http://biz.yahoo.com/e/161021/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
PBYI,PBYI:US,BBG0018YXYX7,"Puma Biotech, Which Had Weak Demand For A Secondary Offering, Is Also Part Of The SEC Tick Size Pilot Program",2016-10-21 16:34:17 +0000,http://finance.yahoo.com/news/puma-biotech-had-weak-demand-163417429.html,"Puma Biotech, Which Had Weak Demand For A Secondary Offering, Is Also Part Of The SEC Tick Size Pilot Program"
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Biotech, Which Had Weak Demand For A Secondary Offering, Is Also Part Of The SEC Tick Size Pilot Program",2016-10-21 16:34:17 +0000,http://finance.yahoo.com/news/puma-biotech-had-weak-demand-163417429.html,"Puma Biotech, Which Had Weak Demand For A Secondary Offering, Is Also Part Of The SEC Tick Size Pilot Program"
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares,2016-10-21 12:31:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-announces-underwriters-full-123100395.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the underwriters for its public offering of 3,750,000 shares of its common stock at $40.00 per share have elected to exercise in full their option to purchase up to an additional 562,500 shares of common stock at the public offering price, less the underwriting discounts and commissions."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares,2016-10-21 12:31:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-announces-underwriters-full-123100395.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the underwriters for its public offering of 3,750,000 shares of its common stock at $40.00 per share have elected to exercise in full their option to purchase up to an additional 562,500 shares of common stock at the public offering price, less the underwriting discounts and commissions."
PBYI,PBYI:UW,BBG002NFCGM3,"Wall Street Treads Water After U.S. Presidential Debate, Jobless Claims Rise",2016-10-20 13:47:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/InIXPEWnMLI/wall-street-treads-water-after-us-presidential-debate-jobless-claims-rise-cm695796,U S stocks were struggling for a direction ahead of Thursday s open a day after the third and final presidential debate and as investors digested a raft of economic data including a higher than expected rise in jobless claims U S stocks were struggling for a direction ahead of Thursday s
PBYI,PBYI:US,BBG0018YXYX7,"Wall Street Treads Water After U.S. Presidential Debate, Jobless Claims Rise",2016-10-20 13:47:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/InIXPEWnMLI/wall-street-treads-water-after-us-presidential-debate-jobless-claims-rise-cm695796,U S stocks were struggling for a direction ahead of Thursday s open a day after the third and final presidential debate and as investors digested a raft of economic data including a higher than expected rise in jobless claims U S stocks were struggling for a direction ahead of Thursday s
PBYI,PBYI:US,BBG0018YXYX7,"Pre-Market Most Active for Oct 20, 2016 :  FMSA, RIGL, RAD, EBAY, VZ, DB, GRUB, PBYI, TVIX, ERIC, QQQ, ONVO",2016-10-20 12:57:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0jE6rSQ5X-M/pre-market-most-active-for-oct-20-2016-fmsa-rigl-rad-ebay-vz-db-grub-pbyi-tvix-eric-qqq-onvo-cm695755,The NASDAQ 100 Pre Market Indicator is down 1 39 to 4 835 22 The total Pre Market volume is currently 11 093 104 shares traded The following are the most active stocks for the pre market session Fairmount Santrol Holdings Inc FMSA is 0 11 at 9 59 with 5 356
PBYI,PBYI:UW,BBG002NFCGM3,"Pre-Market Most Active for Oct 20, 2016 :  FMSA, RIGL, RAD, EBAY, VZ, DB, GRUB, PBYI, TVIX, ERIC, QQQ, ONVO",2016-10-20 12:57:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0jE6rSQ5X-M/pre-market-most-active-for-oct-20-2016-fmsa-rigl-rad-ebay-vz-db-grub-pbyi-tvix-eric-qqq-onvo-cm695755,The NASDAQ 100 Pre Market Indicator is down 1 39 to 4 835 22 The total Pre Market volume is currently 11 093 104 shares traded The following are the most active stocks for the pre market session Fairmount Santrol Holdings Inc FMSA is 0 11 at 9 59 with 5 356
PBYI,PBYI:US,BBG0018YXYX7,"U.S. Futures Rise After Final U.S. Presidential Debate, Data Eyed",2016-10-20 12:47:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Lj7qIJz4CfA/us-futures-rise-after-final-us-presidential-debate-data-eyed-cm695753,U S stock futures edged higher on Thursday a day after the third and final presidential debate and as investors looked ahead to a raft of economic data while quarterly earnings also boosted investor sentiment U S stock futures edged higher on Thursday a day after the third and
PBYI,PBYI:UW,BBG002NFCGM3,"U.S. Futures Rise After Final U.S. Presidential Debate, Data Eyed",2016-10-20 12:47:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Lj7qIJz4CfA/us-futures-rise-after-final-us-presidential-debate-data-eyed-cm695753,U S stock futures edged higher on Thursday a day after the third and final presidential debate and as investors looked ahead to a raft of economic data while quarterly earnings also boosted investor sentiment U S stock futures edged higher on Thursday a day after the third and
PBYI,PBYI:UW,BBG002NFCGM3,Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble,2016-10-20 12:40:00 +0000,https://www.thestreet.com/story/13860505/1/puma-bio-s-desperate-money-grab-signals-breast-cancer-drug-trouble.html?puc=yahoo&cm_ven=YAHOO,Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble
PBYI,PBYI:US,BBG0018YXYX7,Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble,2016-10-20 12:40:00 +0000,https://www.thestreet.com/story/13860505/1/puma-bio-s-desperate-money-grab-signals-breast-cancer-drug-trouble.html?puc=yahoo&cm_ven=YAHOO,Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble
PBYI,PBYI:US,BBG0018YXYX7,"Ups And Downs In Biotech This Week: PTC Therapeutics, Inc. (PTCT), Puma Biotechnology Inc (PBYI) and Nektar Therapeutics (NKTR)",2016-10-20 08:43:43 +0000,http://www.insidermonkey.com/blog/ups-and-downs-in-biotech-this-week-ptc-therapeutics-inc-ptct-puma-biotechnology-inc-pbyi-and-nektar-therapeutics-nktr-482305/,"Ups And Downs In Biotech This Week: PTC Therapeutics, Inc. (PTCT), Puma Biotechnology Inc (PBYI) and Nektar Therapeutics (NKTR)"
PBYI,PBYI:UW,BBG002NFCGM3,"Ups And Downs In Biotech This Week: PTC Therapeutics, Inc. (PTCT), Puma Biotechnology Inc (PBYI) and Nektar Therapeutics (NKTR)",2016-10-20 08:43:43 +0000,http://www.insidermonkey.com/blog/ups-and-downs-in-biotech-this-week-ptc-therapeutics-inc-ptct-puma-biotechnology-inc-pbyi-and-nektar-therapeutics-nktr-482305/,"Ups And Downs In Biotech This Week: PTC Therapeutics, Inc. (PTCT), Puma Biotechnology Inc (PBYI) and Nektar Therapeutics (NKTR)"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Prices Public Offering of Common Stock,2016-10-20 03:28:06 +0000,http://www.publicnow.com/view/4AAB1DE1AE1681F907E814CC9E3B85C0A98F5819,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Prices Public Offering of Common Stock,2016-10-20 03:28:06 +0000,http://www.publicnow.com/view/4AAB1DE1AE1681F907E814CC9E3B85C0A98F5819,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public ..."
PBYI,PBYI:UW,BBG002NFCGM3,PBYI Makes Notable Cross Below Critical Moving Average,2016-10-19 21:46:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/07r_4eEhXpk/pbyi-makes-notable-cross-below-critical-moving-average-cm695610,In trading on Wednesday shares of Puma Biotechnology Inc Symbol PBYI crossed below their 200 day moving average of 43 34 changing hands as low as 42 15 per share Puma Biotechnology Inc shares are currently trading off about 18 6 on the day The chart below shows the one
PBYI,PBYI:US,BBG0018YXYX7,PBYI Makes Notable Cross Below Critical Moving Average,2016-10-19 21:46:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/07r_4eEhXpk/pbyi-makes-notable-cross-below-critical-moving-average-cm695610,In trading on Wednesday shares of Puma Biotechnology Inc Symbol PBYI crossed below their 200 day moving average of 43 34 changing hands as low as 42 15 per share Puma Biotechnology Inc shares are currently trading off about 18 6 on the day The chart below shows the one
PBYI,PBYI:US,BBG0018YXYX7,"Health Care Sector Update for 10/19/2016: MRNS,CERU,PBYI",2016-10-19 20:27:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kav3qBghUns/health-care-sector-update-for-10192016-mrnscerupbyi-cm695598,Top Health Care StocksTop Health Care Stocks JNJ 0 62 JNJ 0 62 PFE 0 17 PFE 0 17 MRK 0 MRK 0 ABT 2 79 ABT 2 79 AMGN 1 03 AMGN 1 03 Health care stocks were moderately lower Wednesday with the NYSE Health Care Index slipping about 0 3 while shares of health care companies in
PBYI,PBYI:UW,BBG002NFCGM3,"Health Care Sector Update for 10/19/2016: MRNS,CERU,PBYI",2016-10-19 20:27:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kav3qBghUns/health-care-sector-update-for-10192016-mrnscerupbyi-cm695598,Top Health Care StocksTop Health Care Stocks JNJ 0 62 JNJ 0 62 PFE 0 17 PFE 0 17 MRK 0 MRK 0 ABT 2 79 ABT 2 79 AMGN 1 03 AMGN 1 03 Health care stocks were moderately lower Wednesday with the NYSE Health Care Index slipping about 0 3 while shares of health care companies in
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech Gears Up for Secondary Offering,2016-10-19 19:43:42 +0000,http://finance.yahoo.com/news/puma-biotech-gears-secondary-offering-194342781.html,Puma Biotech Gears Up for Secondary Offering
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech Gears Up for Secondary Offering,2016-10-19 19:43:42 +0000,http://finance.yahoo.com/news/puma-biotech-gears-secondary-offering-194342781.html,Puma Biotech Gears Up for Secondary Offering
PBYI,PBYI:US,BBG0018YXYX7,"Health Care Sector Update for 10/19/2016: XOMA, CERU, PBYI, NVS",2016-10-19 18:48:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rf52UrouFkg/health-care-sector-update-for-10192016-xoma-ceru-pbyi-nvs-cm695546,Top Health Care StocksTop Health Care Stocks JNJ 0 62 JNJ 0 62 PFE 0 11 PFE 0 11 MRK 0 05 MRK 0 05 ABT 2 43 ABT 2 43 AMGN 0 67 AMGN 0 67 Health care stocks were cutting earlier losses with the NYSE Health Care Index slipping about 0 1 while shares of health care companies in
PBYI,PBYI:UW,BBG002NFCGM3,"Health Care Sector Update for 10/19/2016: XOMA, CERU, PBYI, NVS",2016-10-19 18:48:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rf52UrouFkg/health-care-sector-update-for-10192016-xoma-ceru-pbyi-nvs-cm695546,Top Health Care StocksTop Health Care Stocks JNJ 0 62 JNJ 0 62 PFE 0 11 PFE 0 11 MRK 0 05 MRK 0 05 ABT 2 43 ABT 2 43 AMGN 0 67 AMGN 0 67 Health care stocks were cutting earlier losses with the NYSE Health Care Index slipping about 0 1 while shares of health care companies in
PBYI,PBYI:US,BBG0018YXYX7,Why Puma Biotechnology Inc. Sold Lower Today,2016-10-19 18:47:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JdvNj66kN_g/why-puma-biotechnology-inc-sold-lower-today-cm695530,Image source Getty Images What happened Puma Biotechnology NYSE PBYI is down 18 at 12 45 p m EDT today after announcing a secondary offering of shares yesterday after the bell So what Puma Biotechnology is looking to raise 150 million 160 selling shares which
PBYI,PBYI:UW,BBG002NFCGM3,Why Puma Biotechnology Inc. Sold Lower Today,2016-10-19 18:47:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JdvNj66kN_g/why-puma-biotechnology-inc-sold-lower-today-cm695530,Image source Getty Images What happened Puma Biotechnology NYSE PBYI is down 18 at 12 45 p m EDT today after announcing a secondary offering of shares yesterday after the bell So what Puma Biotechnology is looking to raise 150 million 160 selling shares which
PBYI,PBYI:US,BBG0018YXYX7,"Wednesday Sector Laggards: Biotechnology, Drugs",2016-10-19 18:47:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eRUlFdVlonE/wednesday-sector-laggards-biotechnology-drugs-cm695522,In trading on Wednesday biotechnology shares were relative laggards down on the day by about 1 Helping drag down the group were shares of Puma Biotechnology PBYI down about 16 6 and shares of Sangamo Biosciences SGMO down about 9 6 on the day Also lagging the
PBYI,PBYI:UW,BBG002NFCGM3,"Wednesday Sector Laggards: Biotechnology, Drugs",2016-10-19 18:47:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eRUlFdVlonE/wednesday-sector-laggards-biotechnology-drugs-cm695522,In trading on Wednesday biotechnology shares were relative laggards down on the day by about 1 Helping drag down the group were shares of Puma Biotechnology PBYI down about 16 6 and shares of Sangamo Biosciences SGMO down about 9 6 on the day Also lagging the
PBYI,PBYI:US,BBG0018YXYX7,"Wednesday's ETF Movers: OIH, XBI",2016-10-19 18:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J3puybJQLmg/wednesdays-etf-movers-oih-xbi-cm695520,In trading on Wednesday the Oil Services ETF OIH is outperforming other ETFs up about 3 6 on the day Components of that ETF showing particular strength include shares of Transocean RIG up about 7 1 and shares of Weatherford International WFT up about 7 1 on the day
PBYI,PBYI:UW,BBG002NFCGM3,"Wednesday's ETF Movers: OIH, XBI",2016-10-19 18:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J3puybJQLmg/wednesdays-etf-movers-oih-xbi-cm695520,In trading on Wednesday the Oil Services ETF OIH is outperforming other ETFs up about 3 6 on the day Components of that ETF showing particular strength include shares of Transocean RIG up about 7 1 and shares of Weatherford International WFT up about 7 1 on the day
PBYI,PBYI:US,BBG0018YXYX7,Why Puma Biotechnology Inc. Sold Lower Today,2016-10-19 17:01:29 +0000,http://www.fool.com/investing/2016/10/19/why-puma-biotechnology-inc-sold-lower-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Puma Biotechnology Inc. Sold Lower Today
PBYI,PBYI:UW,BBG002NFCGM3,Why Puma Biotechnology Inc. Sold Lower Today,2016-10-19 17:01:29 +0000,http://www.fool.com/investing/2016/10/19/why-puma-biotechnology-inc-sold-lower-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Puma Biotechnology Inc. Sold Lower Today
PBYI,PBYI:US,BBG0018YXYX7,"Why Traders Are Watching Manhattan Associates, Meridian Bioscience, Puma Biotechnology, Tesla and More",2016-10-19 13:07:08 +0000,http://www.insidermonkey.com/blog/why-traders-are-watching-manhattan-associates-meridian-bioscience-puma-biotechnology-tesla-and-more-482040/,"Why Traders Are Watching Manhattan Associates, Meridian Bioscience, Puma Biotechnology, Tesla and More"
PBYI,PBYI:UW,BBG002NFCGM3,"Why Traders Are Watching Manhattan Associates, Meridian Bioscience, Puma Biotechnology, Tesla and More",2016-10-19 13:07:08 +0000,http://www.insidermonkey.com/blog/why-traders-are-watching-manhattan-associates-meridian-bioscience-puma-biotechnology-tesla-and-more-482040/,"Why Traders Are Watching Manhattan Associates, Meridian Bioscience, Puma Biotechnology, Tesla and More"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering,2016-10-18 21:53:00 +0000,https://www.thestreet.com/story/13858128/1/puma-biotechnology-pbyi-stock-down-in-after-hours-trading-on-public-offering.html?puc=yahoo&cm_ven=YAHOO,Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering,2016-10-18 21:53:00 +0000,https://www.thestreet.com/story/13858128/1/puma-biotechnology-pbyi-stock-down-in-after-hours-trading-on-public-offering.html?puc=yahoo&cm_ven=YAHOO,Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech shares slide on secondary stock offering,2016-10-18 20:36:22 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=680402D0-304F-427B-AD0F-49D9F00FB2A8&siteid=yhoof2,Puma Biotech shares slide on secondary stock offering
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech shares slide on secondary stock offering,2016-10-18 20:36:22 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=680402D0-304F-427B-AD0F-49D9F00FB2A8&siteid=yhoof2,Puma Biotech shares slide on secondary stock offering
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces Proposed Public Offering of Common Stock,2016-10-18 20:28:10 +0000,http://www.publicnow.com/view/F0B04987A4229CD3F92C2D6E125FA4BB75F9E64C,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it is commencing an underwritten public offering of $150 million of shares of its common ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces Proposed Public Offering of Common Stock,2016-10-18 20:28:10 +0000,http://www.publicnow.com/view/F0B04987A4229CD3F92C2D6E125FA4BB75F9E64C,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it is commencing an underwritten public offering of $150 million of shares of its common ..."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi",2016-10-17 10:04:30 +0000,http://biz.yahoo.com/e/161017/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi"
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi",2016-10-17 10:04:30 +0000,http://biz.yahoo.com/e/161017/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi"
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. – PBYI",2016-10-15 02:07:00 +0000,http://finance.yahoo.com/news/puma-investigation-initiated-former-louisiana-020700876.html,"[Business Wire] - Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Puma Biotechnology, Inc."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. – PBYI",2016-10-15 02:07:00 +0000,http://finance.yahoo.com/news/puma-investigation-initiated-former-louisiana-020700876.html,"[Business Wire] - Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Puma Biotechnology, Inc."
PBYI,PBYI:US,BBG0018YXYX7,"Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Investors Survive Defendants' Motion to Dismiss in Securities Class Action",2016-10-12 18:52:00 +0000,http://finance.yahoo.com/news/robbins-arroyo-llp-puma-biotechnology-185200744.html,"[Business Wire] - Shareholder rights law firm Robbins Arroyo LLP announces that a lawsuit was filed against Puma Biotechnology, Inc. in the U.S. District Court for the Central District of California, alleging violations of the Securities Exchange Act of 1934 by Puma's officers and directors."
PBYI,PBYI:UW,BBG002NFCGM3,"Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Investors Survive Defendants' Motion to Dismiss in Securities Class Action",2016-10-12 18:52:00 +0000,http://finance.yahoo.com/news/robbins-arroyo-llp-puma-biotechnology-185200744.html,"[Business Wire] - Shareholder rights law firm Robbins Arroyo LLP announces that a lawsuit was filed against Puma Biotechnology, Inc. in the U.S. District Court for the Central District of California, alleging violations of the Securities Exchange Act of 1934 by Puma's officers and directors."
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Biotechnology, Inc. Shareholder Alert: Schubert Firm Investigates Company's Top Executives",2016-10-11 15:30:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-inc-shareholder-alert-153000533.html,"[PR Newswire] - SAN FRANCISCO, Oct. 11, 2016 /PRNewswire/ -- Shareholder and consumer rights law firm Schubert Jonckheer & Kolbe LLP today launched an investigation into potential claims on behalf of shareholders of Puma ..."
PBYI,PBYI:US,BBG0018YXYX7,"Puma Biotechnology, Inc. Shareholder Alert: Schubert Firm Investigates Company's Top Executives",2016-10-11 15:30:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-inc-shareholder-alert-153000533.html,"[PR Newswire] - SAN FRANCISCO, Oct. 11, 2016 /PRNewswire/ -- Shareholder and consumer rights law firm Schubert Jonckheer & Kolbe LLP today launched an investigation into potential claims on behalf of shareholders of Puma ..."
PBYI,PBYI:UW,BBG002NFCGM3,"Johnson & Weaver, LLP Initiates Investigations of Puma Biotechnology, Inc., Virtus Investment Partners, Inc., AAC Holdings, Inc. and Spectrum Pharmaceuticals, Inc.; Encourages Long-Term Investors to Contact the Firm Regarding Their Legal Ri",2016-10-10 14:32:00 +0000,http://finance.yahoo.com/news/johnson-weaver-llp-initiates-investigations-143200777.html,"[PR Newswire] - SAN DIEGO, Oct. 10, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP, is investigating potential claims against Puma Biotechnology, Inc., Virtus Investment Partners, Inc., AAC Holdings, Inc., and Spectrum Pharmaceuticals, Inc., as detailed below. Johnson & Weaver, LLP, is investigating potential violations of federal and state laws by certain officers and directors of Puma Biotechnology, Inc. (PBYI). On September 30, 2016, a federal court denied a motion to dismiss a securities fraud class action filed against Puma and certain executives."
PBYI,PBYI:US,BBG0018YXYX7,"Johnson & Weaver, LLP Initiates Investigations of Puma Biotechnology, Inc., Virtus Investment Partners, Inc., AAC Holdings, Inc. and Spectrum Pharmaceuticals, Inc.; Encourages Long-Term Investors to Contact the Firm Regarding Their Legal Ri",2016-10-10 14:32:00 +0000,http://finance.yahoo.com/news/johnson-weaver-llp-initiates-investigations-143200777.html,"[PR Newswire] - SAN DIEGO, Oct. 10, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP, is investigating potential claims against Puma Biotechnology, Inc., Virtus Investment Partners, Inc., AAC Holdings, Inc., and Spectrum Pharmaceuticals, Inc., as detailed below. Johnson & Weaver, LLP, is investigating potential violations of federal and state laws by certain officers and directors of Puma Biotechnology, Inc. (PBYI). On September 30, 2016, a federal court denied a motion to dismiss a securities fraud class action filed against Puma and certain executives."
PBYI,PBYI:UW,BBG002NFCGM3,"Noteworthy Tuesday Option Activity: RGLD, PBYI, PII",2016-10-04 21:44:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9mCtt6SZvN0/noteworthy-tuesday-option-activity-rgld-pbyi-pii-cm688809,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Royal Gold Inc Symbol RGLD where a total volume of 3 894 contracts has been traded thus far today a contract volume which is representative of approximately 389
PBYI,PBYI:US,BBG0018YXYX7,"Noteworthy Tuesday Option Activity: RGLD, PBYI, PII",2016-10-04 21:44:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9mCtt6SZvN0/noteworthy-tuesday-option-activity-rgld-pbyi-pii-cm688809,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Royal Gold Inc Symbol RGLD where a total volume of 3 894 contracts has been traded thus far today a contract volume which is representative of approximately 389
PBYI,PBYI:UW,BBG002NFCGM3,Lawsuit for Investors in shares of Puma Biotechnology Inc (NYSE:PBYI) against Directors announced by Shareholders Foundation,2016-10-04 14:15:00 +0000,http://finance.yahoo.com/news/lawsuit-investors-shares-puma-biotechnology-141500599.html,"[GlobeNewswire] - SAN DIEGO, Oct. 04, 2016-- The Shareholders Foundation, Inc. announces that a lawsuit was filed by an investor in shares of Puma Biotechnology Inc against certain directors of Puma Biotechnology Inc over ..."
PBYI,PBYI:US,BBG0018YXYX7,Lawsuit for Investors in shares of Puma Biotechnology Inc (NYSE:PBYI) against Directors announced by Shareholders Foundation,2016-10-04 14:15:00 +0000,http://finance.yahoo.com/news/lawsuit-investors-shares-puma-biotechnology-141500599.html,"[GlobeNewswire] - SAN DIEGO, Oct. 04, 2016-- The Shareholders Foundation, Inc. announces that a lawsuit was filed by an investor in shares of Puma Biotechnology Inc against certain directors of Puma Biotechnology Inc over ..."
PBYI,PBYI:UW,BBG002NFCGM3,5 Top Performing Stocks of the Best ETF of Q3,2016-09-30 15:24:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1i38wrWT5co/5-top-performing-stocks-of-the-best-etf-of-q3-cm687111,After a huge sell off at the start of the year the biotech sector has made a strong comeback with BioShares Biotechnology Clinical Trials Fund BBC topping the list of the best performing ETFs of 3Q16 The fund delivered impressive returns of about 29 6 in the quarter and has a Zacks ETF Rank
PBYI,PBYI:US,BBG0018YXYX7,5 Top Performing Stocks of the Best ETF of Q3,2016-09-30 15:24:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1i38wrWT5co/5-top-performing-stocks-of-the-best-etf-of-q3-cm687111,After a huge sell off at the start of the year the biotech sector has made a strong comeback with BioShares Biotechnology Clinical Trials Fund BBC topping the list of the best performing ETFs of 3Q16 The fund delivered impressive returns of about 29 6 in the quarter and has a Zacks ETF Rank
PBYI,PBYI:UW,BBG002NFCGM3,5 Top Performing Stocks of the Best ETF of Q3,2016-09-30 13:13:01 +0000,http://finance.yahoo.com/news/5-top-performing-stocks-best-131301185.html,5 Top Performing Stocks of the Best ETF of Q3
PBYI,PBYI:US,BBG0018YXYX7,5 Top Performing Stocks of the Best ETF of Q3,2016-09-30 13:13:01 +0000,http://finance.yahoo.com/news/5-top-performing-stocks-best-131301185.html,5 Top Performing Stocks of the Best ETF of Q3
PBYI,PBYI:US,BBG0018YXYX7,SEC Issues Charges Over Biotech Insider Activity,2016-09-30 13:10:25 +0000,http://finance.yahoo.com/news/sec-issues-charges-over-biotech-131025682.html,SEC Issues Charges Over Biotech Insider Activity
PBYI,PBYI:UW,BBG002NFCGM3,SEC Issues Charges Over Biotech Insider Activity,2016-09-30 13:10:25 +0000,http://finance.yahoo.com/news/sec-issues-charges-over-biotech-131025682.html,SEC Issues Charges Over Biotech Insider Activity
PBYI,PBYI:UW,BBG002NFCGM3,"Biotech Stock Mailbag: Dynavax, Puma, Ariad",2016-09-30 11:00:00 +0000,https://www.thestreet.com/story/13836613/1/biotech-stock-mailbag-dynavax-puma-ariad.html?puc=yahoo&cm_ven=YAHOO,"Biotech Stock Mailbag: Dynavax, Puma, Ariad"
PBYI,PBYI:US,BBG0018YXYX7,"Biotech Stock Mailbag: Dynavax, Puma, Ariad",2016-09-30 11:00:00 +0000,https://www.thestreet.com/story/13836613/1/biotech-stock-mailbag-dynavax-puma-ariad.html?puc=yahoo&cm_ven=YAHOO,"Biotech Stock Mailbag: Dynavax, Puma, Ariad"
PBYI,PBYI:US,BBG0018YXYX7,SEC charges former Puma Biotech employee with insider trading,2016-09-29 20:05:34 +0000,http://finance.yahoo.com/news/sec-charges-former-puma-biotech-200534954.html,"[Reuters] - The U.S. Securities and Exchange Commission said on Thursday it had charged a former employee of Puma Biotechnology with insider trading, and that the Justice Department was pursuing a parallel criminal case. The SEC alleged that Robert Gadimian, who served as the senior director of regulatory affairs for the company, profited by $1.1 million by trading ahead of news announcements about a Puma breast cancer treatment drug."
PBYI,PBYI:UW,BBG002NFCGM3,SEC charges former Puma Biotech employee with insider trading,2016-09-29 20:05:34 +0000,http://finance.yahoo.com/news/sec-charges-former-puma-biotech-200534954.html,"[Reuters] - The U.S. Securities and Exchange Commission said on Thursday it had charged a former employee of Puma Biotechnology with insider trading, and that the Justice Department was pursuing a parallel criminal case. The SEC alleged that Robert Gadimian, who served as the senior director of regulatory affairs for the company, profited by $1.1 million by trading ahead of news announcements about a Puma breast cancer treatment drug."
PBYI,PBYI:US,BBG0018YXYX7,2 Longs And 2 Shorts to Watch,2016-09-27 17:00:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oH4cfiLHY6k/2-longs-and-2-shorts-to-watch-cm685486,"Array BioPharma Inc. ( ARRY ) had an explosive move on Monday, up $2.96, or 81%, to $6.61, on 101 million shares.  The company said its melanoma treatment met its primary goal in a late-stage trial.  Afterhours the stock was trading even higher, and looks like it has more room to run.  There's key resistance between"
PBYI,PBYI:UW,BBG002NFCGM3,2 Longs And 2 Shorts to Watch,2016-09-27 17:00:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oH4cfiLHY6k/2-longs-and-2-shorts-to-watch-cm685486,"Array BioPharma Inc. ( ARRY ) had an explosive move on Monday, up $2.96, or 81%, to $6.61, on 101 million shares.  The company said its melanoma treatment met its primary goal in a late-stage trial.  Afterhours the stock was trading even higher, and looks like it has more room to run.  There's key resistance between"
PBYI,PBYI:US,BBG0018YXYX7,"Momentum Carries Lululemon Lower, Pushes Biotech Names Higher",2016-09-27 15:49:00 +0000,http://www.forbes.com/sites/greatspeculations/2016/09/27/momentum-carries-lululemon-lower-pushes-biotech-names-higher/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,"Momentum Carries Lululemon Lower, Pushes Biotech Names Higher"
PBYI,PBYI:UW,BBG002NFCGM3,"Momentum Carries Lululemon Lower, Pushes Biotech Names Higher",2016-09-27 15:49:00 +0000,http://www.forbes.com/sites/greatspeculations/2016/09/27/momentum-carries-lululemon-lower-pushes-biotech-names-higher/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,"Momentum Carries Lululemon Lower, Pushes Biotech Names Higher"
PBYI,PBYI:UW,BBG002NFCGM3,6 Biotech and Biohealth Analyst Picks for 50% to 150% Upside,2016-09-25 14:45:24 +0000,http://247wallst.com/healthcare-business/2016/09/25/6-biotech-and-biohealth-analyst-picks-for-50-to-150-upside/,6 Biotech and Biohealth Analyst Picks for 50% to 150% Upside
PBYI,PBYI:US,BBG0018YXYX7,6 Biotech and Biohealth Analyst Picks for 50% to 150% Upside,2016-09-25 14:45:24 +0000,http://247wallst.com/healthcare-business/2016/09/25/6-biotech-and-biohealth-analyst-picks-for-50-to-150-upside/,6 Biotech and Biohealth Analyst Picks for 50% to 150% Upside
PBYI,PBYI:US,BBG0018YXYX7,Could Puma Biotech Double After This FDA Approval?,2016-09-25 14:20:41 +0000,http://247wallst.com/healthcare-business/2016/09/25/could-puma-biotech-double-after-this-fda-approval/,Could Puma Biotech Double After This FDA Approval?
PBYI,PBYI:UW,BBG002NFCGM3,Could Puma Biotech Double After This FDA Approval?,2016-09-25 14:20:41 +0000,http://247wallst.com/healthcare-business/2016/09/25/could-puma-biotech-double-after-this-fda-approval/,Could Puma Biotech Double After This FDA Approval?
PBYI,PBYI:US,BBG0018YXYX7,Puma Races To Eight-Month High On Breast Cancer Drug Success,2016-09-22 20:31:37 +0000,http://www.investors.com/news/technology/puma-races-to-eight-month-high-on-breast-cancer-drug-success/,Puma Races To Eight-Month High On Breast Cancer Drug Success
PBYI,PBYI:UW,BBG002NFCGM3,Puma Races To Eight-Month High On Breast Cancer Drug Success,2016-09-22 20:31:37 +0000,http://www.investors.com/news/technology/puma-races-to-eight-month-high-on-breast-cancer-drug-success/,Puma Races To Eight-Month High On Breast Cancer Drug Success
PBYI,PBYI:UW,BBG002NFCGM3,Greater Expectations For Puma Technology Boost Credit Suisse Target Price To $111,2016-09-22 19:42:06 +0000,http://finance.yahoo.com/news/greater-expectations-puma-technology-boost-194206068.html,Greater Expectations For Puma Technology Boost Credit Suisse Target Price To $111
PBYI,PBYI:US,BBG0018YXYX7,Greater Expectations For Puma Technology Boost Credit Suisse Target Price To $111,2016-09-22 19:42:06 +0000,http://finance.yahoo.com/news/greater-expectations-puma-technology-boost-194206068.html,Greater Expectations For Puma Technology Boost Credit Suisse Target Price To $111
PBYI,PBYI:UW,BBG002NFCGM3,Why Key Analyst Sees Puma Biotech Practically Doubling,2016-09-22 15:50:43 +0000,http://247wallst.com/healthcare-business/2016/09/22/why-key-analyst-sees-puma-biotech-practically-doubling/,Why Key Analyst Sees Puma Biotech Practically Doubling
PBYI,PBYI:US,BBG0018YXYX7,Why Key Analyst Sees Puma Biotech Practically Doubling,2016-09-22 15:50:43 +0000,http://247wallst.com/healthcare-business/2016/09/22/why-key-analyst-sees-puma-biotech-practically-doubling/,Why Key Analyst Sees Puma Biotech Practically Doubling
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Shares Leap Forward,2016-09-22 14:56:00 +0000,http://realmoney.thestreet.com/articles/09/22/2016/puma-biotechnology-shares-leap-forward?puc=yahoo&cm_ven=YAHOO,Puma Biotechnology Shares Leap Forward
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Shares Leap Forward,2016-09-22 14:56:00 +0000,http://realmoney.thestreet.com/articles/09/22/2016/puma-biotechnology-shares-leap-forward?puc=yahoo&cm_ven=YAHOO,Puma Biotechnology Shares Leap Forward
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology: That's Some Target Increase!!!,2016-09-22 14:11:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/22/puma-biotechnology-thats-some-target-increase/?mod=yahoobarrons&ru=yahoo,Puma Biotechnology: That's Some Target Increase!!!
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology: That's Some Target Increase!!!,2016-09-22 14:11:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/22/puma-biotechnology-thats-some-target-increase/?mod=yahoobarrons&ru=yahoo,Puma Biotechnology: That's Some Target Increase!!!
PBYI,PBYI:US,BBG0018YXYX7,"Top Analyst Upgrades and Downgrades: Alibaba, Amazon, Bed Beth & Beyond, Puma Biotechnology, SeaWorld and More",2016-09-22 13:05:48 +0000,http://247wallst.com/investing/2016/09/22/top-analyst-upgrades-and-downgrades-alibaba-amazon-bed-beth-beyond-puma-biotechnology-seaworld-and-more/,"Top Analyst Upgrades and Downgrades: Alibaba, Amazon, Bed Beth & Beyond, Puma Biotechnology, SeaWorld and More"
PBYI,PBYI:UW,BBG002NFCGM3,"Top Analyst Upgrades and Downgrades: Alibaba, Amazon, Bed Beth & Beyond, Puma Biotechnology, SeaWorld and More",2016-09-22 13:05:48 +0000,http://247wallst.com/investing/2016/09/22/top-analyst-upgrades-and-downgrades-alibaba-amazon-bed-beth-beyond-puma-biotechnology-seaworld-and-more/,"Top Analyst Upgrades and Downgrades: Alibaba, Amazon, Bed Beth & Beyond, Puma Biotechnology, SeaWorld and More"
PBYI,PBYI:US,BBG0018YXYX7,4 health-care stocks to watch,2016-09-21 19:38:44 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=CCF56263-1AE7-4530-9EE1-DE0ED3FFB8FB&siteid=yhoof2,4 health-care stocks to watch
PBYI,PBYI:UW,BBG002NFCGM3,4 health-care stocks to watch,2016-09-21 19:38:44 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=CCF56263-1AE7-4530-9EE1-DE0ED3FFB8FB&siteid=yhoof2,4 health-care stocks to watch
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up",2016-09-21 17:23:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rZ7e8Fgiuks/puma-pbyi-neratinibs-nda-accepted-for-review-stock-up-cm682770,Puma Biotechnology Inc s PBYI shares gained 10 5 after the company announced that its New Drug Application NDA for its lead candidate neratinib PB272 has been accepted for review by the FDA The company is looking to get neratinib approved as an extended adjuvant treatment
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up",2016-09-21 17:23:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rZ7e8Fgiuks/puma-pbyi-neratinibs-nda-accepted-for-review-stock-up-cm682770,Puma Biotechnology Inc s PBYI shares gained 10 5 after the company announced that its New Drug Application NDA for its lead candidate neratinib PB272 has been accepted for review by the FDA The company is looking to get neratinib approved as an extended adjuvant treatment
PBYI,PBYI:US,BBG0018YXYX7,3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions,2016-09-21 16:23:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JDiIhkH5gYk/3-clinical-stage-biotechs-to-buy-ahead-of-fda-decisions-cm682680,Image source Getty Images Roughly 90 of drugs in clinical trials never make it to the Food and Drug Administration for review so it s not surprising that a green light can be a market moving event especially when it s granted to drugs targeting billion dollar blockbuster
PBYI,PBYI:UW,BBG002NFCGM3,3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions,2016-09-21 16:23:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JDiIhkH5gYk/3-clinical-stage-biotechs-to-buy-ahead-of-fda-decisions-cm682680,Image source Getty Images Roughly 90 of drugs in clinical trials never make it to the Food and Drug Administration for review so it s not surprising that a green light can be a market moving event especially when it s granted to drugs targeting billion dollar blockbuster
PBYI,PBYI:US,BBG0018YXYX7,3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions,2016-09-21 15:01:23 +0000,http://www.fool.com/investing/2016/09/21/3-clinical-stage-biotechs-to-buy-ahead-of-fda-deci.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions
PBYI,PBYI:UW,BBG002NFCGM3,3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions,2016-09-21 15:01:23 +0000,http://www.fool.com/investing/2016/09/21/3-clinical-stage-biotechs-to-buy-ahead-of-fda-deci.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up",2016-09-21 14:51:02 +0000,http://finance.yahoo.com/news/puma-pbyi-neratinibs-nda-accepted-145102430.html,"Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up"
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up",2016-09-21 14:51:02 +0000,http://finance.yahoo.com/news/puma-pbyi-neratinibs-nda-accepted-145102430.html,"Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up"
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech. upgraded by Stifel,2016-09-21 11:22:27 +0000,http://finance.yahoo.com/q/ud?s=PBYI,Puma Biotech. upgraded by Stifel
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech. upgraded by Stifel,2016-09-21 11:22:27 +0000,http://finance.yahoo.com/q/ud?s=PBYI,Puma Biotech. upgraded by Stifel
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Biotechnology (PBYI) Shares March Higher, Can It Continue?",2016-09-21 11:21:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0tjmD6-mch4/puma-biotechnology-pbyi-shares-march-higher-can-it-continue-cm682418,As of late it has definitely been a great time to be an investor in Puma Biotechnology Inc PBYI The stock has moved higher by 7 9 in the past month while it is also above its 20 Day SMA too This combination of strong price performance and favorable technical could suggest that the
PBYI,PBYI:US,BBG0018YXYX7,"Puma Biotechnology (PBYI) Shares March Higher, Can It Continue?",2016-09-21 11:21:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0tjmD6-mch4/puma-biotechnology-pbyi-shares-march-higher-can-it-continue-cm682418,As of late it has definitely been a great time to be an investor in Puma Biotechnology Inc PBYI The stock has moved higher by 7 9 in the past month while it is also above its 20 Day SMA too This combination of strong price performance and favorable technical could suggest that the
PBYI,PBYI:US,BBG0018YXYX7,"Puma Biotechnology (PBYI) Shares March Higher, Can It Continue?",2016-09-21 09:45:09 +0000,http://finance.yahoo.com/news/puma-biotechnology-pbyi-shares-march-094509368.html,"Puma Biotechnology (PBYI) Shares March Higher, Can It Continue?"
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Biotechnology (PBYI) Shares March Higher, Can It Continue?",2016-09-21 09:45:09 +0000,http://finance.yahoo.com/news/puma-biotechnology-pbyi-shares-march-094509368.html,"Puma Biotechnology (PBYI) Shares March Higher, Can It Continue?"
PBYI,PBYI:US,BBG0018YXYX7,"MSTX Crashes On EPIC Data, MIRN Ditches MRX34, More Good News From SRPT",2016-09-21 02:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AYXMV9I-zTU/mstx-crashes-on-epic-data-mirn-ditches-mrx34-more-good-news-from-srpt-20160921-00036,"MSTX Crashes On EPIC Data, MIRN Ditches MRX34, More Good News From SRPT"
PBYI,PBYI:UW,BBG002NFCGM3,"MSTX Crashes On EPIC Data, MIRN Ditches MRX34, More Good News From SRPT",2016-09-21 02:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AYXMV9I-zTU/mstx-crashes-on-epic-data-mirn-ditches-mrx34-more-good-news-from-srpt-20160921-00036,"MSTX Crashes On EPIC Data, MIRN Ditches MRX34, More Good News From SRPT"
PBYI,PBYI:UW,BBG002NFCGM3,Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm,2016-09-20 20:52:44 +0000,http://www.investors.com/research/ibd-industry-themes/biotech-stocks-stay-hot-as-sarepta-drug-approval-gives-shot-in-arm/,Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm
PBYI,PBYI:US,BBG0018YXYX7,Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm,2016-09-20 20:52:44 +0000,http://www.investors.com/research/ibd-industry-themes/biotech-stocks-stay-hot-as-sarepta-drug-approval-gives-shot-in-arm/,Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm
PBYI,PBYI:UW,BBG002NFCGM3,Why Puma Biotechnology Inc Roared Higher Today,2016-09-20 20:21:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XvjHBfrU954/why-puma-biotechnology-inc-roared-higher-today-cm682249,Image source Getty Images What happened Puma Biotechnology NYSE PBYI was up as much as much as 15 today after announcing that the Food and Drug Administration accepted the company s marketing application for its breast cancer drug neratinib although it s given up some
PBYI,PBYI:US,BBG0018YXYX7,Why Puma Biotechnology Inc Roared Higher Today,2016-09-20 20:21:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XvjHBfrU954/why-puma-biotechnology-inc-roared-higher-today-cm682249,Image source Getty Images What happened Puma Biotechnology NYSE PBYI was up as much as much as 15 today after announcing that the Food and Drug Administration accepted the company s marketing application for its breast cancer drug neratinib although it s given up some
PBYI,PBYI:US,BBG0018YXYX7,"Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy",2016-09-20 20:21:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YawhPysiZmE/forget-sarepta-therapeutics-here-are-3-other-biotech-stocks-to-buy-cm682236,Image source Stockmonkeys com via Flickr When the FDA approved 160 Sarepta Therapeutics NASDAQ SRPT controversial Duchenne muscular dystrophy drug Exondys 51 it caused shares in the company to surge 74 a market cap of 2 4 billion may fairly value it now If so
PBYI,PBYI:UW,BBG002NFCGM3,"Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy",2016-09-20 20:21:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YawhPysiZmE/forget-sarepta-therapeutics-here-are-3-other-biotech-stocks-to-buy-cm682236,Image source Stockmonkeys com via Flickr When the FDA approved 160 Sarepta Therapeutics NASDAQ SRPT controversial Duchenne muscular dystrophy drug Exondys 51 it caused shares in the company to surge 74 a market cap of 2 4 billion may fairly value it now If so
PBYI,PBYI:US,BBG0018YXYX7,"Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy",2016-09-20 19:01:06 +0000,http://www.fool.com/investing/2016/09/20/forget-sarepta-therapeutics-here-are-3-other-biote.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy"
PBYI,PBYI:UW,BBG002NFCGM3,"Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy",2016-09-20 19:01:06 +0000,http://www.fool.com/investing/2016/09/20/forget-sarepta-therapeutics-here-are-3-other-biote.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy"
PBYI,PBYI:UW,BBG002NFCGM3,Why Puma Biotechnology Inc Roared Higher Today,2016-09-20 18:27:55 +0000,http://www.fool.com/investing/2016/09/20/why-puma-biotechnology-inc-roared-higher-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Puma Biotechnology Inc Roared Higher Today
PBYI,PBYI:US,BBG0018YXYX7,Why Puma Biotechnology Inc Roared Higher Today,2016-09-20 18:27:55 +0000,http://www.fool.com/investing/2016/09/20/why-puma-biotechnology-inc-roared-higher-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Puma Biotechnology Inc Roared Higher Today
PBYI,PBYI:UW,BBG002NFCGM3,"Tuesday's ETF Movers: XBI, ITB",2016-09-20 18:20:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wivqnvesik0/tuesdays-etf-movers-xbi-itb-cm682171,In trading on Tuesday the SPDR S amp P Biotech ETF XBI is outperforming other ETFs up about 2 6 on the day Components of that ETF showing particular strength include shares of Sarepta Therapeutics SRPT up about 13 1 and shares of Puma Biotechnology PBYI up about 9 7 on
PBYI,PBYI:US,BBG0018YXYX7,"Tuesday's ETF Movers: XBI, ITB",2016-09-20 18:20:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wivqnvesik0/tuesdays-etf-movers-xbi-itb-cm682171,In trading on Tuesday the SPDR S amp P Biotech ETF XBI is outperforming other ETFs up about 2 6 on the day Components of that ETF showing particular strength include shares of Sarepta Therapeutics SRPT up about 13 1 and shares of Puma Biotechnology PBYI up about 9 7 on
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events",2016-09-20 17:13:00 +0000,http://biz.yahoo.com/e/160920/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events"
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events",2016-09-20 17:13:00 +0000,http://biz.yahoo.com/e/160920/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events"
PBYI,PBYI:US,BBG0018YXYX7,Here’s Why These Five Stocks Are on the Move Today,2016-09-20 16:29:55 +0000,http://www.insidermonkey.com/blog/heres-why-these-five-stocks-are-on-the-move-today-5-475757/,Here’s Why These Five Stocks Are on the Move Today
PBYI,PBYI:UW,BBG002NFCGM3,Here’s Why These Five Stocks Are on the Move Today,2016-09-20 16:29:55 +0000,http://www.insidermonkey.com/blog/heres-why-these-five-stocks-are-on-the-move-today-5-475757/,Here’s Why These Five Stocks Are on the Move Today
PBYI,PBYI:US,BBG0018YXYX7,Why Puma Biotechnology (PBYI) Stock Is Surging Today,2016-09-20 15:35:00 +0000,https://www.thestreet.com/story/13745975/1/why-puma-biotechnology-pbyi-stock-is-surging-today.html?puc=yahoo&cm_ven=YAHOO,Why Puma Biotechnology (PBYI) Stock Is Surging Today
PBYI,PBYI:UW,BBG002NFCGM3,Why Puma Biotechnology (PBYI) Stock Is Surging Today,2016-09-20 15:35:00 +0000,https://www.thestreet.com/story/13745975/1/why-puma-biotechnology-pbyi-stock-is-surging-today.html?puc=yahoo&cm_ven=YAHOO,Why Puma Biotechnology (PBYI) Stock Is Surging Today
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech Rises on Key FDA Approval,2016-09-20 15:15:23 +0000,http://247wallst.com/healthcare-business/2016/09/20/puma-biotech-rises-on-key-fda-approval/,Puma Biotech Rises on Key FDA Approval
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech Rises on Key FDA Approval,2016-09-20 15:15:23 +0000,http://247wallst.com/healthcare-business/2016/09/20/puma-biotech-rises-on-key-fda-approval/,Puma Biotech Rises on Key FDA Approval
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology: Sarepta Isn't the Only Biotech Getting a Boost From the FDA,2016-09-20 13:51:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/20/puma-biotechnology-sarepta-isnt-the-only-biotech-getting-a-boost-from-the-fda/?mod=yahoobarrons&ru=yahoo,Puma Biotechnology: Sarepta Isn't the Only Biotech Getting a Boost From the FDA
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology: Sarepta Isn't the Only Biotech Getting a Boost From the FDA,2016-09-20 13:51:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/20/puma-biotechnology-sarepta-isnt-the-only-biotech-getting-a-boost-from-the-fda/?mod=yahoobarrons&ru=yahoo,Puma Biotechnology: Sarepta Isn't the Only Biotech Getting a Boost From the FDA
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces U.S. FDA Acceptance of New Drug Application for PB272 (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,2016-09-20 12:18:12 +0000,http://www.publicnow.com/view/F49193A6D6B7778B3A4319995EA305EB340A00A8,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces U.S. FDA Acceptance of New Drug Application for PB272 (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,2016-09-20 12:18:12 +0000,http://www.publicnow.com/view/F49193A6D6B7778B3A4319995EA305EB340A00A8,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Inc. (PBYI) Has Broken Out To An 8-Month High,2016-09-20 09:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kpE6O_u71YY/puma-biotechnology-inc-pbyi-has-broken-out-to-an-8month-high-20160920-00187,Puma Biotechnology Inc. (PBYI) Has Broken Out To An 8-Month High
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Inc. (PBYI) Has Broken Out To An 8-Month High,2016-09-20 09:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kpE6O_u71YY/puma-biotechnology-inc-pbyi-has-broken-out-to-an-8month-high-20160920-00187,Puma Biotechnology Inc. (PBYI) Has Broken Out To An 8-Month High
PBYI,PBYI:UW,BBG002NFCGM3,"After Losing Medivation, Who Is Gilead Going After Next?",2016-09-19 19:00:00 +0000,http://www.forbes.com/sites/kenkam/2016/09/19/who-is-gilead-about-to-buy/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,"After Losing Medivation, Who Is Gilead Going After Next?"
PBYI,PBYI:US,BBG0018YXYX7,"After Losing Medivation, Who Is Gilead Going After Next?",2016-09-19 19:00:00 +0000,http://www.forbes.com/sites/kenkam/2016/09/19/who-is-gilead-about-to-buy/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,"After Losing Medivation, Who Is Gilead Going After Next?"
PBYI,PBYI:US,BBG0018YXYX7,"Puma Biotechnology, Inc. :PBYI-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016",2016-09-13 19:14:45 +0000,http://www.capitalcube.com/blog/index.php/puma-biotechnology-inc-pbyi-us-earnings-analysis-q2-2016-by-the-numbers-september-13-2016/,"Puma Biotechnology, Inc. :PBYI-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016"
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Biotechnology, Inc. :PBYI-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016",2016-09-13 19:14:45 +0000,http://www.capitalcube.com/blog/index.php/puma-biotechnology-inc-pbyi-us-earnings-analysis-q2-2016-by-the-numbers-september-13-2016/,"Puma Biotechnology, Inc. :PBYI-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology (PBYI): Moving Average Crossover Alert,2016-09-13 16:49:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/774kcMAh3u4/puma-biotechnology-pbyi-moving-average-crossover-alert-cm678851,Are you a technical investor If so it may be time to consider Puma Biotechnology Inc PBYI for your portfolio The company just saw its 50 Day Moving Average breakout above its 200 Day Simple moving average a trend that could indicate some bullishness in the future for PBYI This trend
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology (PBYI): Moving Average Crossover Alert,2016-09-13 16:49:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/774kcMAh3u4/puma-biotechnology-pbyi-moving-average-crossover-alert-cm678851,Are you a technical investor If so it may be time to consider Puma Biotechnology Inc PBYI for your portfolio The company just saw its 50 Day Moving Average breakout above its 200 Day Simple moving average a trend that could indicate some bullishness in the future for PBYI This trend
PBYI,PBYI:UW,BBG002NFCGM3,4 Momentum Stocks to Watch,2016-09-13 15:12:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dZFdV7kL0Sg/4-momentum-stocks-to-watch-cm678803,"By Harry Boxer   These four stocks have strong technical momentum.   Clovis Oncology, Inc.  ( CLVS ), which poppped nearly 30% three weeks ago and then flagged, broke out of the flag last week and looks to be consolidating ahead of its next up-move.  On Monday it gained 40 cents to 28.05 on strong volume of 2.8"
PBYI,PBYI:US,BBG0018YXYX7,4 Momentum Stocks to Watch,2016-09-13 15:12:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dZFdV7kL0Sg/4-momentum-stocks-to-watch-cm678803,"By Harry Boxer   These four stocks have strong technical momentum.   Clovis Oncology, Inc.  ( CLVS ), which poppped nearly 30% three weeks ago and then flagged, broke out of the flag last week and looks to be consolidating ahead of its next up-move.  On Monday it gained 40 cents to 28.05 on strong volume of 2.8"
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology (PBYI): Moving Average Crossover Alert,2016-09-13 14:13:02 +0000,http://finance.yahoo.com/news/puma-biotechnology-pbyi-moving-average-141302841.html,Puma Biotechnology (PBYI): Moving Average Crossover Alert
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology (PBYI): Moving Average Crossover Alert,2016-09-13 14:13:02 +0000,http://finance.yahoo.com/news/puma-biotechnology-pbyi-moving-average-141302841.html,Puma Biotechnology (PBYI): Moving Average Crossover Alert
PBYI,PBYI:US,BBG0018YXYX7,3 Hottest Cancer Biotech Acquisition Targets After Medivation,2016-09-06 20:00:00 +0000,http://www.forbes.com/sites/kenkam/2016/09/06/3-hottest-cancer-biotech-acquisition-targets-after-medivation/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,3 Hottest Cancer Biotech Acquisition Targets After Medivation
PBYI,PBYI:UW,BBG002NFCGM3,3 Hottest Cancer Biotech Acquisition Targets After Medivation,2016-09-06 20:00:00 +0000,http://www.forbes.com/sites/kenkam/2016/09/06/3-hottest-cancer-biotech-acquisition-targets-after-medivation/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,3 Hottest Cancer Biotech Acquisition Targets After Medivation
PBYI,PBYI:UW,BBG002NFCGM3,PBYI Crosses Above Average Analyst Target,2016-08-24 12:43:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zmwfL35yW6g/pbyi-crosses-above-average-analyst-target-cm669351,"In recent trading, shares of Puma Biotechnology, Inc. (Symbol PBYI) have crossed above the average analyst 12 month target price of $55.33, changing hands for $56.62 share. When a stock reaches the target an analyst has set, the analyst"
PBYI,PBYI:US,BBG0018YXYX7,PBYI Crosses Above Average Analyst Target,2016-08-24 12:43:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zmwfL35yW6g/pbyi-crosses-above-average-analyst-target-cm669351,"In recent trading, shares of Puma Biotechnology, Inc. (Symbol PBYI) have crossed above the average analyst 12 month target price of $55.33, changing hands for $56.62 share. When a stock reaches the target an analyst has set, the analyst"
PBYI,PBYI:UW,BBG002NFCGM3,4 Biotech Stock Charts You Must See,2016-08-23 16:07:00 +0000,https://www.thestreet.com/story/13682913/1/4-biotech-stock-charts-you-must-see.html?puc=yahoo&cm_ven=YAHOO,4 Biotech Stock Charts You Must See
PBYI,PBYI:US,BBG0018YXYX7,4 Biotech Stock Charts You Must See,2016-08-23 16:07:00 +0000,https://www.thestreet.com/story/13682913/1/4-biotech-stock-charts-you-must-see.html?puc=yahoo&cm_ven=YAHOO,4 Biotech Stock Charts You Must See
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Neratinib's Application Validated in EU, Stock Up",2016-08-23 15:50:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O3W6c2mH264/puma-pbyi-neratinibs-application-validated-in-eu-stock-up-cm669000,"Puma Biotechnology, Inc. 's PBYI shares were up 9.1% after the company announced that its Marketing Authorization Application (MAA) for neratinib has been validated and is now under assessment by the European Medicines Agency (EMA).  The"
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Neratinib's Application Validated in EU, Stock Up",2016-08-23 15:50:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O3W6c2mH264/puma-pbyi-neratinibs-application-validated-in-eu-stock-up-cm669000,"Puma Biotechnology, Inc. 's PBYI shares were up 9.1% after the company announced that its Marketing Authorization Application (MAA) for neratinib has been validated and is now under assessment by the European Medicines Agency (EMA).  The"
PBYI,PBYI:US,BBG0018YXYX7,4 Biotechs Breaking Out With Strong Momentum,2016-08-23 15:36:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H4yGSRaME3M/4-biotechs-breaking-out-with-strong-momentum-cm669025,"By Harry Boxer   Here are four biotech stocks with strong technical momentum.  Advaxis, Inc. ( ADXS ) broke out of a 5-month coiling consolidation earlier this month, more than doubling on news of an immunotherapy agreement with Amgen, and now is in a bullish, low-volume flag.  On Monday the stock popped 49 cents,"
PBYI,PBYI:UW,BBG002NFCGM3,4 Biotechs Breaking Out With Strong Momentum,2016-08-23 15:36:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H4yGSRaME3M/4-biotechs-breaking-out-with-strong-momentum-cm669025,"By Harry Boxer   Here are four biotech stocks with strong technical momentum.  Advaxis, Inc. ( ADXS ) broke out of a 5-month coiling consolidation earlier this month, more than doubling on news of an immunotherapy agreement with Amgen, and now is in a bullish, low-volume flag.  On Monday the stock popped 49 cents,"
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Neratinib's Application Validated in EU, Stock Up",2016-08-23 13:37:01 +0000,http://finance.yahoo.com/news/puma-pbyi-neratinibs-application-validated-133701006.html,"Puma (PBYI) Neratinib's Application Validated in EU, Stock Up"
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Neratinib's Application Validated in EU, Stock Up",2016-08-23 13:37:01 +0000,http://finance.yahoo.com/news/puma-pbyi-neratinibs-application-validated-133701006.html,"Puma (PBYI) Neratinib's Application Validated in EU, Stock Up"
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events",2016-08-22 20:20:21 +0000,http://biz.yahoo.com/e/160822/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events"
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events",2016-08-22 20:20:21 +0000,http://biz.yahoo.com/e/160822/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events"
PBYI,PBYI:UW,BBG002NFCGM3,"After Medivation, These 6 Biotech Stocks Could Be M&A Targets Next",2016-08-22 18:57:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/22/after-medivation-these-6-biotech-stocks-could-be-ma-targets-next/?mod=yahoobarrons&ru=yahoo,"After Medivation, These 6 Biotech Stocks Could Be M&A Targets Next"
PBYI,PBYI:US,BBG0018YXYX7,"After Medivation, These 6 Biotech Stocks Could Be M&A Targets Next",2016-08-22 18:57:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/22/after-medivation-these-6-biotech-stocks-could-be-ma-targets-next/?mod=yahoobarrons&ru=yahoo,"After Medivation, These 6 Biotech Stocks Could Be M&A Targets Next"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe,2016-08-22 12:18:06 +0000,http://www.publicnow.com/view/7A95A12B2F372645CB5919800B89D69899B9680B,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the Marketing Authorization Application (MAA) for neratinib has been validated by the European ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe,2016-08-22 12:18:06 +0000,http://www.publicnow.com/view/7A95A12B2F372645CB5919800B89D69899B9680B,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the Marketing Authorization Application (MAA) for neratinib has been validated by the European ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe,2016-08-22 12:05:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-announces-european-medicines-120500087.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the Marketing Authorization Application for neratinib has been validated by the European Medicines Agency ."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe,2016-08-22 12:05:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-announces-european-medicines-120500087.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the Marketing Authorization Application for neratinib has been validated by the European Medicines Agency ."
PBYI,PBYI:US,BBG0018YXYX7,"The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours",2016-08-19 15:50:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VEpkuzv5nv4/the-zacks-analyst-blog-highlights-apple-exact-sciences-amkor-technology-puma-biotechnology-and-chemours-cm667750,"For Immediate Release  Chicago, IL   August 19, 2016   Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events"
PBYI,PBYI:UW,BBG002NFCGM3,"The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours",2016-08-19 15:50:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VEpkuzv5nv4/the-zacks-analyst-blog-highlights-apple-exact-sciences-amkor-technology-puma-biotechnology-and-chemours-cm667750,"For Immediate Release  Chicago, IL   August 19, 2016   Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events"
PBYI,PBYI:UW,BBG002NFCGM3,"The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours",2016-08-19 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-apple-133001103.html,"The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours"
PBYI,PBYI:US,BBG0018YXYX7,"The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours",2016-08-19 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-apple-133001103.html,"The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours"
PBYI,PBYI:US,BBG0018YXYX7,4 Biggest Winners from This Earnings Season,2016-08-18 20:45:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XgpT7w1CQKg/4-biggest-winners-from-this-earnings-season-cm667322,"As the earnings season nears its end and we begin adding up the numbers, things seem to be improving for corporate results as a whole. Though both earnings and revenues continue to decline year over year, results"
PBYI,PBYI:UW,BBG002NFCGM3,4 Biggest Winners from This Earnings Season,2016-08-18 20:45:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XgpT7w1CQKg/4-biggest-winners-from-this-earnings-season-cm667322,"As the earnings season nears its end and we begin adding up the numbers, things seem to be improving for corporate results as a whole. Though both earnings and revenues continue to decline year over year, results"
PBYI,PBYI:UW,BBG002NFCGM3,4 Biggest Winners from This Earnings Season,2016-08-18 18:39:06 +0000,http://finance.yahoo.com/news/4-biggest-winners-earnings-season-183906439.html,4 Biggest Winners from This Earnings Season
PBYI,PBYI:US,BBG0018YXYX7,4 Biggest Winners from This Earnings Season,2016-08-18 18:39:06 +0000,http://finance.yahoo.com/news/4-biggest-winners-earnings-season-183906439.html,4 Biggest Winners from This Earnings Season
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Posts Narrower Loss in Q2, Focus on Neratinib",2016-08-11 11:53:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DoCYkwVdAKQ/puma-pbyi-posts-narrower-loss-in-q2-focus-on-neratinib-cm663514,"Puma Biotechnology, Inc.PBYI reported a second quarter 2016 loss of $2.05 per share, much narrower than the Zacks Consensus Estimate of $2.20 but wider than the year ago loss of $2.01. With no approved product in Puma Biotech's portfolio"
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Posts Narrower Loss in Q2, Focus on Neratinib",2016-08-11 11:53:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DoCYkwVdAKQ/puma-pbyi-posts-narrower-loss-in-q2-focus-on-neratinib-cm663514,"Puma Biotechnology, Inc.PBYI reported a second quarter 2016 loss of $2.05 per share, much narrower than the Zacks Consensus Estimate of $2.20 but wider than the year ago loss of $2.01. With no approved product in Puma Biotech's portfolio"
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Posts Narrower Loss in Q2, Focus on Neratinib",2016-08-10 14:17:02 +0000,http://finance.yahoo.com/news/puma-pbyi-posts-narrower-loss-141702506.html,"Puma (PBYI) Posts Narrower Loss in Q2, Focus on Neratinib"
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Posts Narrower Loss in Q2, Focus on Neratinib",2016-08-10 14:17:02 +0000,http://finance.yahoo.com/news/puma-pbyi-posts-narrower-loss-141702506.html,"Puma (PBYI) Posts Narrower Loss in Q2, Focus on Neratinib"
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech reports 2Q loss,2016-08-09 22:02:28 +0000,http://sg.finance.yahoo.com/news/puma-biotech-reports-2q-loss-220228300.html,Puma Biotech reports 2Q loss
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech reports 2Q loss,2016-08-09 22:02:28 +0000,http://sg.finance.yahoo.com/news/puma-biotech-reports-2q-loss-220228300.html,Puma Biotech reports 2Q loss
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2016-08-09 21:22:17 +0000,http://biz.yahoo.com/e/160809/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2016-08-09 21:22:17 +0000,http://biz.yahoo.com/e/160809/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Reports Second Quarter 2016 Financial Results,2016-08-09 20:50:16 +0000,http://www.publicnow.com/view/AF82E1CCBE7D476A4444C42B8E4FDF12B75D4F5B,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2016. Unless otherwise stated, ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Reports Second Quarter 2016 Financial Results,2016-08-09 20:50:16 +0000,http://www.publicnow.com/view/AF82E1CCBE7D476A4444C42B8E4FDF12B75D4F5B,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2016. Unless otherwise stated, ..."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report",2016-08-09 20:11:27 +0000,http://biz.yahoo.com/e/160809/pbyi10-q.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report"
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report",2016-08-09 20:11:27 +0000,http://biz.yahoo.com/e/160809/pbyi10-q.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report"
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology's Alan Auerbach Hopes to Catch Lightning in a Bottle (Again),2016-08-07 04:16:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y5irX6pVFgo/puma-biotechnologys-alan-auerbach-hopes-to-catch-lightning-in-a-bottle-again-cm661476,"After developing the top selling prostate cancer drug Zytiga, healthcare entrepreneur Alan Auerbach sold Cougar Biotech to Johnson & Johnson  for $1 billion back in 2009. Today, Auerbach is at the helm of Puma Biotechnology (NYSE"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology's Alan Auerbach Hopes to Catch Lightning in a Bottle (Again),2016-08-07 04:16:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y5irX6pVFgo/puma-biotechnologys-alan-auerbach-hopes-to-catch-lightning-in-a-bottle-again-cm661476,"After developing the top selling prostate cancer drug Zytiga, healthcare entrepreneur Alan Auerbach sold Cougar Biotech to Johnson & Johnson  for $1 billion back in 2009. Today, Auerbach is at the helm of Puma Biotechnology (NYSE"
PBYI,PBYI:UW,BBG002NFCGM3,"Why Puma Biotechnology, Inc. Stock Soared 65.1% in July",2016-08-04 21:52:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7eHWPygpj_8/why-puma-biotechnology-inc-stock-soared-651-in-july-cm660738,"Image source  Getty Images.  What  Shares of Puma Biotechnology, Inc. (NYSE  PBYI)  a clinical stage biopharmaceutical company developing a cancer therapy, shot up 65.1% in July, according to data from S&P"
PBYI,PBYI:US,BBG0018YXYX7,"Why Puma Biotechnology, Inc. Stock Soared 65.1% in July",2016-08-04 21:52:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7eHWPygpj_8/why-puma-biotechnology-inc-stock-soared-651-in-july-cm660738,"Image source  Getty Images.  What  Shares of Puma Biotechnology, Inc. (NYSE  PBYI)  a clinical stage biopharmaceutical company developing a cancer therapy, shot up 65.1% in July, according to data from S&P"
PBYI,PBYI:US,BBG0018YXYX7,What's in the Cards for Puma (PBYI) This Earnings Season?,2016-08-03 20:58:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rTJ4S1Et0GU/whats-in-the-cards-for-puma-pbyi-this-earnings-season-cm659759,"Puma Biotechnology, Inc.PBYI is expected to report second quarter 2016 results on Aug 8. The company's track record has been mostly disappointing. While it missed estimates in three of the trailing four quarters, it met the same in one."
PBYI,PBYI:UW,BBG002NFCGM3,What's in the Cards for Puma (PBYI) This Earnings Season?,2016-08-03 20:58:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rTJ4S1Et0GU/whats-in-the-cards-for-puma-pbyi-this-earnings-season-cm659759,"Puma Biotechnology, Inc.PBYI is expected to report second quarter 2016 results on Aug 8. The company's track record has been mostly disappointing. While it missed estimates in three of the trailing four quarters, it met the same in one."
PBYI,PBYI:US,BBG0018YXYX7,What's in the Cards for Puma (PBYI) This Earnings Season?,2016-08-03 14:51:02 +0000,http://finance.yahoo.com/news/whats-cards-puma-pbyi-earnings-145102693.html,What's in the Cards for Puma (PBYI) This Earnings Season?
PBYI,PBYI:UW,BBG002NFCGM3,What's in the Cards for Puma (PBYI) This Earnings Season?,2016-08-03 14:51:02 +0000,http://finance.yahoo.com/news/whats-cards-puma-pbyi-earnings-145102693.html,What's in the Cards for Puma (PBYI) This Earnings Season?
PBYI,PBYI:UW,BBG002NFCGM3,These Legendary CEO's Could Catch Lightning in a Bottle -- Again.,2016-08-01 21:53:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lAERsKD_Z-0/these-legendary-ceos-could-catch-lightning-in-a-bottle-again-cm658422,"Great management can make a big difference in whether a company succeeds, especially in the highly regulated healthcare market. While healthcare CEOs may not be as well known as CEOs in other industries, we've identified four healthcare"
PBYI,PBYI:US,BBG0018YXYX7,These Legendary CEO's Could Catch Lightning in a Bottle -- Again.,2016-08-01 21:53:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lAERsKD_Z-0/these-legendary-ceos-could-catch-lightning-in-a-bottle-again-cm658422,"Great management can make a big difference in whether a company succeeds, especially in the highly regulated healthcare market. While healthcare CEOs may not be as well known as CEOs in other industries, we've identified four healthcare"
PBYI,PBYI:US,BBG0018YXYX7,PBYI Makes Bullish Cross Above Critical Moving Average,2016-07-29 17:22:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ckSDogwDwsU/pbyi-makes-bullish-cross-above-critical-moving-average-cm657382,"In trading on Friday, shares of Puma Biotechnology, Inc. (Symbol PBYI) crossed above their 200 day moving average of $49.52, changing hands as high as $49.88 per share. Puma Biotechnology, Inc. shares are currently trading up about 1.1% on"
PBYI,PBYI:UW,BBG002NFCGM3,PBYI Makes Bullish Cross Above Critical Moving Average,2016-07-29 17:22:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ckSDogwDwsU/pbyi-makes-bullish-cross-above-critical-moving-average-cm657382,"In trading on Friday, shares of Puma Biotechnology, Inc. (Symbol PBYI) crossed above their 200 day moving average of $49.52, changing hands as high as $49.88 per share. Puma Biotechnology, Inc. shares are currently trading up about 1.1% on"
PBYI,PBYI:UW,BBG002NFCGM3,"Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs",2016-07-29 11:01:00 +0000,https://www.thestreet.com/story/13656674/1/biotech-stock-mailbag-puma-roars-relypsa-soars-xbiotech-bombs.html?puc=yahoo&cm_ven=YAHOO,"Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs"
PBYI,PBYI:US,BBG0018YXYX7,"Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs",2016-07-29 11:01:00 +0000,https://www.thestreet.com/story/13656674/1/biotech-stock-mailbag-puma-roars-relypsa-soars-xbiotech-bombs.html?puc=yahoo&cm_ven=YAHOO,"Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs"
PBYI,PBYI:US,BBG0018YXYX7,A Look At Puma Biotechnology Inc (PBYI)’s Breast Cancer Candidate,2016-07-25 18:21:30 +0000,http://www.insidermonkey.com/blog/a-look-at-puma-biotechnology-inc-pbyis-breast-cancer-candidate-466394/,A Look At Puma Biotechnology Inc (PBYI)’s Breast Cancer Candidate
PBYI,PBYI:UW,BBG002NFCGM3,A Look At Puma Biotechnology Inc (PBYI)’s Breast Cancer Candidate,2016-07-25 18:21:30 +0000,http://www.insidermonkey.com/blog/a-look-at-puma-biotechnology-inc-pbyis-breast-cancer-candidate-466394/,A Look At Puma Biotechnology Inc (PBYI)’s Breast Cancer Candidate
PBYI,PBYI:UW,BBG002NFCGM3,"Why Southwestern Energy, Puma Biotechnology, and Boston Beer Jumped Today",2016-07-22 23:08:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r7C1zmK0GfA/why-southwestern-energy-puma-biotechnology-and-boston-beer-jumped-today-cm653645,"Image source  Boston Beer via samueladams.com.  Friday brought a positive end to the week on Wall Street, and major market benchmarks finished up between 0.25% and 0.5%, to post gains overall since last"
PBYI,PBYI:US,BBG0018YXYX7,"Why Southwestern Energy, Puma Biotechnology, and Boston Beer Jumped Today",2016-07-22 23:08:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r7C1zmK0GfA/why-southwestern-energy-puma-biotechnology-and-boston-beer-jumped-today-cm653645,"Image source  Boston Beer via samueladams.com.  Friday brought a positive end to the week on Wall Street, and major market benchmarks finished up between 0.25% and 0.5%, to post gains overall since last"
PBYI,PBYI:UW,BBG002NFCGM3,"Close Update: Stocks End Week With Gains as Utilities, Telecoms Advance",2016-07-22 21:06:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kh94Mfsqoz8/close-update-stocks-end-week-with-gains-as-utilities-telecoms-advance-cm653609,"Stocks in the U.S. gained on Friday, ending an earnings heavy week in positive territory with all 10 of the S&P 500's sectors strengthening. Utilities rose 1.3% and telecommunications services increased 1.2% after AT&T ( T ) met expectations"
PBYI,PBYI:US,BBG0018YXYX7,"Close Update: Stocks End Week With Gains as Utilities, Telecoms Advance",2016-07-22 21:06:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kh94Mfsqoz8/close-update-stocks-end-week-with-gains-as-utilities-telecoms-advance-cm653609,"Stocks in the U.S. gained on Friday, ending an earnings heavy week in positive territory with all 10 of the S&P 500's sectors strengthening. Utilities rose 1.3% and telecommunications services increased 1.2% after AT&T ( T ) met expectations"
PBYI,PBYI:US,BBG0018YXYX7,"Why Southwestern Energy, Puma Biotechnology, and Boston Beer Jumped Today",2016-07-22 21:03:00 +0000,http://www.fool.com/investing/2016/07/22/why-southwestern-energy-puma-biotechnology-and-bos.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Southwestern Energy, Puma Biotechnology, and Boston Beer Jumped Today"
PBYI,PBYI:UW,BBG002NFCGM3,"Why Southwestern Energy, Puma Biotechnology, and Boston Beer Jumped Today",2016-07-22 21:03:00 +0000,http://www.fool.com/investing/2016/07/22/why-southwestern-energy-puma-biotechnology-and-bos.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Southwestern Energy, Puma Biotechnology, and Boston Beer Jumped Today"
PBYI,PBYI:US,BBG0018YXYX7,"Health Care Sector Update for 07/22/2016: SRPT,PBYI,CFRX",2016-07-22 20:43:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mQgPhg1Dl-8/health-care-sector-update-for-07222016-srptpbyicfrx-cm653608,"Top Health Care Stocks JNJ 0.15% PFE +0.05% MRK +0.22% ABT +0.08% AMGN +0.88% Health care stocks were finishing moderately higher, with the NYSE Health Care Index rising about 0.4% while shares of health care companies in the S&P"
PBYI,PBYI:UW,BBG002NFCGM3,"Health Care Sector Update for 07/22/2016: SRPT,PBYI,CFRX",2016-07-22 20:43:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mQgPhg1Dl-8/health-care-sector-update-for-07222016-srptpbyicfrx-cm653608,"Top Health Care Stocks JNJ 0.15% PFE +0.05% MRK +0.22% ABT +0.08% AMGN +0.88% Health care stocks were finishing moderately higher, with the NYSE Health Care Index rising about 0.4% while shares of health care companies in the S&P"
PBYI,PBYI:UW,BBG002NFCGM3,"Health Care Sector Update for 07/22/2016: EYES,PBYI,CFRX",2016-07-22 18:06:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PILsu2SBeok/health-care-sector-update-for-07222016-eyespbyicfrx-cm653509,"Top Health Care Stocks JNJ 0.36% PFE +0.10% MRK 0.29% ABT 0.04% AMGN +1.10% Health care stocks were narrowly higher today, with the NYSE Health Care Index rising about 0.2% while shares of health care companies in the S&P"
PBYI,PBYI:US,BBG0018YXYX7,"Health Care Sector Update for 07/22/2016: EYES,PBYI,CFRX",2016-07-22 18:06:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PILsu2SBeok/health-care-sector-update-for-07222016-eyespbyicfrx-cm653509,"Top Health Care Stocks JNJ 0.36% PFE +0.10% MRK 0.29% ABT 0.04% AMGN +1.10% Health care stocks were narrowly higher today, with the NYSE Health Care Index rising about 0.2% while shares of health care companies in the S&P"
PBYI,PBYI:UW,BBG002NFCGM3,Is This the Turning Point Puma Biotech Investors Have Waited For?,2016-07-22 15:10:26 +0000,http://247wallst.com/healthcare-business/2016/07/22/is-this-the-turning-point-puma-biotech-investors-have-waited-for/,Is This the Turning Point Puma Biotech Investors Have Waited For?
PBYI,PBYI:US,BBG0018YXYX7,Is This the Turning Point Puma Biotech Investors Have Waited For?,2016-07-22 15:10:26 +0000,http://247wallst.com/healthcare-business/2016/07/22/is-this-the-turning-point-puma-biotech-investors-have-waited-for/,Is This the Turning Point Puma Biotech Investors Have Waited For?
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-07-22 10:04:56 +0000,http://biz.yahoo.com/e/160722/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-07-22 10:04:56 +0000,http://biz.yahoo.com/e/160722/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Biotech shares jump on breast cancer study, FDA application",2016-07-21 21:49:44 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=30441EF5-1849-4BCA-B4BC-4011A7084ED1&siteid=yhoof2,"Puma Biotech shares jump on breast cancer study, FDA application"
PBYI,PBYI:US,BBG0018YXYX7,"Puma Biotech shares jump on breast cancer study, FDA application",2016-07-21 21:49:44 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=30441EF5-1849-4BCA-B4BC-4011A7084ED1&siteid=yhoof2,"Puma Biotech shares jump on breast cancer study, FDA application"
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial),2016-07-21 20:15:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-announces-interim-5-201500055.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced updated results from the Phase III clinical trial of Puma’s investigational drug PB272 for the extended adjuvant treatment of HER2-positive early stage breast cancer ."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial),2016-07-21 20:15:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-announces-interim-5-201500055.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced updated results from the Phase III clinical trial of Puma’s investigational drug PB272 for the extended adjuvant treatment of HER2-positive early stage breast cancer ."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,2016-07-21 20:11:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-submits-drug-application-201100434.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, has submitted a New Drug Application to the U.S. Food and Drug Administration for its lead product candidate PB272 for the extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab -based therapy."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,2016-07-21 20:11:00 +0000,http://finance.yahoo.com/news/puma-biotechnology-submits-drug-application-201100434.html,"[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, has submitted a New Drug Application to the U.S. Food and Drug Administration for its lead product candidate PB272 for the extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab -based therapy."
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Stock Up, Phase II Data on Neratinib Published",2016-07-08 17:37:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KDxSxpjHOp4/puma-pbyi-stock-up-phase-ii-data-on-neratinib-published-cm646536,"Puma Biotechnology, Inc.PBYI announced that positive results from a randomized phase II study (I SPY 2 Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) on neratinib for the neoadjuvant treatment of breast"
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Stock Up, Phase II Data on Neratinib Published",2016-07-08 17:37:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KDxSxpjHOp4/puma-pbyi-stock-up-phase-ii-data-on-neratinib-published-cm646536,"Puma Biotechnology, Inc.PBYI announced that positive results from a randomized phase II study (I SPY 2 Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) on neratinib for the neoadjuvant treatment of breast"
PBYI,PBYI:UW,BBG002NFCGM3,"Puma (PBYI) Stock Up, Phase II Data on Neratinib Published",2016-07-08 15:28:03 +0000,http://finance.yahoo.com/news/puma-pbyi-stock-phase-ii-152803605.html,"Puma (PBYI) Stock Up, Phase II Data on Neratinib Published"
PBYI,PBYI:US,BBG0018YXYX7,"Puma (PBYI) Stock Up, Phase II Data on Neratinib Published",2016-07-08 15:28:03 +0000,http://finance.yahoo.com/news/puma-pbyi-stock-phase-ii-152803605.html,"Puma (PBYI) Stock Up, Phase II Data on Neratinib Published"
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine,2016-07-07 12:31:06 +0000,http://www.publicnow.com/view/1B2BB90A3C77FD398408959B7202029559191CA4,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the positive results from the I-SPY 2 Phase II clinical trial of neratinib for the neoadjuvant ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine,2016-07-07 12:31:06 +0000,http://www.publicnow.com/view/1B2BB90A3C77FD398408959B7202029559191CA4,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the positive results from the I-SPY 2 Phase II clinical trial of neratinib for the neoadjuvant ..."
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events",2016-07-06 10:06:19 +0000,http://biz.yahoo.com/e/160706/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events"
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events",2016-07-06 10:06:19 +0000,http://biz.yahoo.com/e/160706/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events"
PBYI,PBYI:US,BBG0018YXYX7,Puma (PBYI) Submits Neratinib Marketing Application in EU,2016-06-28 14:51:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-CP3Osirjuo/puma-pbyi-submits-neratinib-marketing-application-in-eu-cm641942,"Puma Biotechnology, Inc.PBYI announced that it has submitted a Marketing Authorisation Application (MAA) in the EU for its lead pipeline candidate, neratinib. The company is looking to get neratinib approved for the extended adjuvant treatment of HER2 positive early"
PBYI,PBYI:UW,BBG002NFCGM3,Puma (PBYI) Submits Neratinib Marketing Application in EU,2016-06-28 14:51:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-CP3Osirjuo/puma-pbyi-submits-neratinib-marketing-application-in-eu-cm641942,"Puma Biotechnology, Inc.PBYI announced that it has submitted a Marketing Authorisation Application (MAA) in the EU for its lead pipeline candidate, neratinib. The company is looking to get neratinib approved for the extended adjuvant treatment of HER2 positive early"
PBYI,PBYI:UW,BBG002NFCGM3,Puma (PBYI) Submits Neratinib Marketing Application in EU,2016-06-28 13:00:01 +0000,http://finance.yahoo.com/news/puma-pbyi-submits-neratinib-marketing-130001714.html,Puma (PBYI) Submits Neratinib Marketing Application in EU
PBYI,PBYI:US,BBG0018YXYX7,Puma (PBYI) Submits Neratinib Marketing Application in EU,2016-06-28 13:00:01 +0000,http://finance.yahoo.com/news/puma-pbyi-submits-neratinib-marketing-130001714.html,Puma (PBYI) Submits Neratinib Marketing Application in EU
PBYI,PBYI:US,BBG0018YXYX7,"AKER Up On Aero-Med Deal, Allergy Under The Weather, RGLS Falls On Clinical Hold",2016-06-28 00:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jGHWMd72RmM/aker-up-on-aeromed-deal-allergy-under-the-weather-rgls-falls-on-clinical-hold-20160628-00006,"AKER Up On Aero-Med Deal, Allergy Under The Weather, RGLS Falls On Clinical Hold"
PBYI,PBYI:UW,BBG002NFCGM3,"AKER Up On Aero-Med Deal, Allergy Under The Weather, RGLS Falls On Clinical Hold",2016-06-28 00:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jGHWMd72RmM/aker-up-on-aeromed-deal-allergy-under-the-weather-rgls-falls-on-clinical-hold-20160628-00006,"AKER Up On Aero-Med Deal, Allergy Under The Weather, RGLS Falls On Clinical Hold"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Submits Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe,2016-06-27 12:21:08 +0000,http://www.publicnow.com/view/5EECB2E4E4BD35FD2CEE32475C17308F0AD9F113,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it has submitted its Marketing Authorization Application (MAA) to the European Medicines ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Submits Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe,2016-06-27 12:21:08 +0000,http://www.publicnow.com/view/5EECB2E4E4BD35FD2CEE32475C17308F0AD9F113,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it has submitted its Marketing Authorization Application (MAA) to the European Medicines ..."
PBYI,PBYI:US,BBG0018YXYX7,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submiss",2016-06-15 20:11:01 +0000,http://biz.yahoo.com/e/160615/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submiss"
PBYI,PBYI:UW,BBG002NFCGM3,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submiss",2016-06-15 20:11:01 +0000,http://biz.yahoo.com/e/160615/pbyi8-k.html,"PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submiss"
PBYI,PBYI:UW,BBG002NFCGM3,Puma (PBYI) Presents Favorable Phase II Data on Neratinib,2016-06-06 16:13:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nb9qyJskjf8/puma-pbyi-presents-favorable-phase-ii-data-on-neratinib-cm630957,"Puma Biotechnology, Inc.PBYI presented positive data from an investigator sponsored phase II study on neratinib in patients with HER2 mutated, non amplified breast cancer. Data were presented at the annual meeting of the American Society of Clinical Oncology. The"
PBYI,PBYI:US,BBG0018YXYX7,Puma (PBYI) Presents Favorable Phase II Data on Neratinib,2016-06-06 16:13:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nb9qyJskjf8/puma-pbyi-presents-favorable-phase-ii-data-on-neratinib-cm630957,"Puma Biotechnology, Inc.PBYI presented positive data from an investigator sponsored phase II study on neratinib in patients with HER2 mutated, non amplified breast cancer. Data were presented at the annual meeting of the American Society of Clinical Oncology. The"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting,2016-06-05 13:18:07 +0000,http://www.publicnow.com/view/F4FF5437B1E102DC24E9292156A9989C6A8A122F,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator-sponsored Phase II trial of neratinib with HER2-mutated, ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting,2016-06-05 13:18:07 +0000,http://www.publicnow.com/view/F4FF5437B1E102DC24E9292156A9989C6A8A122F,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator-sponsored Phase II trial of neratinib with HER2-mutated, ..."
PBYI,PBYI:UW,BBG002NFCGM3,Interesting PBYI Put And Call Options For July 15th,2016-05-23 17:50:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gAp1Nrgt0_A/interesting-pbyi-put-and-call-options-for-july-15th-cm625029,"Investors in Puma Biotechnology, Inc. (Symbol PBYI) saw new options become available today, for the July 15th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the PBYI options chain for the new July"
PBYI,PBYI:US,BBG0018YXYX7,Interesting PBYI Put And Call Options For July 15th,2016-05-23 17:50:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gAp1Nrgt0_A/interesting-pbyi-put-and-call-options-for-july-15th-cm625029,"Investors in Puma Biotechnology, Inc. (Symbol PBYI) saw new options become available today, for the July 15th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the PBYI options chain for the new July"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting,2016-05-18 22:12:05 +0000,http://www.publicnow.com/view/3F88C059C560A682507689D4E589F7CDEE6D5D19,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting,2016-05-18 22:12:05 +0000,http://www.publicnow.com/view/3F88C059C560A682507689D4E589F7CDEE6D5D19,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Present at UBS Global Healthcare Conference,2016-05-17 14:42:08 +0000,http://www.publicnow.com/view/B64A32CA2FB575AEA8DB994659786B9CF91C0264,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Present at UBS Global Healthcare Conference,2016-05-17 14:42:08 +0000,http://www.publicnow.com/view/B64A32CA2FB575AEA8DB994659786B9CF91C0264,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will ..."
PBYI,PBYI:UW,BBG002NFCGM3,"Noteworthy Wednesday Option Activity: PBYI, N, SEAS",2016-05-11 21:23:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kOx6yuqPOgY/noteworthy-wednesday-option-activity-pbyi-n-seas-cm619841,"Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Puma Biotechnology, Inc. (Symbol PBYI), where a total of 3,136 contracts have traded so far, representing approximately 313,600 underlying shares. That amounts"
PBYI,PBYI:US,BBG0018YXYX7,"Noteworthy Wednesday Option Activity: PBYI, N, SEAS",2016-05-11 21:23:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kOx6yuqPOgY/noteworthy-wednesday-option-activity-pbyi-n-seas-cm619841,"Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Puma Biotechnology, Inc. (Symbol PBYI), where a total of 3,136 contracts have traded so far, representing approximately 313,600 underlying shares. That amounts"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech reports 1Q loss,2016-05-10 22:06:46 +0000,http://sg.finance.yahoo.com/news/puma-biotech-reports-1q-loss-220646128.html,Puma Biotech reports 1Q loss
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech reports 1Q loss,2016-05-10 22:06:46 +0000,http://sg.finance.yahoo.com/news/puma-biotech-reports-1q-loss-220646128.html,Puma Biotech reports 1Q loss
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Reports First Quarter 2016 Financial Results,2016-05-10 20:48:04 +0000,http://www.publicnow.com/view/DA4CA685DF331220201F87942FCCD16B507DDBFE,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2016. Unless otherwise stated, all comparisons ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Reports First Quarter 2016 Financial Results,2016-05-10 20:48:04 +0000,http://www.publicnow.com/view/DA4CA685DF331220201F87942FCCD16B507DDBFE,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2016. Unless otherwise stated, all comparisons ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference,2016-05-04 13:00:02 +0000,http://www.publicnow.com/view/7F9551A86341187BAA0B2123809C279388079CE4,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference,2016-05-04 13:00:02 +0000,http://www.publicnow.com/view/7F9551A86341187BAA0B2123809C279388079CE4,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology’s Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016,2016-04-20 13:31:12 +0000,http://www.publicnow.com/view/429A6A3C9C9B274ADE764ABC25DE810DECCDE27E,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that its drug candidate neratinib was highlighted in three poster presentations at the American ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology’s Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016,2016-04-20 13:31:12 +0000,http://www.publicnow.com/view/429A6A3C9C9B274ADE764ABC25DE810DECCDE27E,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that its drug candidate neratinib was highlighted in three poster presentations at the American ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Updates Timeline for Filing New Drug Application,2016-03-28 20:33:08 +0000,http://www.publicnow.com/view/53BF4DC2F3E20384105F95D4C5ACEFD7692EAE63,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that based on its recent meetings with the U.S. Food and Drug Administration (FDA), the Company ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Updates Timeline for Filing New Drug Application,2016-03-28 20:33:08 +0000,http://www.publicnow.com/view/53BF4DC2F3E20384105F95D4C5ACEFD7692EAE63,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that based on its recent meetings with the U.S. Food and Drug Administration (FDA), the Company ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech reports 4Q loss,2016-02-29 22:05:35 +0000,http://sg.finance.yahoo.com/news/puma-biotech-reports-4q-loss-220535065.html,Puma Biotech reports 4Q loss
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech reports 4Q loss,2016-02-29 22:05:35 +0000,http://sg.finance.yahoo.com/news/puma-biotech-reports-4q-loss-220535065.html,Puma Biotech reports 4Q loss
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman’s Consent Solicitation,2016-01-08 13:25:30 +0000,http://www.noodls.com/view/829DCF51BBF7C07CF3BDE65DF6C67EE506EEAFFA,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that shareholders representing over 80% of the Company's shares outstanding have rejected the ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman’s Consent Solicitation,2016-01-08 13:25:30 +0000,http://www.noodls.com/view/829DCF51BBF7C07CF3BDE65DF6C67EE506EEAFFA,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that shareholders representing over 80% of the Company's shares outstanding have rejected the ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Present at J.P. Morgan Healthcare Conference,2016-01-04 21:40:28 +0000,http://www.noodls.com/view/E11B0C218A603BF0936BE075A551F489886D5CD3,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Present at J.P. Morgan Healthcare Conference,2016-01-04 21:40:28 +0000,http://www.noodls.com/view/E11B0C218A603BF0936BE075A551F489886D5CD3,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will ..."
PBYI,PBYI:UW,BBG002NFCGM3,Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card,2015-12-30 14:44:27 +0000,http://www.noodls.com/view/E79852C96C6034F269D9083AC3592C9AA5AD51CF,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI) ('Puma' or the 'Company') announced that Glass Lewis & Co., another leading independent proxy advisory firm, recommends that Puma shareholders ..."
PBYI,PBYI:US,BBG0018YXYX7,Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card,2015-12-30 14:44:27 +0000,http://www.noodls.com/view/E79852C96C6034F269D9083AC3592C9AA5AD51CF,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI) ('Puma' or the 'Company') announced that Glass Lewis & Co., another leading independent proxy advisory firm, recommends that Puma shareholders ..."
PBYI,PBYI:UW,BBG002NFCGM3,Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card,2015-12-30 13:52:09 +0000,http://www.noodls.com/view/AA8CA6B40A6F863BF73A5325F4DC67DF723938F2,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI) ('Puma' or the 'Company') announced that independent proxy advisory firm Egan-Jones Proxy Services recommends that Puma shareholders ..."
PBYI,PBYI:US,BBG0018YXYX7,Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card,2015-12-30 13:52:09 +0000,http://www.noodls.com/view/AA8CA6B40A6F863BF73A5325F4DC67DF723938F2,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI) ('Puma' or the 'Company') announced that independent proxy advisory firm Egan-Jones Proxy Services recommends that Puma shareholders ..."
PBYI,PBYI:US,BBG0018YXYX7,ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card,2015-12-23 14:09:04 +0000,http://www.noodls.com/view/1D6CA4D7DE3F9121310DE78D9D0537F43A9CDFB2,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI) ('Puma' or the 'Company') today announced that ISS, the leading independent proxy advisory firm, recommends that Puma shareholders revoke ..."
PBYI,PBYI:UW,BBG002NFCGM3,ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card,2015-12-23 14:09:04 +0000,http://www.noodls.com/view/1D6CA4D7DE3F9121310DE78D9D0537F43A9CDFB2,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI) ('Puma' or the 'Company') today announced that ISS, the leading independent proxy advisory firm, recommends that Puma shareholders revoke ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Expands Third Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients,2015-12-18 12:21:16 +0000,http://www.noodls.com/view/1B7AF300BE24B5BF42BAF2B9DF3BEC241169258E,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has expanded the third cohort from its Phase II clinical trial of its lead drug candidate PB272 (neratinib) ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Expands Third Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients,2015-12-18 12:21:16 +0000,http://www.noodls.com/view/1B7AF300BE24B5BF42BAF2B9DF3BEC241169258E,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has expanded the third cohort from its Phase II clinical trial of its lead drug candidate PB272 (neratinib) ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology to Host Conference Call to Discuss Loperamide Prophylaxis to Reduce Neratinib-Related Diarrhea,2015-12-16 21:32:08 +0000,http://www.noodls.com/view/A28BD7162FA073F67ABE22A614DC9280AB120DD4,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, will host a conference call and slide presentation to discuss preliminary results of its Phase II study ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology to Host Conference Call to Discuss Loperamide Prophylaxis to Reduce Neratinib-Related Diarrhea,2015-12-16 21:32:08 +0000,http://www.noodls.com/view/A28BD7162FA073F67ABE22A614DC9280AB120DD4,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, will host a conference call and slide presentation to discuss preliminary results of its Phase II study ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Presents 3-Year Disease Free Survival Data from Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) at the 2015 San Antonio Breast Cancer Symposium,2015-12-11 16:09:40 +0000,http://www.noodls.com/view/EAAA45F4EA74F810FEFA3B2623F059AC3055A423,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the presentation of updated results from the Phase III clinical trial of Puma's investigational ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Presents 3-Year Disease Free Survival Data from Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) at the 2015 San Antonio Breast Cancer Symposium,2015-12-11 16:09:40 +0000,http://www.noodls.com/view/EAAA45F4EA74F810FEFA3B2623F059AC3055A423,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the presentation of updated results from the Phase III clinical trial of Puma's investigational ..."
PBYI,PBYI:US,BBG0018YXYX7,"Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2015 San Antonio Breast Cancer Symposium",2015-12-10 13:27:18 +0000,http://www.noodls.com/view/F92DBC4874F725861C441768A2DABC0BFC8EDFB7,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that interim results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology Announces Results of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer,2015-12-10 13:27:18 +0000,http://www.noodls.com/view/5296D977CE9EB0EC528C51C0567CF05B0D93E3B1,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from a randomized Phase II clinical trial of Puma's investigational drug PB272 (neratinib) ..."
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2015 San Antonio Breast Cancer Symposium",2015-12-10 13:27:18 +0000,http://www.noodls.com/view/F92DBC4874F725861C441768A2DABC0BFC8EDFB7,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that interim results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 ..."
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology Announces Results of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer,2015-12-10 13:27:18 +0000,http://www.noodls.com/view/5296D977CE9EB0EC528C51C0567CF05B0D93E3B1,"[at noodls] - LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from a randomized Phase II clinical trial of Puma's investigational drug PB272 (neratinib) ..."
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech reports 3Q loss,2015-11-10 00:31:40 +0000,http://sg.finance.yahoo.com/news/puma-biotech-reports-3q-loss-003140871.html,Puma Biotech reports 3Q loss
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech reports 3Q loss,2015-11-10 00:31:40 +0000,http://sg.finance.yahoo.com/news/puma-biotech-reports-3q-loss-003140871.html,Puma Biotech reports 3Q loss
PBYI,PBYI:UW,BBG002NFCGM3,Correction: Puma Biotechnology-Ahead of the Bell story,2015-05-15 17:50:30 +0000,http://sg.finance.yahoo.com/news/correction-puma-biotechnology-ahead-bell-175030900.html,Correction: Puma Biotechnology-Ahead of the Bell story
PBYI,PBYI:US,BBG0018YXYX7,Correction: Puma Biotechnology-Ahead of the Bell story,2015-05-15 17:50:30 +0000,http://sg.finance.yahoo.com/news/correction-puma-biotechnology-ahead-bell-175030900.html,Correction: Puma Biotechnology-Ahead of the Bell story
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotechnology plunges on breast cancer drug data,2015-05-14 19:12:54 +0000,http://sg.finance.yahoo.com/news/puma-biotechnology-plunges-breast-cancer-124958086.html,Puma Biotechnology plunges on breast cancer drug data
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotechnology plunges on breast cancer drug data,2015-05-14 19:12:54 +0000,http://sg.finance.yahoo.com/news/puma-biotechnology-plunges-breast-cancer-124958086.html,Puma Biotechnology plunges on breast cancer drug data
PBYI,PBYI:US,BBG0018YXYX7,"US STOCKS-Wall St rises as jobless claims fall, dollar weakens",2015-05-14 17:24:52 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-rises-172452113.html,"US STOCKS-Wall St rises as jobless claims fall, dollar weakens"
PBYI,PBYI:UW,BBG002NFCGM3,"US STOCKS-Wall St rises as jobless claims fall, dollar weakens",2015-05-14 17:24:52 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-rises-172452113.html,"US STOCKS-Wall St rises as jobless claims fall, dollar weakens"
PBYI,PBYI:UW,BBG002NFCGM3,"US STOCKS-Wall St opens higher as jobless claims fall, dollar weakens",2015-05-14 14:07:14 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-opens-140714872.html,"US STOCKS-Wall St opens higher as jobless claims fall, dollar weakens"
PBYI,PBYI:US,BBG0018YXYX7,"US STOCKS-Wall St opens higher as jobless claims fall, dollar weakens",2015-05-14 14:07:14 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-opens-140714872.html,"US STOCKS-Wall St opens higher as jobless claims fall, dollar weakens"
PBYI,PBYI:US,BBG0018YXYX7,US STOCKS-Wall St set to open up as weekly jobless claims fall,2015-05-14 13:09:55 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-set-130955071.html,US STOCKS-Wall St set to open up as weekly jobless claims fall
PBYI,PBYI:UW,BBG002NFCGM3,US STOCKS-Wall St set to open up as weekly jobless claims fall,2015-05-14 13:09:55 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-set-130955071.html,US STOCKS-Wall St set to open up as weekly jobless claims fall
PBYI,PBYI:UW,BBG002NFCGM3,US STOCKS-Futures higher ahead of weekly jobless data,2015-05-14 11:36:39 +0000,http://uk.finance.yahoo.com/news/us-stocks-futures-higher-ahead-113639837.html,US STOCKS-Futures higher ahead of weekly jobless data
PBYI,PBYI:US,BBG0018YXYX7,US STOCKS-Futures higher ahead of weekly jobless data,2015-05-14 11:36:39 +0000,http://uk.finance.yahoo.com/news/us-stocks-futures-higher-ahead-113639837.html,US STOCKS-Futures higher ahead of weekly jobless data
PBYI,PBYI:UW,BBG002NFCGM3,Cancer conference data may prompt healthcare share volatility,2015-05-13 16:51:52 +0000,http://uk.finance.yahoo.com/news/cancer-conference-data-may-prompt-165152841.html,Cancer conference data may prompt healthcare share volatility
PBYI,PBYI:US,BBG0018YXYX7,Cancer conference data may prompt healthcare share volatility,2015-05-13 16:51:52 +0000,http://uk.finance.yahoo.com/news/cancer-conference-data-may-prompt-165152841.html,Cancer conference data may prompt healthcare share volatility
PBYI,PBYI:UW,BBG002NFCGM3,"Puma Biotechnology, Cliffs are big market movers",2014-12-03 21:51:18 +0000,http://sg.finance.yahoo.com/news/puma-biotechnology-cliffs-big-market-215118756.html,"Puma Biotechnology, Cliffs are big market movers"
PBYI,PBYI:US,BBG0018YXYX7,"Puma Biotechnology, Cliffs are big market movers",2014-12-03 21:51:18 +0000,http://sg.finance.yahoo.com/news/puma-biotechnology-cliffs-big-market-215118756.html,"Puma Biotechnology, Cliffs are big market movers"
PBYI,PBYI:US,BBG0018YXYX7,"Dow, S&P 500 at records after upbeat Fed report",2014-12-03 21:50:50 +0000,http://uk.finance.yahoo.com/news/dow-p-500-records-upbeat-211338333.html,"Dow, S&P 500 at records after upbeat Fed report"
PBYI,PBYI:UW,BBG002NFCGM3,"Dow, S&P 500 at records after upbeat Fed report",2014-12-03 21:50:50 +0000,http://uk.finance.yahoo.com/news/dow-p-500-records-upbeat-211338333.html,"Dow, S&P 500 at records after upbeat Fed report"
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech sinks on cancer drug filing delay,2014-12-02 22:19:16 +0000,http://sg.finance.yahoo.com/news/puma-biotech-sinks-cancer-drug-221916775.html,Puma Biotech sinks on cancer drug filing delay
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech sinks on cancer drug filing delay,2014-12-02 22:19:16 +0000,http://sg.finance.yahoo.com/news/puma-biotech-sinks-cancer-drug-221916775.html,Puma Biotech sinks on cancer drug filing delay
PBYI,PBYI:UW,BBG002NFCGM3,Puma Biotech beats 3Q profit forecasts,2014-11-10 21:36:57 +0000,http://sg.finance.yahoo.com/news/puma-biotech-beats-3q-profit-213657916--finance.html,Puma Biotech beats 3Q profit forecasts
PBYI,PBYI:US,BBG0018YXYX7,Puma Biotech beats 3Q profit forecasts,2014-11-10 21:36:57 +0000,http://sg.finance.yahoo.com/news/puma-biotech-beats-3q-profit-213657916--finance.html,Puma Biotech beats 3Q profit forecasts
PBYI,PBYI:US,BBG0018YXYX7,Delta and Apple are big market movers,2014-07-23 20:38:49 +0000,http://sg.finance.yahoo.com/news/delta-apple-big-market-movers-203849664--finance.html,Delta and Apple are big market movers
PBYI,PBYI:UW,BBG002NFCGM3,Delta and Apple are big market movers,2014-07-23 20:38:49 +0000,http://sg.finance.yahoo.com/news/delta-apple-big-market-movers-203849664--finance.html,Delta and Apple are big market movers
PBYI,PBYI:US,BBG0018YXYX7,"New drug, study method show breast cancer promise",2013-12-13 17:22:13 +0000,http://sg.finance.yahoo.com/news/drug-study-method-show-breast-161550064--finance.html,"New drug, study method show breast cancer promise"
PBYI,PBYI:UW,BBG002NFCGM3,"New drug, study method show breast cancer promise",2013-12-13 17:22:13 +0000,http://sg.finance.yahoo.com/news/drug-study-method-show-breast-161550064--finance.html,"New drug, study method show breast cancer promise"
